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SUMMARY  
Cognitive symptoms are common in Parkinson disease (PD) and range from mild 
cognitive impairment (PD-MCI) to dementia (PDD). It is not fully understood, whether PD-MCI 
and PDD are consecutive events and evolve into each other or whether they display two 
different entities. The high conversion rate from PD-MCI to PDD points to a progressive 
pattern, while different cognitive profiles seems to be related with higher conversion risk to 
PDD. Clinical diagnostic criteria have been developed in order to diagnose PD-MCI and PDD, 
but there is an important need for the development of a reliable biomarker that can give 
valuable information about the underlying pathological changes and that can discriminate 
between patients without cognitive symptoms (PD-N), PD-MCI and PDD. This biomarker 
should further be able to track the disease progression and thereby help to identify those 
patients with high dementia risk.  
The aim of this study was to derive a multi-modal magnetic resonance imaging (MRI)-
based biomarker for the reliable discrimination of PD patients at different stages of cognitive 
decline and to identify pathologic patterns related with increased dementia risk, as no reliable 
biomarkers are available at this time. We collected the resting-state functional MRI (rs-fMRI), 
diffusion tensor imaging (DTI), perfusion (Arterial Spin Labeling, ASL) and MR spectroscopic 
imaging (MRSI) data together with neuropsychological data from 20 PD-N, 20 PD-MCI and 20 
PDD patients followed at the Neurology Department of Istanbul Faculty of Medicine. 
 We evaluated the rs-fMRI data using binary logistic regression analysis and identified 
the combination of resting-state networks (RSNs) that yield discriminative power based on 
the expression scores of the RSNs among the groups. We identified five RSNs, that were 
successful in discriminating between PDD and the other PD groups. The two modulatory 
default mode network (DMN) and salience network (SN) were significantly stronger expressed 
in the PDD group compared to PD-N, although the increase evolved from PD-N through PD-
MCI to PDD. On the other hand, the frontostriatal network (FSN), posterior-temporal network 
(PTN) and limbic network that are related with executive, visuo-spatial and memory 
dysfunction, were significantly lower expressed in the PDD group.  
The DMN and SN are known to be functionally related in a way that the SN regulates 
the activation and deactivation of the DMN and the central executive network (CEN) in the 
presence or absence of salient stimuli, and that may be an indicator for an altered switching 
mechanism of these RSNs in PDD patients, which is different from altered activation pattern 
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that have been described for other types of dementia cases. The voxel-wise analysis of the 
RSNs revealed complementary results pointing to pathological changes in major hubs of the 
SN (insula), limbic network (thalamus and hippocampus) and FSN (caudate/putamen).  
We further were able to show significant global white matter (WM) degeneration in 
the PDD group using DTI measurements, stemming from pathological changes in various WM 
tracts that relate to RSN alterations observed in PDD. Additionally, we found pattern of 
hypoperfusion (ASL) and metabolic changes (MRSI) mainly in structures that supported the 
findings of the rs-fMRI and DTI measurements. The significant findings from the single MRI 
modalities showed significant correlation with various clinical and neuropsychological 
variables among the patient groups.  
In the end, we tested a discriminative model using the significant parameters of the rs-
fMRI, DTI and ASL data by feeding them stepwise into a discriminant analysis that revealed a 
combination of rs-fMRI and DTI findings to be most successful in discriminating the PDD from 
the PD-N with 100% sensitivity and PDD from PD-MCI cases with 83.3% sensitivity. 
We were able to show progressive neuro-pathological changes at different stages of 
cognitive decline that, after validation, could be used as biomarker for PDD and, due to the 
easy application of MRI measurements, could be established as diagnostic tool and follow-up 
of the PD patients with the aim to generate individual treatment and identification of patients 
with dementia risk. 
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ZUSAMMENFASSUNG 
Kognitive Störungen sind häufig auftretende Symptome in Morbus Parkinson (PD) und 
können von milden kognitiven Störungen (PD-MCI) bis hin zur Demenz (PDD) reichen. Es ist 
derzeit noch nicht völlig erforscht, ob es sich bei PD-MCI und PDD um aufeinander folgende 
Ereignisse handelt, bei denen PD-MCI sich zu PDD entwickelt, oder aber es sich um zwei 
unabhängige Formen kognitiver Störungen handelt. Die hohe Rate von PD-MCI Patienten, die 
im Verlauf der Krankheit eine Demenz entwickelt, deutet auf einen progressiven Verlauf hin, 
wobei die Ausprägung von verschiedenen kognitiven Defiziten mit erhöhtem Demenzrisiko in 
Verbindung gebracht wird.  
Obwohl Kriterien zur klinischen Diagnostik von PD-MCI und PDD entwickelt wurden, 
besteht der Bedarf an der Definition eines verlässlichen Biomarkers, welcher wertvolle 
Informationen nicht nur über die pathophysiologischen Vorgänge liefern kann, sondern 
gleichzeitig auch zwischen kognitiv normalen PD Patienten (PD-N), PD-MCI und PDD 
unterscheiden kann. Solch ein Biomarker sollte zudem über die Eigenschaften verfügen das 
Fortschreiten der Krankheit verfolgen zu können und damit auch die frühe Identifikation von 
Patienten mit erhöhtem Demenzrisiko zu ermöglichen.  
Ziel dieser Studie was es, mit Hilfe multi-modaler MRT Methoden einen Biomarker zur 
verlässlichen Unterscheidung von PD Patienten mit unterschiedlichen Graden an kognitiver 
Beeinträchtigung zu entwickeln und die pathologischen Muster, die mit erhöhtem 
Demenzrisiko in Verbindung stehen, zu identifizieren, da bisher noch kein verlässlicher 
Biomarker für PDD beschrieben wurde. Wir haben die Daten der funktionalen MRT 
Aufnahmen während des Ruhezustandes (resting-state) (rs-fMRI), die Diffusions-Tensor-
Bildgebungs Aufnahmen (DTI), die MR-Perfusionsbildgebungs Aufnahmen (ASL) und die MR-
Spektroskopischen Bildgebungs (MRSI) Aufnahmen von 20 PD-N, 20 PD-MCI und 20 PDD 
Patienten, die an der Neurologischen Abteilung der medizinischen Fakultät der Universität 
Istanbul betreut werden, untersucht. 
Die rs-fMRI Daten werteten wir mittels der “binary logistic regression / Binären 
logistischen Regressions” Methode aus und identifizierten die Kombination an Ruhezustands 
Netzwerken (resting-state networks, RSNs) im Gehirn der Patienten, die aufgrund des Grades 
ihrer Ausprägung im Vergleich mit den anderen Patintengruppen die höchste 
Unterscheidungsstärke zeigten. Dabei identifizierten wir fünf Netzwerke, die über signifikante 
Unterscheidungsstärke zwischen den Patientengruppen verfügten. Die zwei modulatorischen 
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Netzwerke, das „default mode network / Standartmodus Netzwerk“ (DMN) und das „salience 
network“ (SN), waren in der PDD Gruppe signifikant stärker ausgeprägt als in den nicht-
dementen Patienten, obwohl anzumerken ist, dass der Anstieg fließend von PD-N über PD-
MCI nach PDD verlief. Dem gegenüber, waren das frontostriatale Netzwerk (FSN), das 
posterior-temporale Netzwerk (PTN) und das limbische Netzwerk, welche wiederum mit 
exekutiven, Gedächtnis und visuell-räumlichen Störungen in Verbindung stehen, in der PDD 
Gruppe signifikant schwächer ausgeprägt als in den anderen Patientengruppen. 
Das DMN und das SN sind auf eine Weise funktional miteinander verbunden, in der 
das SN die Aktivität des DMN und des „zentralen exekutiven Netzwerkes / central executive 
network“ (CEN) in An- und Abwesenheit von hervorstechenden Stimuli reguliert. Das könnte 
ein Hinweis auf die Störung dieses Umschalte-Mechanismus in PDD Patienten sein, wobei 
andere Muster der Dysregulation dieser gleichen Netzwerke zuvor für andere Formen der 
Demenz beschrieben wurden. Die Voxel-basierte Analyse der RSNs erbrachte komplementäre 
Ergebnisse und diese deuten darauf hin, dass es zu pathologisch Veränderungen in 
Hauptzentren des SNs (Insula), dem limbischen Netzwerkes (Thalamus und Hippocampus) und 
dem FSNs (Caudat Nucleus/Putamen) in PDD Patienten kommt. 
Darüber hinaus war es uns möglich die Degeneration in weiten Teilen der weißen 
Substanz bei PDD Patienten nachzuweisen, die auf pathologischen Veränderungen in 
verschiednen Trakten der weißen Substanz beruhen und die wiederum mit den zuvor 
identifizierten RSNs in Verbindung stehen. Ergänzend lieferten die ASL und MRSI Methoden 
Ergebnisse über reduzierte Durchblutungsmuster und veränderte Metabolitkonzentrationen 
in Strukturen des Gehirns, die in grossen Teilen mit den Ergebnissen der identifizierten RSNs 
und den strukturellen Veränderungen in den Trakten der weißen Substanz übereinstimmten. 
Die signifikanten Ergebnisse der einzelnen MRT Modalitäten waren korreliert mit vielen der 
klinischen und neuropsychologischen Variablen über die gesamte Patientengruppe. 
In einem letzten Schritt prüften wir die Diskriminationsstärke der kombinierten 
signifikanten rs-fMRI, DTI und ASL Variablen, indem diese schrittweise in eine 
Diskriminanzanalyse gegeben wurden und das erhaltene Model, aus einer Kombination von 
RSNs und DTI Variablen, verfügte über 100% Sensitivität in der Unterscheidung von PDD und 
PD-N und 83.3% Sensitivität zwischen PDD und PD-MCI Patienten. 
Es war uns möglich progressive neuropathologische Veränderungen während 
unterschiedlicher kognitiver Stadien in PD mittels multi-modaler MRT Aufnahmen zu 
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identifizieren und sind der Auffassung, dass diese Veränderungen, nach Validation in einer 
größeren Studiengruppe, als möglicher Biomarker für PDD genutzt und aufgrund der 
einfachen Handhabung der MRT Messungen auch als diagnostisches Mittel im Klinik-Alltag 
eingesezt werden kann. Die Nutzung multi-modaler MRT Aufnahmen zur Diagnose und 
Kontrolle des Krankheitsverlaufs ermöglicht die frühzeitge Identifikation von PD Patienten mit 
erhöhtem Demenzrisiko und schafft somit die Grundlage für die optimale Behandlung mit dem 
Ziel der Verlangsamung der kognitiven Symptome und trägt somit zum wesentlichen Erhalt 
der Lebensqualität der Patienten bei. 
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1 INTRODUCTION 
“Some have regarded its characteristic symptoms as distinct and different diseases, and 
others have given its name to diseases differing essentially from it; whilst the unhappy 
sufferer has considered it as an evil, from the domination of which he had no prospect of 
escape.”- James Parkinson (1817) 
 
This statement is taken from James Parkinson’s “An assay of the shaking palsy” (1817), in 
which he is the first to describe the symptoms of the second most prevalent 
neurodegenerative disease of our time after Alzheimer’s disease (AD) and that was later 
named after him: Parkinson’s disease (PD). 
Besides the dominant motor symptoms of Parkinson’s disease, non-motor symptoms are 
increasingly recognized as part of PD and do not only cover features such as mood disorders, 
psychosis, sleep disturbances and autonomic dysfunction, but also mild to severe cognitive 
dysfunction. Studies showed, that mild cognitive impairment in Parkinson’s disease (PD-MCI) 
is frequent (20-50%) and may represent the earliest stage of cognitive decline in PD (Goldman 
and Litvan 2011). It was further shown, that during the course of the disease up to 80% of the 
PD cases developed dementia symptoms (Aarsland et al. 2003; Hely et al. 2008), hence PD-
MCI might be a major risk factor for the development of dementia in PD (PDD) (Goldman and 
Litvan 2011). Yet, the neuropathological counterparts of the cognitive dysfunctions and the 
conditions for the possible expression of PD-MCI and transition to PDD are unknown. 
Recently, the diagnosis of PD-MCI and PDD solely relies on the judgement of the clinicians, but 
reliable biological markers are needed for a clear diagnosis of PD-MCI and PDD, as it allows to 
identify PD patients with high dementia risk and offer individual treatment for those patients. 
As Magnetic Resonance Imaging (MRI) techniques are yet to be established as means for 
diagnosis and follow-up of cognitive decline in PD, the investigation of the cognitive 
dysfunctions in PD and the definition of a discriminative biomarker for PDD using multi-modal 
MRI measurements build the subject of this thesis. 
 
The definition of PD, the neurological basis of the motor symptoms in PD, the neuropathology 
and the cognitive deficits in PD will be briefly discussed in the following. 
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1.1 Parkinson`s Disease 
Above all, PD is a hypokinetic movement disorder defined by its characteristic motor 
symptoms of bradykinesia/akinesia, tremor at rest, rigidity, postural instability and gait 
impairment (UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria; Gibb and 
Lees, 1988; Hughes et al., 1992; Watts and Koller, 2004, p.233) most likely based on the 
degeneration of dopaminergic neurons in the substantia nigra, a part of the basal ganglia (BG). 
PD is known to affect men twice as much as women (Watts and Koller, 2004) and age is one 
of the most prominent risk factors for PD. In 50% of the cases the disease onset lays between 
50-60 years, and in 30% of the cases the disease starts after 60 years, while almost 10 % of 
the PD patients are under 40 years (Thümler, 2002). It is estimated that around 6-7 million 
people around the world are affected by PD, with a prevalence rate of 0.5-1% in population 
of industrial countries over 60 years of age, going up to 1-4% of the population at higher ages 
and with an incidence rate between 8-18 per 100,000 persons a year (de Lau and Breteler, 
2006; Pringsheim et al. 2014). Higher prevalence rates in Northern Europe and Northern 
America have been noticed compared to lowest prevalence rates in Southern Europe, Asia 
and Africa (Watts and Koller, 2004; Pringsheim et al. 2014). 
 
1.1.1 Types of PD 
With its unknown etiology (Watts and Koller, 2004, p.223), the idiopathic PD represents 
approximately 75-90% of the cases (de Lau and Breteler, 2006), is the most frequent type of 
all Parkinsonian Syndromes (PS) and covers among the akinetic-rigid type, the equivalent type, 
the tremor-predominant type of PD and also cases of mono-symptomatic resting tremor. 
Other than for general PS diagnosis, the diagnosis of PD requires at least two out of three 
characteristic symptoms, namely bradykinesia, tremor or rigidity. Additionally, the unilateral 
onset of symptoms and positive L-Dopa response are helpful criteria in the diagnosis of PD 
(Hughes et al. 1992). As postural instability is common in all forms of PS, it is not included in 
the main criteria for PD (Watts and Koller, 2004, p.233). However, final PD diagnosis can only 
be made after the patient’s death and brain dissection. 
The secondary form represents another group of PS and is mainly caused by drug intake, head 
trauma (Taylor et al., 1999), toxins like methanol, carbon monoxide and pesticides (Rajput et 
al., 1986; Tanner et al 1990) or by metabolic or vascular reasons such as encephalitis (Ogata 
et al., 1997). 
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The third group of PS is known as Parkinsonism-plus syndrome and covers besides multiple 
system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) 
and dementia with Lewy bodies (DLB). DLB represents a form of dementia with similar 
features to Alzheimer‘s disease and should not be mistaken for PD dementia (PDD), which will 
be described later. Finally, PS may also occur as the result of hereditary neurodegenerative 
diseases. 
For the sake of simplicity, the abbreviation PD will be used for idiopathic PD in this study. 
 
1.1.2 Clinical manifestations of PD 
One of the cardinal features present in most of the patients is the resting tremor. The tremor 
at rest is defined by involuntary rhythmic muscle contraction and relaxation, especially 
occurring in parts of the limbs such as fingers, hands, arms, and legs. However, eyes, face, 
head and trunk can also be affected. Intentional movement of the affected body parts can 
interrupt the tremor, and it disappears during sleep, while stress, excitement or situations 
with higher cognitive load can lead to an increase of the tremor (Watts and Koller, 2004, 
p.235). 
Bradykinesia and akinesia are early appearing symptoms in PD as well and describe the 
slowing or loss of spontaneous movements, the impairment of automatic movements and 
delayed motor initiation (start hesitation) as well as monotonic (dysphonia) and cluttered 
speech (dysarthria), writing disorders (micrographia) and mask-like face. 
As another cardinal feature of PD, rigidity describes the increased muscle tone leading to 
increased resistance of flexors and extensors resulting in inflected posture of the extremities 
and head. Postural instability and gait disturbances are common manifestations in the later 
phase of the disease. 
Typical for PD is the rule of asymmetric onset of the motor symptoms, which often become 
bilateral during the course of the disease and can be described using the Hoehn & Yahr Scale 
(Hoehn and Yahr, 1967). 
 
1.1.3 Possible causes of PD 
Although the etiology of the idiopathic PD is still unknown, it is speculated that the interplay 
of genetic predisposition, environmental factors and/or disorders of the mitochondrial 
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oxidative metabolism may lead to the main pathological findings in PD (Watts and Koller, 
2004). 
What we already know is, that the degeneration of dopamine (DA) producing cells in the 
pigmented region of the substantia nigra pars compacta (SNpc) leads to a neurobiochemical 
imbalance and the degeneration of the nigrostriatal pathways, thereby causing the motor 
symptoms in idiopathic PD. 
PD is a slowly progressing disease and the motor signs usually become obvious only after the 
degeneration of about 80 % of the DA producing cells in the SNpc (Watts and Koller, 2004). 
As the tyrosin hydroxylase (TH) is highly specific for the cells in the SNpc and catalyzes the 
conversion of L-Tyrosin to L-Dopa, TH plays an essential and rate-limiting role for the DA 
synthesis and DA concentration in the related brain regions (Watts and Koller, 2004) 
Main steps of DA synthesis are: 
 
L-Tyrosin 
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝐻𝐻𝑇𝑇𝐻𝐻𝑇𝑇𝑇𝑇𝐻𝐻𝑇𝑇𝐻𝐻𝐻𝐻𝑇𝑇𝐻𝐻
�⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯�L-Dopa (L-3,4-dihydroxyphenylalanine)
𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷−𝐻𝐻𝐻𝐻𝑑𝑑𝐻𝐻𝑇𝑇𝑑𝑑𝑇𝑇𝐻𝐻𝑇𝑇𝐻𝐻𝐻𝐻𝑇𝑇𝐻𝐻
�⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯� 𝐷𝐷𝐷𝐷. 
 
1.1.4 Neuropathology of PD 
1.1.4.1 Pathophysiology of basal ganglia in PD 
As the dysfunction of the basal ganglia is thought to be the main cause of the motor symptoms 
in idiopathic PD, the pathophysiology of the BG in PD will be discussed shortly in the following. 
The basal ganglia are part of the motor system located in the telencephalon of the human 
brain. They are composed of structures such as the striatum (putamen and caudate nucleus), 
the pallidum (globus pallidus interna (GPi) and externa (GPe)), the substantia nigra (SN pars 
reticulata and SN pars compacta) and the subthalamic nucleus (STN). The various structures 
of the BG are subdivided into several functional territories such as oculomotor, skeletomotor, 
associative and limbic divisions depending on their physiological properties and cortical and 
thalamic connections (Watts and Koller, 2004; Alexander et al., 1990) that form parallel 
organized loops reentering the cortical areas (Watts and Koller, 2004). By large, they are 
involved in the processing and the control of the planned actions or movement sequences and 
modulate planned actions of cortical areas by modulating thalamic input to the cortex (Watts 
and Koller, 2004). The different nuclei of the BG are heavily interconnected, but less 
connections exist among the discrete functional loops. 
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The majority of the BG neurons possess GABA (gamma-aminobutyric acid) as the main 
transmitter and thus have inhibitory effects on target neurons. Striatal neurons inhibit the 
discharge of neurons of the SN pars reticulata (SNpr) which in turn leads via disinhibition to 
an activation or increase of firing rates of the postsynaptic cells of the SN such as those in the 
thalamus. Different striatal neurons carry DA receptors (D1, D2,) thus DA release of the SNpc 
acts excitatory on GABAergic striatal neurons bearing D1-receptors and inhibitory on those 
bearing D2-receptors (Kandel et al., 2000). 
 
The BG are characterized by two different pathways. In the direct pathway, the striatum which 
receives transient excitatory inputs from the cortex and SNpc, sends direct GABAergic 
efferents to the GPi/SNpr, which send tonic inhibitory GABAergic output to the thalamus. 
Hence, with the increased activity in the direct pathway the disinhibited thalamus, which has 
glutamatergic excitatory projections to the cortex, increases the excitability of the cortex 
(Figure 1-1). The other large part of information leaves the BG by the indirect pathway. The 
indirect pathway takes its origin from the GABAergic neurons of the striatum that receive 
inhibitory input from SNpc through D2 receptors and project to GPe. In two arms of the 
indirect pathway the GABAergic GPe neurons either send efferents to the GABAergic GPi cells 
or to the neurons of the subthalamic nucleus, which receive a strong excitatory input from the 
cortex and send excitatory glutamatergic efferents to the GPi. Both arms of the indirect 
pathway oppose the disinhibitory effect of the direct pathway and lead to decreased thalamo-
cortical activations (Figure 1-1) (Kandel et al., 2000, Watts and Koller, 2004). 
 
The dopamine signal of the SNpc triggers the different processing pathways in the BG by 
differential activation of the D1 or D2 receptors on the striatal neurons and modulates the 
response of the thalamic nuclei, which in turn indirectly affect cortical motor activities. The 
BG are involved during learning and/or adaptation of tasks, and in the initiation and execution 
of movements via feedback loops to the cortex, but the exact role of the BG during this process 
still needs further clarification (Watts and Koller, 2004). 
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Figure 1-1: Simplified diagram of the two pathways of basal ganglia circuit. 
SNc: SN pars compacta, SNr: SN pars reticulate, STN: Subthalamic nucleus. 
 
 
 
Figure 1-2: Simplified diagram of the two pathways of basal ganglia circuit as it is thought to be disturbed in 
Parkinson`s Disease. Dashed lines display the DA depletion based activation imbalance of the two pathways. SNc: 
SN pars compacta, SNr: SN pars reticulate, STN: Subthalamic nucleus. 
 
Most of the common described movement disorders are due to a disruption of the activation 
balance of the direct and indirect pathways in the BG (Watts and Koller, 2004). Hyperkinetic 
disorders are thought to be based on the shift of the activation balance towards the direct 
pathway leading to reduced inhibitory BG output to the thalamus. In contrast to hyperkinetic 
diseases such as Chorea, Ballismus and Dystonia, Parkinson’s disease is a typical hypokinetic 
movement disorder (Watts and Koller, 2004). Hypokinetic diseases may arise from a stronger 
activation of the indirect pathway leading to an increase of the inhibitory BG output to the 
thalamus and thereby leading to increased inhibition of the thalamo-cortical neurons. In PD, 
the degeneration of the nigrostriatal pathway due to the degeneration of DA producing cells 
in the SNpc is thought to lead to differential changes in the striatopallidal projections resulting 
in increased inhibitory BG output to the thalamus (Figure 1-2). 
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Although, several drug therapies are available against the motor symptoms of PD in order to 
enhance the patient’s daily living conditions, for example by means of the substitution 
treatment with L-Dopa, not many therapy options exist against the second group of 
symptoms, namely the cognitive and behavioral impairments. 
 
1.1.4.2 Synucleinopathies 
Besides the pallor of the SNpc, histological studies revealed the presence of Lewy Bodies (LB) 
and Lewy neurites (LN) in different regions of the brain in PD (Braak et al. 2003; Chung et al. 
2001; Dickson 2012; Forno 1996; Hughes et al. 1992; McCann et al. 2014). LBs are eosinophilic 
cytoplasmatic inclusions mostly composed of aggregated alpha-synuclein, ubiquitin and other 
proteins and were first described by Friedrich H. Lewy in the 1910s. The abnormal 
accumulation of alpha-synuclein in neurons, nerve fibers or glial cells is one main 
characteristic of the so-called alpha-synucleinopathies (McCann et al. 2014). Other members 
of the alpha-synucleinopathies are dementia with Lewy Bodies (DLB) and Multiple System 
Atrophy (MSA). Braak and colleagues (2003) were able to show that the distribution of the LB 
pathology related with PD seems to evolve from brainstem towards limbic areas, forebrain 
and the cortex and that these phases can be staged from 1-6 (Braak et al. 2002; Braak et al. 
2003; Lin and Wu 2015). 
 
1.2 Cognitive symptoms in PD 
A spectrum of cognitive dysfunctions, ranging from mild cognitive impairment (MCI) to 
dementia have been described in PD (Litvan et al. 2012). Mild cognitive impairment in 
Parkinson’s disease (PD-MCI) has been increasingly recognized as a distinct entity in PD, and 
studies suggest that PD-MCI may represent the earliest stage of cognitive decline and might 
be a main risk factor for developing dementia in PD (PDD) (Goldman and Litvan, 2011). Hence, 
PD-MCI may represent an intermediate state between normal cognition (PD-N) and PDD 
(Goldman and Litvan, 2011). PD-MCI appears to be common even at the time of PD diagnosis 
and prior to initiation of dopaminergic therapy (Muslimovic et al., 2005; Litvan et al. 2011). 
Litvan and colleagues (2011) report that about 26.7% of non-demented PD patients have PD-
MCI and that PD-MCI predicts the development of dementia, which can occur in up to 80% of 
PD patients over the long term (Aarsland et al. 2003; Litvan et al. 2012). 
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1.2.1 Clinical definition and diagnosis of PD-MCI 
Several criteria for the definition of MCI were proposed by Petersen et al. (2004, 2006 and 
2009), the National Institute on Aging and the Alzheimer’s Association MCI criteria committee 
(Albert et al., 2011) and the DSM-5 Neurocognitive Disorders Work Group (Jeste et al., 2010; 
Ganguli et al., 2011). MCI is mainly characterized by subjective cognitive complaint and 
evidence of cognitive abnormalities unusual for age but with no/only minimal effect on daily 
function (Petersen et al., 2004). 
In order to characterize MCI associated with PD and identify possible predictors for the 
conversion to dementia, the Movement Disorder Society (MDS) Task Force proposed criteria 
for PD-MCI that include the characterization of the clinical syndrome and methods for PD-MCI 
diagnosis (Litvan et al., 2012). The criteria were developed comparable to the PDD criteria 
earlier proposed by Dubois et al. (2007) and Emre et al. (2007), and offer a two-level 
assessment scheme for the diagnosis of PD-MCI (Litvan et al., 2012). 
Level I (abbreviated assessment) criteria allow for the diagnosis of PD-MCI based on the 
validation of global cognitive abilities and/or the use of only a limited battery of 
neuropsychological tests. That means, in order to be diagnosed as PD-MCI, the patient has to 
show impairment on minimum two tests when (a) less than two tests within each of the five 
cognitive domains are carried out or (b) when less than five cognitive domains are tested 
(Litvan et al., 2012). Complementary, the Level II (comprehensive assessment) criteria allow 
for the additional sub-typing of PD-MCI using comprehensive neuropsychological tests 
including at least two tests for each of the five cognitive domains (attention and working 
memory, executive functions, language, memory, and visuospatial functions). Impaired 
performance on at least two tests, representing either one single cognitive domain or in 
different cognitive domains are required for PD-MCI diagnosis according Level II criteria 
(Litvan et al., 2012). 
 
Regarding the affected cognitive domain, subtypes of PD-MCI have been formulated. There is 
a huge heterogeneity among these sub-types and while according to Litvan et al. (2011) and 
Yarnall et al. (2013) the non-amnestic single-domain type seems to be the most common 
subtype, others report about frequent multiple domain impairment with predominant deficits 
in executive function, memory, and visuospatial function (Goldman et al. 2013; Lawrence, 
Gasson, and Loftus 2016). Another subtype is the amnestic domain subtype. 
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Memory, executive functions and visuo-spatial functions are often reported to be affected in 
PD-MCI patients (Janvin et al., 2006; Watson et al., 2010; Litvan et al., 2012) with manifested 
symptoms such as multi-tasking and planning difficulties, slowing of information processing 
speed, attention and concentration difficulties, memory impairments and word-finding 
difficulties (Goldman and Litvan, 2011). 
 
1.2.1.1 Executive dysfunction 
Performance deficits of non-demented PD patients in tasks related with executive functions 
have been reported. Among these tasks were tests examining divided attention (trail making 
test B), response inhibition (Stroop test), working memory (Digit Span Reverse) and mental 
flexibility (Wisconsin Card Sorting Test) (Bohnen et al., 2006, de Frias et al., 2007, Fama et al., 
2000, Grace et al., 2005, Janvin et al., 2006, Lima et al., 2008, Muslimovic et al., 2008, Siegert 
et al., 2008, Watson et al., 2010). Dysfunction of the prefrontal cortex may cause the 
performance deficits in the executive domain, as the pre-frontal cortex allows the subject to 
pay attention to one event and exclude others and to switch among them (Watson et al., 
2010). 
 
1.2.1.2 Visuo-spatial dysfunction 
On the other hand, visuo-spatial deficits have been reported to develop throughout the course 
of the disease. Visuo-spatial functions cover pattern recognition (facial recognition), 
constructional abilities (figure drawing), color recognition (color naming) and spatial analysis 
(ability to identify multiple objects in a visual field) which are necessary for the processing of 
visual information (Watson et al., 2010). Dysfunction of parietal areas including the parietal, 
occipital and temporal lobes have been associated with deficits in visual-spatial skill (Watson 
et al., 2010). A widely used neuropsychological tool for the investigation of visuo-spatial 
abilities of patients is the Benton Judgment of Line Orientation test (JOLO) (Benton et al., 
1978). Beyond poor performance in the JOLO (Janvin et al., 2006, Martin et al., 2009, 
Muslimovic et al., 2007, Uc et al., 2006), facial recognition and form-discrimination (Pereira et 
al., 2009) and block construction (Goldman et al., 1998, Uc et al., 2006) abilities have been 
reported to be disturbed in PD patients even without dementia symptoms. Gullet and co-
workers (2013) demonstrated right parietal, occipital as well as bilateral frontal activation in 
the JOLO test during functional MRI, and PD is known to adversely affect these pathways. 
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1.2.2 Clinical definition and diagnosis of PDD 
Dementia is common in PD, and the systematic review of Aarsland et al. 2005 showed a 24-
31% prevalence of PDD in PD. PDD represents 3-4 % of all dementia cases in the population. 
Dementia incidence is 6 times higher in PD compared to normal population (Emre et al., 2007) 
and in the 10-year follow-up study of Williams-Gray et al. (2013) the authors report about a 
dementia incidence rate of 54.7 per 1000 person over the years. 
PDD is characterized by a gradually intensifying cognitive loss affecting domains of attention, 
executive and visuospatial functions as well as memory, with relatively preserved core 
language functions, while a dysexecutive profile seems do dominate the cognitive 
characteristics (Emre et al. 2007). 
 
The MDS Task Force proposed criteria for the clinical diagnosis of dementia in PD, and one of 
the core features for PDD is the previous diagnosis of idiopathic PD and the onset of dementia 
symptoms after established PD (Emre et al., 2007). Furthermore, dysfunction in more than 
one of four cognitive domains (attention, executive function, memory and visuo-spatial 
function) must be present and severe enough to affect daily living activities independent from 
motor dysfunction. The presence of at least one behavioral feature such as personality 
change, apathy, hallucination or delusion support the PDD diagnosis (Emre et al., 2007). 
PDD and Dementia with Lewy Bodies (DLB) are both Lewy Body Dementias, share clinical and 
pathological features and therefore should not be confused. PDD and DLB are mostly 
differentiated by their time-course, such that PDD is diagnosed when dementia symptoms 
follow well established PD motor symptoms, while DLB is characterized by dementia 
symptoms appearing prior to the onset of motor symptoms or developing within one year 
after the motor symptoms. This discrimination is also known as the 1-year rule. 
 
1.2.3 Proposed risk factors of PDD 
Known risk factors for the development of PDD beyond PD-MCI (Goldman and Litvan, 2011; 
Galtier, Nieto, Lorenzo, & Barroso, 2016) are old age at disease onset, long disease duration, 
the severity and symmetry of motor symptoms, the dominant axial symptoms, autonomic 
symptoms appearing at an early stage and the early development of confusions and 
hallucinations (Emre et al., 2007; Hanagasi, Tufekcioglu, & Emre, 2017). The poor response to 
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dopaminergic treatment, excessive day-time sleepiness and REM sleep behavior disorder are 
also associated with higher dementia risk in PD (Hanagasi, Tufekcioglu, & Emre, 2017). The 
non-tremor phenotype, low performance in the semantic verbal fluency test and difficulties 
in copying the intersecting pentagon figures are also related with higher dementia risk 
(Williams-Gray et al., 2007 and 2009). 
 
However, there are controversial results regarding different cognitive profiles and their 
dementia risks, such that Dubois et al. (2007), Emre et al. (2007) and Hanagasi et al. (2017) 
report about PDD risk associated with frontal-striatal dysfunction, while Williams-Gray et al. 
(2007 and 2009) found association between dementia risk and more posterior cortically based 
and visuo-spatial dysfunction, suggesting there might be distinct cognitive syndromes with 
different PDD prognosis (Litvan et al. 2012). Anyway, PDD is characterized by a dysexecutive 
cognitive profile displaying impairment in planning, abstract thinking and mental flexibility as 
a result of deficits in attention and visuo-spatial functions and moderately impaired episodic 
memory, while the core language functions are relatively preserved (Emre et al., 2007; 
Hanagasi, Tufekcioglu, & Emre, 2017). Impaired attention may not only affect daily living but 
also influence the patient’s abilities in the other cognitive domains, hence poor memory or 
executive test performance may rely on attentional deficits. The dysexecutive profile in PDD 
is commonly accompanied by behavioral symptoms such as apathy and psychosis. 
 
1.3 Need for a reliable discriminative biomarker for cognitive decline in PD 
Although diagnostic criteria for cognitive decline have been developed in the recent years 
(Litvan et al., 2012; Emre et al., 2007), the diagnosis of PD-MCI or PDD is still only based on 
the judgment of a clinician, and there are no reliable biomarkers for the identification of 
patients with high dementia risk. Besides the Unified Parkinson's Disease Rating Scale 
(UPDRS), which is one of the most common tools to scale the Parkinson’s disease status in 
clinical environment by interview and clinical observation, neuropsychological tests (NPTs) 
such as the Mini Mental State Examination (MMSE), Montreal-Cognitive Assessment (MOCA) 
and Addenbrooke's Cognitive Examination - Revised (ACE-R) have been established as 
sensitive and specific cognitive screening instruments for early cognitive dysfunction by 
covering cognitive domains such as orientation/attention, memory, verbal fluency, language 
and visuo-spatial abilities (Mioshi et al., 2006). But, the diagnosis according to these criteria 
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happens to be a result of arbitrary stated standard deviations of neuropsychological test 
scores which don’t allow for a reliable biomarker for the different stages of cognitive decline 
in PD. Additionally, a study on the normalization of ACE-R for Turkish population showed that 
the scores are more robust and discriminative for the higher-educated people, while their 
correlation with detailed neuropsychological test results decreases with decreasing 
educational years (Uysal Cantürk, 2013), which emphasizes the importance to develop a 
biology-based reliable and easily applicable marker for the evaluation of patient’s cognitive 
state. On the other hand, as PD-MCI and PDD cover a heterogeneous spectrum of cognitive 
dysfunctions, it is not well understood, whether these cognitive conditions display different 
severity states during disease progression or they may represent different pathological 
patterns. As the high conversion rate from PD-MCI to PDD (Litvan et al., 2011 and 2012) may 
point to a continuous course of the same patho-physiological background, it is important to 
identify the clinical and pathological characteristics of the cognitive impairment in PD and 
identify their pattern predictive for the conversion from PD-MCI to PDD. 
Frontostriatal executive dysfunction and dementia in PD have been reported as cognitive 
correlates of sequentially occurring pathological changes, namely Lewy body deposition in the 
nigrostriatal system during the early stages of the disease followed by pathological changes 
within the cortex occurring in later stages of the disease (Braak et al., 2002). These findings 
led to the assumption that executive dysfunction evolves into dementia and thus has been 
described as key feature in PDD (Dubois and Pillon, 1996; Emre et al., 2007). However, 
Williams-Gray and co-workers (2007 and 2009) described two types of cognitive dysfunction 
in the early stages of the disease, which differ in terms of their prognosis by performing a 
longitudinal investigation of Parkinson’s disease patients. They showed that frontostriatal 
executive deficits were common in early disease stages, but did not appear to evolve into 
dementia over 3.5 years of follow-up, whereas the more posterior cortex-based deficits did 
(Williams-Gray et al., 2007). 
In addition, they also mentioned a genetic impact on the cognitive deficits, such as the 
involvement of functional polymorphism in the catechol-O-methyltransferase gene (COMT, 
Val158Met) onto performance and frontal activation in executive tasks, while the inverted 
genomic region containing the microtubule-associated protein tau gene (MAPT, H1 haplotype) 
was strongly associated with dementia risk over 3.5 years in the follow-up (Goris et al., 2007; 
Williams-Gray et al., 2009). 
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Because different sub-types with significantly different prognoses seem to be correlated with 
neurobiological changes in various anatomic structures and molecular mechanisms, it gets 
important to follow the underlying neuropathological changes along the progression of the 
disease leading to the cognitive deficits with methods that have anatomical localization 
capability in line with their sensitivity to changes in neural activations and metabolic and 
molecular changes in the brain tissue. Therefore, the combined use of a set of MRI-based 
neuroimaging modalities that reflect such changes with a high spatial resolution seems to be 
a plausible approach for deriving a reliable biomarker for the various subtypes of cognitive 
impairments in PD patients. 
Identifying a progressive pathological pattern related to the cognitive decline would not only 
help to identify those PD patients at high risk of progressive cognitive decline and developing 
dementia, but also those who may benefit from early clinical interventions at a pre-dementia 
state (Litvan et al., 2012). Early interventions are especially important for the patients in order 
to maintain the patient’s life quality and delaying the worsening of the impairments. 
 
Some structural, functional and metabolic MRI studies attempt to describe specific markers 
for cognitive decline in PD and PD-MCI and for their transition towards PDD. But no consistent 
reliable MRI-based biomarker for PD-MCI nor PDD have been described so far. A brief 
overview about the recent literature addressing these questions will be given in the following 
sections. 
 
1.4 Literature Review of MRI Related Findings of Cognitive Decline in PD 
The MRI research describing cognitive decline in PD can be generally classified as studies based 
on functional, structural, metabolic and perfusion imaging techniques. Most of the MRI 
studies investigated changes related with PD-MCI, while there are a limited number of studies 
investigating PDD. The majority of the PDD related MRI studies have been volumetric studies 
using the voxel-based morphometry method for the quantification of brain atrophy. However, 
these studies lack detailed information about the functional changes leading to PDD. 
Some of the most important MR-based findings for cognitive decline in PD and the basics of 
these techniques are presented in the following. 
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1.4.1 Functional MRI 
Functional MRI (fMRI) studies generally rely on the blood oxygenation level dependent (BOLD) 
signal, which is based on the different magnetic effects of oxy- and deoxy-hemoglobin on the 
dephasing period of the resonating proton spins in the tissue. As deoxy-hemoglobin increases 
the speed of the dephasing, its increased level in the capillaries and vessels around neuronal 
populations of increased activity leads to a faster decrease of the MRI signal, while the relative 
increase of the oxy-hemoglobin in a region produces the opposite effect. This contrast 
produces the BOLD signal as a measure of the hemodynamic changes due to neurovascular 
coupling in brain tissue: The increased metabolic activity of the neural populations leading to 
increasing oxygen consumption initially creates a small decrease in the MRI signal, the initial 
dip, which is replaced by a large increase due to the vascular response, hence increase in oxy-
hemoglobin, peaking around 8 s after the increase of the neural activity lasting almost 20 s to 
return to the initial level. 
Functional MRI works can be generally separated into task-based functional MRI (task-fMRI) 
and resting state functional MRI (rs-fMRI) studies. 
In the task-fMRI technique, activation maps are estimated, based on BOLD signal changes in 
the brain of a person performing a given task in contrast to a baseline condition. In contrast, 
rs-fMRI is based on measurement of low-frequency ‘intrinsic’ fluctuations in MRI signals while 
the brain is at rest (Fox and Raichle, 2007; Smith et al., 2012). 
The functional brain connectivity is defined in terms of the covariance of BOLD fluctuations 
received from various locations of the brain (Biswal et al., 1995). While they can be computed 
based on activation areas in task-fMRI data, the presence of intrinsic BOLD fluctuations during 
‘rest’ also allows to estimate temporal correlations or coherences among various brain areas 
in rs-fMRI data. Brain regions showing coherent fluctuations in rs-fMRI constitute the resting 
state networks (RSNs). 
While seed-based functional connectivity analyses build a hypothesis-driven framework, a 
blind separation method based on the spatial or temporal independence of decomposed 
components of a compound data based solely on a mathematical constraint, the Independent 
Component Analysis (ICA), also provided similar, reproducible RSN patterns from rs-fMRI data. 
One very important property of this approach is that it is a data-driven approach, which does 
not rely on or require any hypothesis-based initial seed regions, which makes it prone to any 
subjective decisions about the nodes of an RSN. 
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Notably, the spatial topography of the RSNs resemble brain regions that are active during a 
variety of cognitive, motor and sensory tasks in task-fMRI studies (Smyser et al., 2013). While 
most of the RSNs are task-positive, increasing their intrinsic connectivity during specific tasks, 
the default mode network (DMN) shows increased intrinsic connectivity during rest (Raichle 
2015). 
 
Baggio et al. (2014) investigated the functional connectivity of the resting state networks in 
PD, PD-MCI and healthy subjects and found reduced long range connectivity and higher local 
inter-connectivity for PD-MCI. In another study of Baggio et al. (2015), the authors found 
reduced connectivity between the dorsal attention network (DAN) and right fronto-insular 
areas, while there was increased connectivity of the DMN with the medial and lateral occipital-
parietal areas. The data further revealed reduced within-DAN, within-DMN and DAN-FPN 
(dorsal attention network-frontoparietal network) connectivity, as well as loss of normal DAN-
DMN anticorrelation in PD-MCI patients (Baggio et al., 2015). 
Amboni et al. (2015) in contrast showed lower DMN connections in both PD and PD-MCI, while 
PD-MCI additionally showed decreased bilateral prefrontal cortex connections in FPN. In a 
combined rs-fMRI and SPECT study by Lebedev and colleagues (2014) the resting state fMRI 
correlates of cognitive impairment in PD and the impact of dopamine deficiency on these 
networks were investigated and better executive performance was associated with increased 
dorsal fronto-parietal cortical processing and inhibited subcortical and primary sensory 
involvement, while better memory performance correlated with increased prefronto-limbic 
processing (Lebedev et al., 2014). 
 
Decreased connectivity in the medial and middle orbitofrontal cortex and the occipital lobe, 
but increased connectivity in the superior parietal cortex, posterior cingulate gyrus, 
supramarginal gyrus and supplementary motor area were detected for PD patients compared 
to controls (Goettlich et al., 2013) as well as decreased functional connectivity of the right 
medial temporal lobe and bilateral inferior parietal cortex within the DMN in PD compared to 
healthy subjects (HS) (Tessitore et al., 2012). Furthermore, Rektorova (2012) showed 
decreased connectivity in right frontal gyrus and bilateral inferior occipital gyrus in PDD 
compared with PD and controls. 
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Corticostriatal functional connectivity was disrupted in PDD compared to PD and healthy 
subjects in a study by Seibert et al. (2012), especially between the prefrontal cortex and 
caudate. 
 
In short, there are varying results reported on the DMN connectivity patterns, one of the 
mostly investigated RSNs in cognitive disorders, while the task-positive networks have been 
reported in general to reduce their functional connectivity with decreasing cognitive 
performance. 
There are also several task-based fMRI studies on PD, PD-MCI and PDD, however, they will not 
be introduced here in detail as they are out of the scope of the present study. 
 
1.4.2 Structural MRI 
1.4.2.1 Diffusion Tensor Imaging - DTI 
Diffusion tensor imaging (DTI) is an MRI technique enabling to produce neural tract images 
based on the measurement of the restricted diffusion of water in tissue (Mukherjee et al., 
2008). The DTI related measurements are the fractional anisotropy (FA), mean diffusivity 
(MD), radial diffusivity (RD) and axial diffusivity (AD). Changes in these measurements can 
relate to biological changes in the neural tissue. FA is used as a measure of microstructural 
integrity and density of the neuronal tracts, and decreases with axonal loss and demyelination 
as the diffusion of water in the intercellular space would decrease the anisotropy of diffusion 
(Feldman et al, 2010). The degree of displacement of the water molecules in the neurons is 
characterized by the MD given in micrometers per millisecond (μm/ms) and is an inverse 
marker for cell-membrane density (Feldman et al, 2010). MD increases along demyelination 
processes and neural degeneration. RD on the other hand also increases together with 
demyelination and changes in axonal diameters. Lastly, the AD represents the direction of 
diffusion that is parallel to the white matter (WM) tract and decreases with axonal injury but 
is also known to increase during maturation (Feldman et al., 2010). 
 
Chen et al. (2015) investigated the anatomical and functional changes related to PDD in a 
combined DTI and fMRI study and found that PDD is associated with reduced functional 
connectivity between the right posterior cingulate cortex (PCC) and medial temporal lobe as 
well as microstructural damage of the left hippocampus. Agosta et al. (2014) found 
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abnormalities in the anterior and superior corona radiata, genu and body of corpus callosum, 
anterior inferior fronto-occipital, uncinate and superior longitudinal fascicules of PD-MCI 
patients compared with PD and healthy controls. Deng et al. (2012) additionally detected 
changes in the left frontal/right temporal white matter and bilateral anterior cingulum 
bundles of PD-MCI patients by comparison with controls. Melzer et al. (2013) aimed to 
characterize the different cognitive states in PD and identified decreased factional anisotropy 
(FA) and increased mean diffusivity (MD) levels in PD-MCI and PDD compared to controls. 
Significantly lower FA values in PDD patients in many major tracts compared to control 
subjects as well as significantly lower FA values at the prefrontal white matter and the genu 
of the corpus callosum as compared to PD patients have been described by Kamagata et al. 
(2013). Furthermore, there was a significant correlation between the Mini-Mental State 
Examination (MMSE) scores and the FA values of the prefrontal white matter and the genu of 
the corpus callosum in patients with PD from which they conclude a relationship between 
cognitive impairment and alteration of the prefrontal white matter and genu of the corpus 
callosum (Kamagata et al., 2013). Lee (2010) compared DTI data of PDD and Lewy body 
dementia (LBD) patients and found lower diffusivity in posterior temporal, posterior cingulate 
and visual association fibers of PDD patients. Hattori et al. (2012) detected a widespread lower 
fractional anisotropy (FA) in superior longitudinal fascicule, anterior limb of the internal 
capsule, and inferior longitudinal fascicule of PDD patients, by comparison with controls and 
further suggest that white matter damage underlies cognitive impairment in PD, and cognitive 
impairment in PD progresses with functional alteration (hypoperfusion) followed by structural 
alterations in which white matter alteration precedes gray matter atrophy. 
 
1.4.2.2 Anatomical changes – Atrophy and White Matter Hyperintensities 
Morales et al. (2013) found different cerebral white matter values and volumes of the lateral 
ventricles and hippocampi for the PD-cognitively intact, PD-MCI and PDD groups and defined 
these as the most predictive neuroanatomical findings to distinguish between these groups. 
The hippocampal volume and white matter hyperintensity as a major factor predicting the 
development of mild cognitive impairment and dementia in PD has also been described by 
Kandiah et al. (2014). 
Furthermore, Rektorova et al. (2014) reported that gray matter changes in PDD involve areas 
associated with Alzheimer-like pathology while fronto-parietal abnormalities are possibly an 
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early marker of PD cognitive decline and mentioned these findings are consistent with a non-
linear cognitive progression in PD. These findings are supported by an earlier study of Mak et 
al. (2013) who found that domain specific cognitive impairment in mild PD is associated with 
distinct areas of gray matter atrophy and that these regions of atrophy are early in the disease 
course and may serve as a biomarker for dementia in PD. 
In a study by Compta et al. (2013) thinner superior-frontal/anterior cingulate and precentral 
regions were found to be baseline predictors for PDD. 
In a combined (18F-fluorodeoxyglucose, FDG) positron emission tomography (PET) and MRI 
study from Gonzales-Redendo and colleagues (2014) investigating the extension and 
topographical distribution of hypometabolism and atrophy in the different cognitive states of 
PD they found hypometabolism exceeded atrophy in the angular gyrus, occipital, orbital and 
anterior frontal lobes in PD-MCI and that in patients with dementia, the hypometabolic areas 
observed in PD-MCI were replaced by areas of atrophy, which were surrounded by extensive 
zones of hypometabolism. They conclude that there is a gradient of severity in cortical changes 
associated with the development of cognitive impairment in Parkinson’s disease in which 
hypometabolism and atrophy represent consecutive stages of the same process in most of the 
cortical regions affected (Gonzales-Redendo et al., 2014). 
In a study by Lee and colleagues (2013) PD-MCI patients were prospectively followed-up for a 
minimum of 2 years, and showed that atrophy in the frontostriatal areas and cholinergic 
structures, as well as frontal lobe associated cognitive performance, may act as predictors of 
dementia in PD-MCI patients, suggesting distinctive patterns of cognitive profiles and a 
neuroanatomical basis for progressive PD-MCI (Lee et al., 2013). Shin et al. (2012) 
demonstrated that the burden of white matter hyperintensities (WMH) within cholinergic 
pathways was significantly higher in patients with PDD relative to other groups, and that 
cholinergic WMH was significantly correlated with a decline in frontal executive function and 
attention. Sunwoo and colleagues (2014) were able to reproduce the findings of Shin et al. 
(2012) as PD and PD-MCI patients were prospectively followed-up for 2 years and 
demonstrated that the WMH burden is a significant predictor of conversion from PD-MCI to 
PD dementia and its relation to ongoing decline in frontal-lobe-based cognitive performance. 
Based on the structural MRI findings, the neuroimaging data provides a relatively high 
sensitivity as well as specificity for cognitive impairment and prediction of dementia compared 
with neuropsychological test (NPT) scores. 
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1.4.3 Metabolic Neuroimaging Techniques and Magnetic Resonance Spectroscopic 
Imaging (MRSI) 
Diverse neuroimaging modalities can investigate the metabolic changes in the brain and have 
been quantified for the different cognitive conditions in PD (Duncan et al., 2013). 
Hypometabolism, amyloid-load and dopaminergic as well as cholinergic dysfunctions are the 
most described metabolic findings for cognitively impaired PD patients. 
Thus, PD-MCI related hypometabolism in posterior and prefrontal cortical areas were 
described in several studies (Lyoo et al., 2010; Silbert and Kaye 2010; Bohnen et al., 2011). For 
both, PD-MCI and early stage PDD, increasing amyloid load in posterior cortical areas were 
identified (Hilker et al., 2005, Bohnen et al., 2006; Pappata et al., 2011), and widespread 
dopaminergic and cholinergic dysfunctions have been reported (Wolk et al., 2009; Silbert and 
Kaye 2010). When compared to cognitively unimpaired PD patients Positron Emission 
Tomography (PET) studies show the presence of parietal, temporal and occipital 
hypoperfusion in PD-MCI (Nobili et al., 2009). Hypometabolism was shown in prefrontal and 
parietal areas in PD-MCI (Huang et al., 2008), and in bilateral posterior parietal lobe and right 
occipital lobe in PD-MCI by comparison with controls (Nobili et al., 2011). Studies using Single 
Photon Emission Computed Tomography (SPECT) technique revealed low cerebral blood flow 
(CBF) values, as well as minor and diffuse hypoperfusion focus in frontal and temporoparietal 
lobes in PDD (Derejko et al., 2001). 
 
1.4.3.1 Magnetic Resonance Spectroscopic Imaging – MRSI 
Proton MR spectroscopic imaging (1H-MRSI) is a noninvasive, ionizing radiation free MRI 
technique that provides information about the metabolic changes in the brain. Similar to MRI, 
MRSI uses signals from the hydrogen proton, but it uses the signal to determine the relative 
concentrations of the target brain metabolites in a specific brain volume (Castillo et al., 1996). 
The technique is based on the principle that protons in different molecular structures resonate 
in different frequencies due to chemical shifts, depending on the magnetic field generated in 
the opposing direction to the magnetic field created by the electron cloud around protons. 
There are four important metabolites reflecting the neurodegenerative processes, the 
N-acetylaspartate (NAA), choline (Cho), glutamine/glutamate complex (Glx) and myo-inositol 
(mI) (Nie et al., 2013; Pagonabarraga et al., 2013). While the NAA is thought to represent a 
neural marker and mI a glial marker indicating demyelination, Cho is a marker for both 
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neurons and glia cells. Creatine (Cr) on the other hand is used as reference value, as it is known 
to be more stable in the tissue. 
 
Pagonabarraga et al. (2012) investigated the 1H-MRSI features of PD, PD-MCI and PDD in 
comparison to controls and found decreased N-acetylaspartate (NAA) concentrations in the 
right dorso-lateral pre-frontal cortex (DL-PFC) in PD-MCI compared with PD patients 
correlated with frontal subcortical tasks, while the NAA concentrations in the left 
hippocampus were decreased in PDD compared to PD-MCI and correlated with confrontation 
naming. As the presence of NAA and choline point to a neurodegenerative process in the first 
line, the authors’ findings support that executive impairment is related to dorsolateral 
prefrontal dysfunction from the early stages, while progression to dementia is linked to the 
additional impairment of temporal lobe structures (Pagonabarraga et al., 2012). 
Complementing this findings Nie and colleagues (2013) found decreased NAA/Cr ratios at the 
occipital lobe and increased choline/Cr ratios at posterior cingulate related to PD-MCI and 
conclude that metabolite changes in these structures occur in the early cognitive impairment 
phase of PD patients, hence can be used as marker for the detection of PD-MCI (Nie et al., 
2013). Griffith et al. (2008) observed a decrease in NAA, NAA/Cr, and Glutamate/Cr primarily 
in posterior cingulate gyrus for PDD compared to PD and controls, while Summerfield et al. 
(2002) obtained a lower NAA/Cr in the occipital lobe in PDD, compared to PD. A lower NAA/Cr 
at posterior cingulate gyrus was also observed in PD-MCI patients in a study conducted by 
Camicioli et al. (2004). 
 
1.4.4 Arterial Spin Labeling – ASL as Method to Measure Brain Perfusion 
The benefit of the arterial spin labeling (ASL) MR imaging technique is that it allows to 
calculate the cerebral blood flow without the use of any radioactive or contrast agents like it 
is necessary in PET and SPECT (Detre et al., 1994). In ASL, the arterial blood water is 
magnetically labeled just below the region of interest (closer to the heart) by applying a 180-
degree radiofrequency inversion pulse. The result of this pulse is the inversion of the net 
magnetization of the blood water and consequently the MR signal as well as image intensity. 
The image taken during this time-window will provide an estimate of the blood flow in the 
region of interest (ROI) (http://fmri.research.umich.edu/research/main_topics/asl.php). 
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Only a few studies using ASL for the investigation of the cognitive impairment in PD exist. 
Melzer et al. (2011) attempted to describe a PD related perfusion network by using the ASL 
technique and found hypoperfusion in precuneus, cuneus and middle frontal gyrus in PDD. 
Kamagata et al. (2011) detected hypoperfusion in the posterior cortex in PD and PDD patients 
using ASL perfusion MRI. Both studies mention the possible application of ASL technique as a 
tracking tool for the disease progression due to the non-invasive and safe method (Melzer et 
al., 2011). Prolonged overall arterial arrival times (AAT) and neuropsychological test score 
(MOCA) correlated regional CBF values were found for PD patients compared to controls (Al-
Bachari et al., 2014). Fernandez-Seara et al. (2015) used the ASL technique to investigate the 
resting state of PD patients and detected increased connectivity of the subthalamic nucleus 
and cognitive and motor areas. 
 
Although these studies give promising insight about the changes related with cognitive decline 
in PD, they are partially controversial and lack the formulation of a reliable biomarker for the 
development of PDD. Many studies are insufficient regarding study-size, follow-up and the 
compared groups (PD/PD-MCI, PD/PDD, PD-MCI/PDD, lack of HS). But most importantly, there 
are only few studies trying to combine the different imaging modalities. 
 
1.5 AIM OF THE STUDY 
The aim of this study is to track the progression of the neuropathological changes related to 
cognitive impairment in PD patients by using multimodal magnetic resonance imaging (MRI) 
techniques in a cross-sectional study design. Based on measurements of PD patients at 
different stages of the cognitive decline, we attempt to describe a discriminant biomarker for 
PDD. Intending to do so, the combined functional, structural, metabolic and perfusion 
neuroimaging modalities of PD-N (PD without cognitive symptoms), PD-MCI and PDD patients 
will be evaluated in combination with the clinical profile and neuropsychological test scores. 
 
 
 
 
 
 
48 
 
1.5.1 Integration of the brains functional connectivity derived from rs-fMRI and structural 
connectivity derived from Diffusion Tensor Imaging 
The resting-state functional MRI (rs-fMRI) and Diffusion Tensor Imaging (DTI) data from all 
study groups will be obtained and integrated in order to investigate the large-scale functional 
connectivities of the brain related to cognitive decline in PD. 
The cumulated knowledge on neuroimaging findings suggests that correlates of behavioral 
changes are better reflected in connectivity patterns of the brain than anatomic or functional 
changes occurring at specific local portions of the neural tissue. The temporal correlations of 
hemodynamic signals obtained with rs-fMRI allow the visualization of a series of functionally 
meaningful connectivities in the brain, namely the intrinsic connectivity networks (ICNs) or 
resting-state networks (RSNs). The independence from any task condition makes this type of 
functional measurements easier to apply in clinical settings. The integration of these 
functional connectivity (FC) results with anatomical connectivity (AC) patterns derived from 
Diffusion Tensor Imaging measurements will decrease the variability and increase their 
sensitivity, because any functional connectivity needs to reside on anatomical connections 
between brain areas. 
 
1.5.2 Integration of MR Spectroscopic Imaging Data 
Magnetic Resonance Spectroscopic Imaging (MRSI) will be performed and allows for the non-
invasively measurement of NAA+NAAG, Cho, Glx and mI metabolite concentrations in the 
brain tissue. The MRSI data will focus on these substances specifically in the frontal parietal 
areas, which seem to be responsible for the executive and visuo-spatial impairments. 
According to a group of previous studies deficits in the parietal areas point to a more malign 
development of cognitive decline in PD (Williams-Gray et al.2009; Rektorova et al. 2012; 
Moustafa et al., 2013; Jellinger2013; Winder-Rhodes et al.,2014; Nombela et al., 2014). Based 
on the positive findings in the literature, the MRSI approach within this multimodal MRI study 
will contribute important findings related to the prediction of developing dementia in PD. 
 
1.5.3 Integration of Brain Perfusion data 
Brain perfusion will be investigated by means of Arterial Spin Labeling measurements, which 
may indirectly reflect the areas where the neurodegenerative process has started and may 
represent reduced metabolic activity in areas with tau abnormalities, which has been already 
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accepted as a reliable FDG-PET marker for the follow-up of PD and AD (Musiek et al., 2012, 
Huang et al., 2008; Nobili et al., 2011; Garraux et al., 2013; Gonzales-Redondo et al., 2014). 
It is not clear whether the hypoperfusion measured with ASL appears to occur before or after 
the neuronal changes measured with other MRI techniques. Nonetheless, ALS is a non-
invasive technique and will be used to measure perfusion in this multimodal MRI study. 
 
1.5.4 Benefits of the cross-sectional study design 
Because a longitudinal study design needs a long-lasting work with some other complexities 
such as the compliance of the initial patient group to repeated measurements along the years, 
a cross-sectional study design on patients at various stages of the disease was preferred for 
this study. By this design, we intend to describe a set of neuroimaging features that show a 
progressive gradual change among PD patients without any cognitive decline (PD-N), patients 
diagnosed as PD-MCI and PDD. This cross-sectional study design will enable to re-create the 
longitudinal neuropathological progression. Identifying a progressive pathological pattern 
based on cross-sectional multimodal investigations would allow characterizing a multimodal 
MRI-based biomarker for the risk of cognitive impairment and by this way the discrimination 
of the PD patients with increased risk to convert to PDD. 
 
1.6 MAIN HYPOTHESES 
1. The main working hypothesis is that a set of derived multimodal MRI parameters will be 
able to provide novel information about the mechanisms underlying the pathogenesis and 
progression of the cognitive decline in PD to PDD. 
2. We hypothesize that a multimodal neuroimaging-based biomarker will be capable to track 
the gradual change of cognitive decline in PD, which will be verified by its correlation with 
the clinical/neuropsychological evaluation of the PD population. Within this framework, 
we assume that a parsimonious set of derived multimodal neuroimaging parameters will 
suffice to describe the progression of the cognitive decline. 
3. We assume that in addition to functional and diffusion MRI measurements, MRSI and ASL 
techniques will provide additional sensitive spectroscopic and perfusional findings that will 
correlate with the cognitive dysfunction in PD. 
4. In case we will be able to define significant pathological differences between the different 
cognitive states of the patients, we mostly expect them to be related to reduced functional 
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connectivity in the RSNs by measures of fMRI, decreased connectivity and FA values of the 
WM tracts by the use of DTI/dMRI measurements, reduced NAA values using MRSI and 
reduced perfusion by ASL measurements, each increasing in severity along the severity of 
the cognitive decline. 
5. As an additional output of the study, the correlations of the investigated neuroimaging 
parameters with the change of neuropsychological test (NPT) scores related with specific 
cognitive domains will allow us to describe neuroimaging counterparts of specific 
neuropsychological tests, which might shed light on the design of future neuroimaging 
studies on cognition in general. 
 
While for other neurodegenerative diseases such as Alzheimer’s disease (AD) MRI techniques 
have already been well established as substantial tool for the diagnosis and follow up of the 
disease, the application and use of MRI techniques in PD are yet to be established. The 
evaluation of multimodal structural, functional and metabolic MRI data collected from PD 
patients at different stages of cognitive impairment will provide important information about 
the pathological basis these cognitive impairments rely on and give insight about the essential 
pathological changes predicting the progression to dementia in PD. The investigation of 
multimodal data will provide a more detailed and complete picture about the PD pathogenesis 
than only single modalities can. Furthermore, multimodal MRI-based measures will allow the 
use of totally non-invasive and task-independent data offering a clinical set-up that could 
easily be applied in future follow-ups and as diagnostic tool for clinicians. Additionally, 
multimodal MRI will plausibly provide more sensitive results than NPT scores alone and will 
be less biased by the motivational level of the patients in the NPTs. To our knowledge such a 
cross-sectional multimodal MRI study design investigating the pathological progression 
related with cognitive decline in PD and PDD has not been performed before. 
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2 METHODS 
2.1 Subjects 
Sixty idiopathic PD patients participated in this study (PD-N= 20, PD-MCI=20, PDD=20). 
Patients followed at the Department of Neurology and Movement Disorders of Istanbul 
Faculty of Medicine diagnosed with idiopathic PD by a neurologist according to the UK -
Parkinson’s Disease Society Brain Bank Criteria were included in the study. Shortly, the basic 
criteria were the presence of bradykinesia/akinesia and at least one of the other cardinal 
features of PD such as rigidity, tremor at rest and the absence of atypical features or secondary 
causes of the disease (Gibb and Lees, 1988, Hughes et al., 1992). While initially the patients 
were recruited taking into consideration comparable age, educational level, duration of 
disease and medication in each group, 4 PD-N, 2 PD-MCI and 2 PDD patients were excluded 
from the study to reduce the difference of the main age among the 3 groups (Table 3-1). The 
study is approved by the Ethics-Committee of the Istanbul Medical Faculty of Medicine in 
accordance with the Principles of the Declaration of Helsinki, and all subjects gave written 
permission for their participation in this study and the measurements. 
As the aim of the study is to investigate the neuroimaging markers of the cognitive decline 
within the Parkinson’s disease and to define a discriminant biomarker for the identification of 
PDD patients, the PD-N group has been considered as the reference group. 
 
2.2 Clinical examination 
2.2.1 Unified Parkinson's disease Rating Scale 
In order to ascertain the disease status, the patients were examined by a neurologist using the 
Unified Parkinson's disease Rating Scale (UPDRS), before the neuropsychological tests and MR 
measurements were carried out. The UPDRS is one of the most common tools to scale the 
Parkinson’s disease status in clinical environment by interviewing and clinical observation, and 
covers among others the evaluation of the patients mental and mood state, the self-
evaluation of daily life, scoring of the motor abilities (UPDRS part III) and staging of the disease 
severity (Hoehn & Yahr scale, Hoehn & Yahr 1967). 
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2.3 Criteria for the Diagnosis of PD-MCI 
All subjects underwent a comprehensive neuropsychological test battery and were diagnosed 
as PD-MCI according to the Level I criteria (Litvan et al., 2012). For this, a cut-off score of ≤83 
of the ACE-R examination (Addenbrook's Cognitive Examination Revised) was used, as 83 
points in the ACE-R showed 80% specificity and 52% sensitivity for PD-MCI in an earlier study 
on the global screening of the Turkish PD population (Uysal Cantürk, 2013). 
 
2.4 Criteria for the Diagnosis of PDD 
The Clinical Diagnostic Criteria for Dementia Associated with Parkinson’s Disease (Emre et al., 
2007) were used for PDD diagnosis. The PDD patients had to show impairment in at least two 
cognitive domains and in contrast to the PD-MCI group, the deficits in the PDD patients have 
to be severe enough to affect the daily life such as hygiene, outside activity and social 
interactions. These are independent from the motor deficits (Emre et al., 2007). 
 
2.5 Exclusion criteria 
All participants of this study were tested for signs of major depression. Subjects with scores 
>16 of 30 in the Geriatric Depression Scale (GDS) were excluded. Antidepressant treatment in 
the PD groups was tolerated as long as the GDS score was ≤ 16. Subjects with history of other 
significant psychiatric or neurological diseases were excluded. Subjects with severe tremor or 
dyskinesia and other conditions prohibiting participation in the MR measurements such as 
deep brain stimulation (DBS), coronary stent implant, old prosthetics or teeth implants, when 
not MR-compatible, were not included. Additionally, subjects with anticholinergic drug 
treatment were excluded due to possible interaction with the brain activity. Because psychotic 
symptoms are common in PD dementia, antipsychotic drug treatment was partly accepted in 
the PDD group. All subjects had minimum educational level of 5 years (primary school) except 
a single PDD case. 
Subjects with severe pathological MRI findings due to tumor, anoxic brain damage, stroke, 
lacunae, other neurological or developmental disorder, white-matter hyperintensities (WMH) 
> 3 according the Fazekas scale in a clinically oriented anatomical MR sequence (FLAIR) were 
excluded. Finally, subjects with head motion > ±3mm translation and rotation in the rs-fMRI 
and diffusion MRI measurements were excluded. 
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2.6 Medication 
The patient groups were medicinally balanced mainly regarding the treatment with L-Dopa, 
dopamine agonists and inhibitors of dopamine decomposition pathway but varied regarding 
other drug treatments, such as anti-dementia drugs and blood-pressure or pain-killers. 
 
2.6.1 Dementia drug treatment in PDD 
Against the cognitive symptoms of dementia, most of the (12) PDD patients were treated with 
the Exelon® Patch. The active substance of Exelon is rivastigmine which acts as an 
acetylcholine esterase inhibitor and leads to an increase of acetylcholine in the brain, and 
thereby helps in reducing the dementia symptoms of the patients. One patient was treated 
with Aricept (active substance is donepezil), which also is an acetylcholine esterase inhibitor. 
 
2.7 Neuropsychological examination 
All study participants (PD-N, PD-MCI and PDD) underwent a wide battery of 
neuropsychological examinations. 
 
2.7.1 Global neuropsychological tests 
The ACE-R, MMSE and MOCA were used for the global neuropsychological evaluation of the 
subjects. 
 
2.7.1.1 Addenbrooke's Cognitive Examination- Revised (ACE-R) 
As a sensitive and specific cognitive screening instrument for early cognitive dysfunction, the 
ACE-R has been established as a reliable test over the last decades. The ACE-R covers five 
cognitive domains such as orientation/attention, memory, verbal fluency, language and visuo-
spatial abilities (Mioshi et al., 2006). The patients performed the Turkish version of the ACE-R, 
and the administration usually lasted between 15-20 minutes. The maximal score of the test 
is 100 points. Based on the previous results of Uysal Cantürk (2013) at the Istanbul Faculty of 
Medicine, the patients were diagnosed as PD-MCI when they obtained ≤ 83 in the ACE-R. 
However, the other test scores, the UPDRS evaluation and the patients subjective complaints 
were considered for the final diagnosis in case the ACE-R performance left subjective doubts 
about the diagnosis. 
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2.7.1.2 Mini Mental State Examination (MMSE) 
The MMSE was originally introduced by Folstein et al. in 1975, and is because of its easy and 
fast administration used in clinical environment in order to obtain an overview about the 
patient’s cognitive status and the progression of the cognitive decline, although it is criticized 
by its lack of sensitivity for the detection of cognitive impairment. In this study, the MMSE 
scores were obtained from within the ACE-R test. 
 
2.7.1.3 The Montreal Cognitive Assessment (MOCA) 
The MOCA was introduced by Nasreddine et al. (2005), and is such as the ACE-R and the MMSE 
a quickly applicable cognitive screening instrument. For the Turkish population, a cut-off score 
of ≤ 21/30 is suggested for dementia, however this diagnosis was made by the clinicians. 
 
2.7.2 Tests investigating the executive functions 
As the executive functions seem to be strongly affected in PD-MCI, the domains of executive 
function were explicitly tested using the Stroop, Wisconsin Card Sorting Test and Symbol Digit 
Modalities Test (SDMT). Additionally, we evaluated sub-scores of the ACE-R test such as verbal 
fluency (phonemic fluency=k letter, semantic fluency=animal naming) and clock drawing 
scores to further score the patients executive abilities. The dysfunction of these domains may 
rely on the dysfunction of the prefrontal cortex, as it allows the subject to pay attention to 
one event and exclude others and to switch among them (Watson et al., 2010). 
 
2.7.2.1 Stroop Test 
Previous studies reported about low performance of PD and PD-MCI patients in the standard 
Stroop test, showing longer reaction times and higher error rates compared to healthy 
controls (Bohnen et al., 2006, Lima et al., 2008). The word-color Stroop task, in which 
participants are either asked to read the written word (red, blue, green, yellow) or to name 
the ink color of the written word, is the most common test in order to demonstrate the Stroop 
effect. The interference effect becomes obvious when the written color and its ink color are 
incongruent. The interference effect for color naming in incongruent conditions is bigger than 
for word reading showing that healthy subjects are more trained to automatically read a word 
and that one has to put more effort/attention to inhibit the automatic word reading in order 
55 
 
to name the ink color of the written word. The Stroop task is considered to measure not only 
selective attention but cognitive flexibility and processing speed, and is therefore a common 
test to evaluate the executive functions of subjects and patients. 
In this study, the word-color Stroop test was performed in Turkish language. The patients had 
normal or corrected to normal vision, and color blindness was excluded. First the patients had 
(1) to name the color of some rows of squares, (2) to read the name of the written words 
(“red” (“kırmızı” in Turkish), “blue” (“mavi” in Turkish) and “green” (“yeşil” in Turkish)) and (3) 
to name the ink color of the written words (Figure 2-1). Each time the seconds to complete 
the task, the number of spontaneous corrections and the mistakes were counted. The time 
difference between the word reading and ink naming (Stroop effect) was calculated. 
 
 
Figure 2-1: Stroop test in which the patients have to name the color of colored squares, read the written words 
and name the color of the written words. con.: congruent, inc.: incongruent 
 
2.7.2.2 Symbol Digit Modalities Test – SDMT 
The SDMT (Smith 1968 and 1982) is an easy applicable tool to test short term memory, visual 
scanning and attention. It is a simple substitution task in which the subjects have to fill boxes 
below the symbols with numbers between 1-9 regarding a symbol reference key (Figure 2-2). 
After 10 training boxes, the test starts and the participants have to fill as much boxes a possible 
within 90 seconds. The written responses were collected in this study, although in some 
patients with severe hand tremor the average of both the written and spoken responses 
where used. 
 
Figure 2-2: The key and the first line of the SDMT including 9 training fields. 
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2.7.2.3 Wisconsin card sorting test - WCST 
In order to test for domains of the executive functions (frontal lobe function) in the study 
groups the WCST was used. The WCST (Berg, 1948) is a widely-used tool to evaluate the 
subject’s ability to deduce concepts and strategy, and to shift the strategy in response to 
concept changes (Eling et al., 2008). Hereby the WCST also covers domains such as mental 
flexibility, short term memory and attention. 
In the test, the subject has to find a shared characteristic of a central appearing card and one 
of the four steady cards displayed below this card based on the feedback of the examiner 
(correct, wrong) (Figure 2-3). The shared characteristic can either be the color, shape or 
number of items on the card. One category contains 10 correct answers in a row, after that 
the rule changes without announcement. In this study, a minimum of 128 cards/maximum 6 
categories were used. The test was conducted computer-based, and the subjects gave verbal 
response to the examiner, who in turn manually gave the answer into the keyboard. The 
number of categories, percentage of perseverative error response and total number of errors 
have been evaluated. 
 
Figure 2-3: Example figure for the WCST. 
 
2.7.2.4 ACE-R sub-tests for executive functions 
2.7.2.5 Verbal fluency test 
Verbal functioning can be quickly assessed using the verbal fluency test, which can be divided 
into phonemic and semantic word fluency. While the performance in the phonemic word 
fluency seems to strongly depend on frontal function, semantic fluency performance may 
stronger rely on the function of temporal areas (Baldo et al., 2006). Worse semantic fluency 
has been reported as a risk factor for PDD. 
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Letter/Phonemic fluency 
In the k-letter task the subjects had to name as many words as possible starting with “k” as 
the first letter in 60 seconds. The subjects were instructed not to use proper nouns such as 
names or cities (e.g. Kemal/Klaus, Kastamonu/Köln). Perseverations, unreal words and proper 
nouns were noted but not counted in the end. The responses for each 15 s were separately 
recorded on the control paper. By this way it was possible to see whether the subjects gave 
steady responses or had higher performance at the beginning or at the end of the test. 
 
Category/Semantic fluency 
In a second task the participants were asked to name as many animals as possible within 60 s 
independent of the starting letter. The responses were noted in the same way as in the 
phonemic fluency task. 
 
2.7.2.6 Clock-drawing test 
The clock-drawing test actually represents parts of both of the executive and visuo-spatial 
functions. In this test, the subjects were asked to freely draw a clock out of their memory and 
set the time to 11:10. Subjects were required to draw a closed circle, put all numbers in the 
right place and indicate the time with the hands in the correct length in order to obtain full 
points (5pt.). While drawing, the examiner gained information about the subjects planning 
skills, visuo-spatial construction abilities and abstract thinking. Rotation, missing numbers, 
wrong placement and inability to show the time provide different information about the 
subject’s cognitive state. 
 
2.7.3 Tests investigating the visuo-spatial function 
Studies showed that besides the executive dysfunction, the presence and degree of the visuo-
spatial dysfunction seem to be crucial for the development of PD-MCI and PDD. Therefore, 
the subject’s visuo-spatial abilities were tested with the Benton Judgement of Line Orientation 
test, the Navon test and sub-parts of the ACE-R test such as the pentagon and cube copying 
and clock-drawing. 
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2.7.3.1 Benton Judgment of Line Orientation Test 
A widely used neuropsychological tool for the investigation of visuo-spatial abilities of patients 
is the Benton Judgment of Line Orientation test (JOLO). In the test, patients have to match 
two lines with different orientation with two lines of a target array composed of 11 lines 
arranged in even steps from 0 to 180º (Figure 2-4). The target array is placed below the two 
lines. In total, 30 pairs of lines have to be matched with the target array. Both of the two lines 
have to be identified correctly in order to get 1 point. The patients had normal or corrected to 
normal vision. 
 
 
Figure 2-4: Example arrangement of the Benton Judgment of Line Orientation test. Patients have to match the 
lines on page (a) with the corresponding lines on page (b). 
 
2.7.3.2 Navon 
In order to control for simultanagnosia in any of the participants the Navon figure test (Navon 
1977) was used. In this test four letters (H, T, L, F) were composed out of different 
(incongruent) small letters (E, R, K, C) (Figure 2-5). The subjects had to identify the little letters 
(local feature) and the big letter (global feature) without the borders to get full points. People 
with simultanagnosia would only identify the local features of the letter but not the global 
features. The identification of only local letter equals 0 points, the detection of the global 
letters with the help of the outer linings equals 1 point and the detection of both local and 
global letters without the help of the outer lines results in the maximum point of 2. 
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Figure 2-5: The Navon test. 
 
2.7.3.3 Pentagon and cube copying 
Patients were asked to copy the two overlapping 5-edged pentagon figures (max. points 1) 
and the 3D cube figure (max. points 2) (Figure 2-6). The figure had to resemble the cube 
illusion and consist out of 12 lines. 
 
Figure 2-6: The Pentagon and Cube figure copy test. 
 
2.8 Psychiatric assessment 
In order to assess the participant’s mental status, the patients were interviewed with the 
geriatric depression scale (GDS), the Beck Anxiety Inventory (BAI, Beck et al., 1988), the Yale-
Brown Obsessive Compulsive Scale (Y-BOCS, Goodman et al., 1989) and the Apathy Evaluation 
Scale (AES, Marin et al., 1991). 
 
2.9 Statistical Analysis of the Neuropsychological Test Scores 
The scores of the neuropsychological tests were compared among the patient groups by using 
one-way Analysis of Variance (ANOVA) method in the SPSS statistics software (IBM SPSS 
Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp). 
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2.10 MR Imaging 
The structural, functional, diffusion, metabolic and perfusion MR imaging was performed with 
a 3T whole-body Phillips MRI scanner (Philips Achieva TX, Enschede, Holland) equipped with 
a 32-channel SENSE head-coil. High-resolution anatomic MR image, resting-state functional 
MR (rs-fMRI) images, diffusion MR (DTI) images, MRSI data and ASL-based perfusion images 
were recorded in one session that lasted about 48 minutes in total. Exceptionally, 
measurements were suspended or paused in case the patients could not tolerate the long 
session, were scared or due to technical problems, and were then completed at a later time-
point maximally within one week. The recording parameters for each modality were selected 
as explained in the following sub-headings. 
 
2.10.1 T1 weighted and FLAIR data acquisition 
Two anatomic images were obtained by using (1) a T1-weighted fast field echo sequence (FFE) 
(TR=8.3ms, TE=3.8ms, FOV=250x250 mm, number of slices=180, voxel size=1x1x1mm3, total 
scan duration=5:55min) and (2) two instances of a T2-weighted fluid attenuated inversion 
recovery (FLAIR) sequence (TR=4800ms, TE=259ms, TI=1650ms, FOV=250x250 mm, number 
of slices=60, voxel size=1.11x1.11x3mm3, total scan duration=0:53min). Both scans covered 
the whole brain. 
 
2.10.2 Resting-state fMRI data acquisition 
The resting-state fMRI data were acquired using the fast field echo planar imaging (FFEPI) 
sequence with the following parameters: TR=2000ms, TE=30ms, FOV=224x240 mm, number 
of slices=36, voxel size=2x2x4mm3, total scan duration=7:30min. In addition to the first 10 
dummy recordings, 214 consecutive time points were sampled yielding 7704 images in total. 
 
2.10.3 Diffusion tensor imaging data acquisition 
The diffusion tensor imaging (DTI) data were recorded using 32 gradient 
directions: TR=10538ms, TE=86ms, FOV=240×240 mm, number of slices=90, voxel 
size=2x2x2mm3, b=1000 s/mm2, total scan duration=07:15min. 
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2.10.4 T2 weighted image acquisition 
In order to facilitate the co-registration of perfusion and structural images, a single shot 
gradient-EPI scan covering the whole head was acquired: TR=10243ms, TE=80ms, 
FOV=240x240 mm, number of slices=90, voxel size=2x2x2mm3, total scan duration=1:42min. 
 
2.10.5 Arterial spin labeling data acquisition 
ASL images were acquired using a multi-slice single-shot gradient-EPI sequence. The following 
parameters were used: TR=250ms, TE=16ms, FOV=240x240mm2, matrix size=80x80, number 
of slices=6, slice thickness=6 mm, slice gap=2 mm, flip angle=40°, Sensitivity encoding 
(SENSE) 1.2, label thickness=130 mm, label gap=20 mm, label delay=300ms, number of 
dynamics=48, total scan duration=4:08min. 
Due to the limited slice number, ASL MR images were acquired in three separate scans. In 
each single scan, 6 slices were obtained. The FOV in the first session was placed bordering the 
superior part of the cortex close to the skull and the FOVs in the second and third ASL-scans 
each were placed next to the lower border of the previous scan. Thereby, almost the whole 
brain was covered without any gap. 
During a single ASL-MRI scanning session each of the 6 slices was acquired at 8 different 
phases (time points) using distinct inversion times (TIs) that are 250ms apart and each 
consecutive slice was acquired 32ms later in time than the previous. This means, the first 
phase of the first slice was acquired at 300ms and the last (8th) phase at 2050ms, while the 
sixth slice’s first phase was acquired at 459ms and the last phase at 2209ms. The signal to 
noise ratio was increased by repeating the measurements 30 times in each scan. By this way, 
1440 images were obtained for each of the Control and Tag Images (total 2880 images). 
 
2.10.6 MRSI data acquisition 
The multi-slice 3-dimensional 1H-MRSI images were acquired using the Point-RESolved 
Spectroscopy (PRESS) sequence with a short echo time and the following 
parameters: TR=1000ms, TE= 52ms, 1024 points, FOV=140x140 mm, number of slices=3, voxel 
size: 10x10x12 mm3, slice-thickness=12 mm, total scan duration=323 s. 
In the same way as for the ALS imaging, the MRSI images were acquired in two separate scans. 
In each scan 3 slices were obtained. The maximum number of voxels per slice was 196 (14x14), 
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but may vary according to the adjustment for each subject’s brain size. The MRSI Images 
where acquired from (1) the fronto-parietal areas and (2) the parieto-occipital areas. 
 
2.10.7 Scan alignment 
The alignment of the FOV in the T1 weighted and rs-fMRI imaging was slightly more inclined 
than the anterior-posterior commissure (AC-PC) plane. T2 weighted, FLAIR, DTI, ASL and MR 
spectroscopy imaging were performed in straight axial orientation (x:0, y:0, z:0). 
 
2.11 MRI DATA ANALYSES 
2.11.1 Analysis of the Resting-state fMRI data 
2.11.1.1 Pre-Processing of the fMRI data 
Statistical Parametric Mapping (SPM8) software (http://www.fil.ion.ucl.ac.uk) in MATLAB 
7.9.0 (The MathWorks, Inc., Natick, MA) was used to preprocess the fMRI data. Pre-processing 
consisted of the following steps: 
1- The fMRI images were spatially realigned to the first volume to correct the bias due to 
head movements. 
2- The high resolution anatomical T1-image was co-registered to the mean fMRI image. 
3- T1 image was segmented using the SPM8 segmentation tool, and a transformation 
matrix to the Montreal Neurological Institute 152 (MNI-152) standard space was 
obtained. 
4- This matrix was used in the normalization of all fMRI images to MNI-152 standard 
space. 
5- After spatial normalization, the fMRI images were spatially smoothed by an isotropic 
Gaussian filter with a full-width at half-maximum (FWHM) of 8 mm to increase the 
signal-to-noise-ratio. 
 
2.11.1.2 Group Independent Component Analysis of the rs-fMRI Data 
After the pre-processing steps, the resting-state functional connectivity networks were 
obtained by applying the Independent Component Analysis (ICA), which is a method used to 
blindly reveal the implicit components, corresponding to discrete sources, in compound 
signals (Hyvärinen and Oja, 2000). Various neuronal networks in the brain can be determined 
by applying the ICA method to the rs-fMRI data either based on spatial or temporal 
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independence among the decomposed components (Smith et al., 2012). Spatial independence 
is the more preferred approach in fMRI literature, which decomposes the 4-dimensional 
(3 spatial dimensions + time) rs-fMRI data into such components that are maximally 
independent from each other in space, while, on the other hand, the BOLD time series are the 
same for all voxels that belong to each spatial component, with different weighting factors for 
each voxel. This data-driven approach has the significant advantage over seed-based 
functional connectivity estimation techniques in terms of using the whole-brain BOLD data 
without imposing any prior hypothesis about the spatial characteristics of the resting-state 
networks. 
Group independent component analysis (Calhoun et al., 2009), an extension of the traditional 
ICA (McKeown et al., 1998), was applied to fMRI data by using the Group ICA fMRI Toolbox 
(GIFT) (Calhoun et al., 2001) (http://icatb.sourceforge.net/). The GIFT software provides 
consistent resting state networks across multiple subjects and sessions. 
Prior to ICA analysis, principal component analysis (PCA) was used to reduce data. The number 
of ICA components was set to 30 and the INFOMAX ICA algorithm was used, while the ICASSO 
analysis was used for ICA algorithm reliability determination. The independent components 
of single subjects were reconstructed using dual regression (spatial-temporal regression) 
method. In the first step of reconstruction, the aggregate component spatial maps were used 
as basic functions and projected onto each subject’s original data resulting in the subject’s 
component time-course. In the next step, the obtained time-course was used as basic function 
and projected onto the subject’s original data resulting in the component spatial map for that 
subject (Rachakonda et al., 2007, Calhoun et al., 2009). As we used the intensity normalization 
during the pre-processing step of the data (at each voxel the time-series was scaled to a have 
a mean of 100), the aggregate components display arbitrary units, while the subjects’ 
reconstructed data display the percent signal change. 
ICA components were visualized using xjView toolbox (http://www.alivelearn.net/xjview), 
and ICAs corresponding to typical artifacts were excluded from further analysis. The remaining 
16 components were assigned to specific RSN patterns as described in the related literature 
(Raichle 2011). Comparisons of the RSNs among the patient groups were carried out by two 
methods: (1) Binary logistic regression analysis of the expression scores for each network 
representing the similarity of the general pattern of the subject RSN to the overall RSN pattern 
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computed from the whole group of subjects, and (2) voxel-wise t-statistics carried out for each 
RSN between pairs of patient groups. 
 
2.11.1.3 Logistic regression analyzes of the GIFT components 
In order to illustrate the individual level of the RSN expression, the expression scores of the 
components in each subject were obtained by calculating the dot product of the subject’s and 
group aggregate spatial maps, which yielded a scalar value that represents the similarity of 
each of the subject’s RSNs to the global RSN pattern obtained from the whole group. The 
expression scores were fed into the forward stepwise conditional binary logistic regression 
analysis in SPSS software (21.0. Armonk, NY: IBM), and the combination of the ICs/RSNs that 
together best discriminate PDD from PD-MCI or PD-N patients and also PDD from the both of 
the other PD groups together (PD-non-demented) were identified. 
Using the dot product in the logistic regression analysis allowed us to quantify the weight of 
each network in each subject’s raw fMRI data in terms of an expression score for each RSN 
and testing the power of these scores in classifying the patients into correct groups without 
the need to define certain threshold values. Additionally, the quantification of each network 
expression in each subject with a single scalar value also allowed us to easily calculate 
correlation coefficients between the RSN expressions and various neuropsychological test 
scores. 
 
2.11.1.4 Voxel-based comparison for functional connectivity 
Additional to the binary logistic regression analysis, we performed whole-brain voxel-wise 
comparisons for the 16 RSNs in order to investigate the difference in functional connectivity 
between the patient groups. One- and two-sample t-tests were conducted on the back-
reconstructed subject data using SPM stats implemented in GIFT toolbox (Ma et al., 2007, 
Calhoun et al., 2009). 
In order to run the comparisons within the specific spatial extent of each network, an explicit 
mask of each network was created based on a one-sample t-test carried out on the 
reconstructed network maps of all subjects. Only voxels with a t value above 3 were included 
in the explicit mask. By this way, a common solution space was created for each network 
before the group comparisons are carried out by two sample t-tests with family-wise error 
(FWE) correction. The clusters obtained with an uncorrected height-threshold of p < 0.001 
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were compared between pairs of patient groups and clusters with cluster-level FWE-corrected 
p < 0.05 are reported. 
 
2.11.2 Analysis of the Diffusion Tensor Imaging (DTI) Data 
2.11.2.1 Processing of the DTI data 
Preprocessing procedures for DTI analyses were carried out with FSL software (FMRIB 
Software Library v5.0, Oxford, UK) (Smith, 2004). Brain extraction for B0 images was 
performed using BET tool in FSL (Jenkinson et al., 2005). B0- and T2-weighted images were co-
registered using the linear image registration tool of FSL (FLIRT) (Jenkinson and Smith, 2001; 
Jenkinson et al., 2002), and binary skull-free B0 masks were used to extract the brain from the 
co-registered T2 images. For the correction of susceptibility induced distortions, the brain 
extracted B0 and T2 images were fed together into the “Topup” tool of FSL (Andersson, 2003). 
The principle behind the Topup procedure is to estimate the susceptibility off-resonance field 
by using two (or more) acquisitions with different acquisition parameters such that the field 
distortions are different. Topup estimates the field, which when applied to the two images 
will maximize their similarity. 
The two unwarped images output by the Topup tool were averaged and thresholded to obtain 
a binary mask to input to the “Eddy” tool of FSL (Jasper et al., 2016) in addition to the 
estimated off-resonance field image and diffusion weighted images in all diffusion directions. 
In addition to the susceptibility-induced distortions there are two more sources of artifacts in 
diffusion weighted images: eddy currents (EC) as a result of rapid switching of the diffusion 
weighting gradients and movements of the subject’s head during the quite long diffusion 
protocol. Eddy tool corrects these three types of imaging artifacts and returns motion 
parameters, which can later be used to evaluate the significance of the differences of 
movement artifacts among the experimental groups. In the present study, the groups did not 
show any significant difference regarding motion parameters. 
After visual inspection of the performed motion and deformation correction, we ran DTIfit in 
FDT (FMRIB's Diffusion Toolbox), a part of FSL (Behrens et al., 2003), for fitting the diffusion 
tensor model at each voxel. By this way, we obtained fractional anisotropy (FA) and mean 
diffusivity (MD) maps as well as the maps of the primary (λ1), secondary (λ2) and tertiary (λ3) 
eigenvalues and corresponding unit eigenvectors. Main diffusion parameters are explained in 
the following formulae: 
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FA = �12 × �(λ1 − λ2)2 + (λ2 − λ3)2 + (λ3 − λ1)2�λ12 + λ22+λ32  Eq. 1 
MD = λ1 + λ2 + λ3 
3
 Eq. 2 
AD =  λ1 Eq. 3 
𝑅𝑅𝐷𝐷 = λ2 + λ3 2  Eq. 4 
 
As many patients, especially PDD patients, showed large ventricles and signs of atrophy, we 
chose the non-linear registration tool of FSL (FNIRT) (Andersson et al., 2007) for the 
registration of the subject FA maps to the 1x1x1mm3 FMRIB58 FA template, which is in the 
same space as the MNI-152 standard image. We visually inspected the non-linear registration 
results of all subjects and identified 11 subjects with unsuccessful registration. For those 
patients, we performed another registration option as follows: the subjects were non-linearly 
registered to each other and the most representative subject, which displayed the least 
average difference from the rest of the subjects, was automatically chosen as the target. The 
chosen target image itself was then linearly affine registered to MNI-152 1x1x1 mm3 standard 
space. After this step, each subject's FA image is nonlinearly transformed to the target and 
then affine transformed to the MNI-152 space. This type of registration is especially useful 
when working with WM images of patient groups, in which the large-scale changes of the 
brain anatomy complicates a reliable registration of each subject’s image directly to the 
standard space. After controlling for correct registration, the same registration to the standard 
space was repeated for the MD and RD maps of each subject by using the subject’s 
transformation matrix computed based on her/his FA map as described above. 
 
2.11.2.2 Region of Interest (ROI) based analysis of the DTI parameters 
For data analysis, the FA maps of all patients were averaged and voxels with intensity <0.2 in 
the obtained mean image were excluded in order to create a gray matter (GM) and 
cerebrospinal fluid (CSF) free study specific white-matter mask, as the FA values of GM and 
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CSF regions are usually below this value. The mask was binarized and multiplied with the Johns 
Hopkins University-International Consortium of Brain Mapping (JHU-ICBM) atlas containing 20 
predefined white-matter tracts, in order to adapt these ROIs to our patient group. The 
included tracts were: anterior thalamic radiation L+R, corticospinal tract L+R, cingulum 
cingulate gyrus L+R, cingulum hippocampus L+R, forceps major, forceps minor, inferior fronto 
occipital fasciculus L+R, inferior longitudinal fasciculus L+R, superior longitudinal fasciculus 
L+R, uncinate fasciculus L+R, superior longitudinal fasciculus temporal part L+R. 
The ROI-based analysis was carried out using the FSLstats tool. The atlas masked with the 
group-specific white-matter mask and the subjects’ FA maps were fed into the FSLstats. The 
mean ± standard deviation of each subject’s voxels within each ROIs were calculated and this 
process was repeated for MD, AD and RD values. 
 
2.11.2.3 Statistical analysis of DTI data 
For comparisons of the PD-N, PD-MCI and PDD groups one-way ANOVAs were first performed 
for FA values of each of the 20 ROIs with Bonferroni adjusted alpha (p < 0.05/20=0.0025). For 
the ROIs, that showed statistically significant FA differences among the 3 groups, further one-
way ANOVAs were carried out for MD, AD and RD values with the same adjusted alpha 
(p < 0.0025) and post-hoc two-sample t-tests between pairs of patient groups (PDD vs PD-N, 
PDD vs PD-MCI and PD-MCI vs PD-N) corrected with a Bonferroni adjusted alpha for the 
number of pair-wise comparisons x number of significant results in the initial ANOVA of FA 
values. 
 
2.11.3 Analysis of the Arterial Spin Labeling (ASL) based perfusion data 
2.11.3.1 Processing of the ASL data 
ASL-perfusion data were pre-processed and analyzed using a recently developed MATLAB-
based program by Arslan and Öztürk-Işık (2016a and b). In order to calculate the cerebral 
blood flow (CBF) maps, the mean magnetization (M0) for each pixel of the control image (not 
labeled) was estimated by fitting multiple inversion time (Ti) data to the longitudinal 
relaxation equation. The perfusion image was calculated by subtracting the labeled from 
unlabeled ASL-MR images (deltaM). Together with the M0 and deltaM, the cerebral blood 
flow was estimated using the general kinetic model (Buxon et al., 1998). 
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Brain extraction was performed for the T2-weighted images using BET in FSL. The skull-free 
T2-weighted images were registered to the MNI-152 2x2x2 mm3 brain standard space. As the 
non-registered T2 and CBF maps were initially in the same plane, the same transformation 
was also applied to the CBF maps during the linear registration process. 
 
2.11.3.2 ROI-based analysis for ASL Data 
We used a ROI-based approach for the analysis of difference in regional cerebral blood flow 
among the patient groups. Therefore, 70 (35 lateralized) predefined ROIs were extracted from 
the Harvard Cortical Structural Atlas (ROI size: max-prob-thr 0, 2mm2), and the mean intensity 
of the voxel within the ROIs was calculated. 
 
2.11.4 Analysis of the Magnetic Resonance Spectroscopic Imaging (MRSI) Data 
2.11.4.1 Pre-processing of the MRSI data 
The MRSI data are expressed by the peak intensities and ratios of the seven prominent 
resonances of NAA at 2.0 ppm (parts per million), creatine (Cr) at 3.0 ppm, choline (Cho) at 
3.2 ppm, glutamine/glutamate complex (Glx) at 2.3 ppm, GABA at 2.4 ppm, myo-inositol (mI) 
at 3.5 ppm and lactate + lipid at 1.3 ppm. 
The quantification of total NAA (tNAA) and N-acetylaspartylglutamate (NAAG), total choline 
(tCho), myo-inositol (mI), total creatine (tCr), and glutamate/glutamine complex (Glx) of each 
voxel was performed using the LCModel (Provencher 2001), and the tCr values were used for 
the normalization of the metabolites. During the calculations of the LCmodel analyses, the 
metabolite concentrations exceeding %30 of the automatically estimated standard deviation 
of that specific metabolite resulted in exclusion of that value. These steps lead to three 
outputs providing an estimated spectrum, the calculated residual noise spectrum and the 
required baseline spectra for the fitting. Adapting a recently developed software by Cengiz 
and Öztürk-Işık (2016a and b) working in MATLAB environment, 1H+ MR spectroscopic peak 
parameter maps were created for each slice and overlaid on the single subject T2 weighted 
images. The overlaid parameter maps were fed into another script (Cengiz and Öztürk-Işık, 
2016a and b), resulting in the linear registration (FLIRT) of the parameter maps to the MNI-
152 standard brain in FSL. 
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2.11.4.2 ROI-based analyses for MRSI data 
We used a ROI-based approach for the evaluation of MRSI data. As slice-size and slice number 
was limited for MRSI data, the number of ROIs was also limited. We chose 54 ROIs from the 
Harvard-Oxford Cortical Structural Atlas, the MNI Structural Atlas and the Harvard-Oxford 
Subcortical Structural Atlas that were covered by the restricted recording area. Independent 
samples t-test were performed for each of the NAA+NAAG/Cr, Cho/Cr, Glx/Cr and mI/Cr 
metabolite ratios of the voxel within the ROIs and compared for PDD vs PD-non-demented 
groups (PD-N and PD-MCI together). 
 
2.11.5 Analysis of the Correlations between the MRI and clinical/neuropsychological 
variables 
In order to associate the cognitive dysfunctions and motor symptoms of the PD patients with 
the functional, structural and perfusional MRI variables, one-tailed non-parametric 
(Spearman’s) bivariate correlation analyses were carried out for the variables of each of these 
modalities that revealed significant differences among the three patient groups and the 
clinical and neuropsychological data collected from the 52 PD patients. 
For Bonferroni correction, the clinical/neuropsychological variables were grouped into 
categories and based on the numbers of parameter in each category the alpha was adjusted: 
clinical data (p < 0.05/5= 0.01; UPDRS-total, UPDRS-III, UPDRS-cognitive score, Hoehn & Yahr, 
GDS), global neuropsychological tests (p < 0.05/7 = 0.0071; MOCA, ACE-R total and from the 
ACE-R derived: semantic fluency, phonemic fluency, pentagon copying, cube copying, clock 
drawing,) and specific neuropsychological tests (p < 0.05/7 = 0.0071; Stroop-mistakes and 
Stroop-effect, SDMT-total and SDMT-correct, WCST-category and WCST-error, JOLO). 
 
2.11.6 Testing the Performance of Multimodal MRI Variables for the Discrimination of the 
PDD Patients by Discriminant Analysis 
The variables of the rs-fMRI, DTI and ASL modalities that when tested in a single modality 
resulted in significant differences between the PD patient groups were fed stepwise into a 
discriminant analysis in order to test the efficiency of a multimodal MRI based classification of 
PD cases into PDD and one of the PD-N or PD-MCI subgroups. This is carried out by testing the 
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performance of a discriminant function on PD-N & PDD groups or PD-MCI & PDD groups by 
stepwise entering the variables from rs-fMRI, DTI and ASL modalities for the classification of 
the cases to one of the two groups with leave-one-out cross-validation. For this purpose, the 
significant expression scores of the RSNs, mean values of the FA, MD, RD and AD in the DTI 
ROIs and mean CBF values obtained from the ROIs of the ASL measurements that resulted in 
significant group differences in variance analyses among the three groups are included in a 
stepwise manner in the discriminant analysis and the sensitivity and specificity of the resulting 
discriminant functions in dissociating the PDD patients from PD-N or PD-MCI groups are 
reported. 
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3 RESULTS 
3.1 Demographic data 
Initially, we collected the data of 60 PD patients (PD-N=20, PD-MCI=20, PDD=20). Because the 
patient groups differed significantly regarding age, and age is known to be a major risk factor 
for PDD, we created age matched patient groups for the final data analysis. The final data set 
was composed of 16 PD-N, 18 PD-MCI and 18 PDD patients (Table 3-1), which according to the 
one-way ANOVA test did not show any significant difference regarding age (p = 0.121), but 
displayed a significant difference between PD-N and PDD groups regarding years of education 
(p = 0.024), while PD-N vs PD-MCI and PD-MCI vs PDD comparisons revealed no significant 
differences in terms of educational years (Table 3-2). As education is expected mainly to play 
a role in terms of cognitive symptoms and the PD-MCI and PDD groups were almost identical 
regarding education, we did not reduce the amount of data further to equalize the education 
among PD-N and PDD groups. 
 
Table 3-1: Definition of the final patient groups and their respective mean age and education in years 
Initial group PD-N PD-MCI PDD ANOVA 
(n=60) M ± sd M ± sd M ± sd F p 
Age 65.65 ± 6.9 (56 – 81) 70.25 ± 5.1 (63 – 79) 72.55 ± 5.5 (63 – 85) F (2,57) = 7.102 0.002 
Education 9.65 ± 4.2 8.05 ± 4.2 6.7 ± 4.0 F (2,57) = 2.580 0.085 
Female, Male 9, 11 3, 17 7, 13 - - 
Age matched 
(n=52) 
PD-N PD-MCI PDD F p 
Age 67.8 ± 5.9 (59 – 81) 69.3 ± 4.5 (63 – 77) 71.3 ± 4.3 (63 – 78) F (2,49) = 2.21 0.121 
Education 10.81 ± 3.8 8.06 ± 4.3 6.89 ± 4.2 F (2,49) = 4.00 0.025 
Female, Male 7, 9 3, 15 5, 13 - - 
Remarks: p < 0.05 
 
 
Table 3-2: Bonferroni corrected (3 groups) multiple comparison results for age and education 
after age matching (n=52) 
 PD-N vs PD-MCI PD-N vs PDD PD-MCI vs PDD 
 p p p 
Age 1.000 0.126 0.682 
Education 0.171 0.024 1.000 
Remarks: p < 0.05 
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3.2 Clinical characteristics of the patient groups 
The statistical comparison of the clinical characteristics revealed significantly longer disease 
duration (overall: p = 0.003) for the PDD group (10.8 ± 7.7 yrs.) compared to PD-N (4.9 ± 
2.9 yrs.) (p = 0.005) and PD-MCI (5.8 ± 3.2 yrs.) (p = 0.018) but not between PD-N and PD-MCI 
(p = 1.0). All three patient groups differed significantly from each other in the total score of 
the UPDRS (p < 0.001). Post-hoc tests showed higher UPDRS score for PDD group compared 
to the PD-N (p < 0.001) and for PDD vs PD-MCI groups (p < 0.001). UPDRS part III also differed 
significantly among the three patient groups (p < 0.001) with higher scores for PDD vs PD-N 
(p < 0.001) and PDD vs PD-MCI (p = 0.004). Motor dysfunction as indicated by the Hoehn & 
Yahr scale also showed a significant overall group effect (p < 0.001), which stemmed from 
significantly more severe motor symptoms of the PDD group compared to PD-N (p < 0.001) 
and PD-MCI (p < 0.001) groups. The cognitive status reflected by UPDRS cognitive scores 
significantly differed among the patient groups (p < 0.001), where PDD patients obtained 
significantly higher scores when compared to PD-N (p < 0.001) and PD-MCI groups (p < 0.001) 
(Table 3-3, Table 3-4). 
 
Table 3-3: Clinical characteristics of the final patient groups and one-way ANOVA 
 PD-N n=16 PD-MCI n=18 PDD n=18 One-way ANOVA  
 M ± sd M ± sd M ± sd F p 
Disease Duration (yrs.) a) 4.88 ± 2.87 5.83 ± 3.2 10.78 ± 7.67 F (2,49) = 6.61 0.003 
UPDRS total b) 40.19 ± 12.76 56.72 ± 22.6 103.72 ± 38.65 F (2,49) = 25.244 0.000 
UPDRS Part III b) 23.06 ± 8.59 33.67 ± 13.34 51.83 ± 22.56 F (2,49) = 13.917 0.000 
UPDRS Cognitive Score b) 0.94 ± 0.99 1.39 1.04 3.61 ± 0.61 F (2,49) = 44.35 0.000 
Hoehn & Yahr  a) 1.69 ± 0.6 1.89 ± 0.47 3 ± 1.09 F (2,49) = 14.640 0.000 
Remark: a): p < 0.05; b): adjusted alpha p < 0.05/3= 0.017.  
 
 
Table 3-4: Post-Hoc - Bonferroni corrected (3 groups) multiple comparison results 
 PD-N vs PD-MCI PD vs PDD PD-MCI vs PDD 
 p p p 
Disease Duration (yrs.) a) 1.000 0.005 0.018 
UPDRS total b) 0.253 0.000 0.000 
UPDRS Part III b) 0.186 0.004 0.000 
UPDRS Cognitive Score b) 0.449 0.000 0.000 
Hoehn & Yahr a) 1.000 0.000 0.000 
Remark: a): p < 0.05; b): adjusted alpha p < 0.05/3 = 0.017. 
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3.3 Psychiatric/Psychological tests 
The patient groups were tested for signs of major depression (exclusion criteria), anxiety, 
apathy and obsessive-compulsive behavior using the Geriatric depression scale (GDS), Beck 
Anxiety Inventory (BAI), Yale-Brown Obsessive Compulsive Scale (Y-BOCS), and Apathy 
Evaluation Scale (AES). The mean scores were statistically compared among the patient groups 
using one-way ANOVA and Bonferroni corrected independent t - test (p < 0.05) in the post-hoc 
test. The groups differed significantly in the GDS (p= 0.002) stemming from higher scores of 
the PDD compared to PD-N (p = 0.005) and PD-MCI (p = 0.005). Importantly, the groups did 
not show signs of major depression, as we used a cut-off of > 16 as an exclusion criterion. The 
groups further differed significantly regarding apathy symptoms (p = 0.022), stemming from 
stronger apathy signs in the PDD patients compared to the PD-N group (p = 0.034) (Table 3-5). 
There were no significant differences regarding signs of anxiety or obsessive-compulsive 
behavior. 
 
Table 3-5: Summary of the psychiatric evaluation of the patient groups 
  
n M sd 
One-way ANOVA Post-hoc  
Test Group F p Contrast p 
GDS PD-N 16 5.31 3.701 F (2,48) = 7.349 0.002 PD-N vs PD-MCI: 1.0 
PD-MCI 18 5.33 3.236   PD-N vs PDD: 0.006 
PDD 17 10.00 5.160   PD-MCI vs PDD: 0.005 
AES PD-N 12 61.92 2.906 F (2,41) = 4.189 0.022 PD-N vs PD-MCI: 1.0 
PD-MCI 16 60.19 5.683   PD-N vs PDD: 0.034 
PDD 16 53.81 11.680   PD-MCI vs PDD: 0.089 
BAI PD-N 12 5.50 4.739 F (2,40) = 2.797 0.073 -  
PD-MCI 16 6.13 4.815     
PDD 15 9.93 6.464     
Y-BOCS 
 
PD-N 12 1.58 4.274 F (2,40) = 0.966 0.389 -  
PD-MCI 16 0.25 0.775     
PDD 15 0.93 1.792     
Remarks: p < 0.05; Geriatric depression scale (GDS), Beck Anxiety Inventory (BAI), Yale-Brown 
Obsessive Compulsive Scale (Y-BOCS), Apathy Evaluation Scale (AES). 
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3.4 Drug treatment of the patient groups 
The respective drug treatment of the three patient groups is displayed in the Table 3-6. While 
the usage of anti-parkinsonian drugs was quite balanced across the patient groups regarding 
their active substances, the PDD group mostly differed from the PD-N and PD-MCI in the 
treatment against cognitive symptoms (acetylcholinesterase inhibitors) and the usage of anti-
psychotic drugs (quetiapine, clozapine). 
 
Table 3-6: PD-related and neuropsychiatric drugs used in the patient groups 
Drug-type Active substance PD-N PD-MCI PDD 
Acetylcholinesterase inhibitors 
(Dementia symptoms) 
Rivastigmine, donepezil 0 0 12 
Antidepressants Citalopram, escitalopram, sertraline, 
venlafaxine 
6 5 8 
Antipsychotics Seroquel (quetiapine), Lithium, 
Leponex (clozapine) 
0 0 7 
Monoamine oxidase (MAO)-B 
inhibitors 
Nervogil and Azilect 
(rasagiline) 
8 12 3 
L-amino acid decarboxylase / DOPA 
decarboxylase inhibitor 
Madopar (benserazide) 4 10 12 
L-Dopa (levodopa) Madopar - HBS 
(benserazide + L-Dopa (L-3.4-
dihydroxyphenylalanine)) 
1 3 3 
 
Stalevo (entacapone/ L-Dopa/ 
carbidopa (lodosyn)) 
8 4 4 
 Sinemet (carbidopa, L-Dopa) 1 2 1 
 Total L-Dopa 10 9 8 
Catechol-O -methyl transferase 
inhibitor 
Comtan (entacapone) 1 2 0 
Dopamine - Agonists Pexola (pramipexol) 4 7 3 
Trivastal (piribedil) 1 1 1 
Apo-go (apomorphine) 0 0 2 
Requip (ropinirole) 2 0 0 
 Total DA-Agonist 7 8 6 
NMDA-blocker 
(indirect DA-agonist) 
PK-Merz (amantadine) 4 5 2 
Anti-cholinergic Sormodren (bornaprin) 1 0 0 
Remarks: Displayed in number of patients. 
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3.5 Neuropsychological data 
All patients underwent a comprehensive neuropsychological investigation, and the PD-MCI 
diagnosis was based on the level I criteria (see introduction and methods). 
All patients completed the ACE-R test (including verbal fluency, pentagon copying, cube 
copying, clock drawing) and MMSE test. One PDD patient did not finish primary school, thus a 
special version of the MMSE was applied. That particular patient still completed ACE-R test, 
but not the JOLO, Stroop, SDMT, Navon and WCST. Beyond this subject, several tests couldn’t 
be administered to some patient’s due to severe cognitive deficits. 
Precisely, six additional PDD patients were not able to perform the Stroop, 11 PDD patients 
were not able to complete the WCST, 2 PDD patients could not finish the MOCA and 9 PDD 
patients did not understand the SDMT during the training part of the SDMT. Six PDD patients 
did not succeed in the training part of the JOLO, thus did not finish the test. 
The MOCA was not applied to 1 PDD, 4 PD-N and 3 PD-MCI patients, and Navon was not 
administered to 3 PDD, 4 PD-N and 3 PD-MCI cases. Hence, various subsets of patient groups 
were statistically compared for the respective tests. 
 
All NPTs were statistically evaluated using the one-way ANOVA test (Table 3-7). For significant 
tests the Bonferroni corrected multiple comparison results were inspected and a significance 
level of either p < 0.05 (independent tests such as ACE-R) or the Bonferroni adjusted alpha 
(dependent tests, e.g. different values for WCST) were reported (Table 3-8). The initial alpha 
(p < 0.05) was adjusted for the number of variables in dependent tests, according Bonferroni 
method (e.g. WCST: p < 0.05/3 = 0.017). 
 
3.5.1 Global tests 
The patient groups differed significantly between each other according the ACE-R (overall: 
p < 0.001) with lower scores for PD-MCI vs PD-N (p = 0.013), PDD vs PD-N (p < 0.001) and for 
PDD vs PD-MCI (p < 0.001) (Table 3-7 and Table 3-8). 
While the PD-N and PD-MCI did not differ significantly for the MMSE (p = 0.936), the PDD 
scored significantly worse compared to PD-N (p < 0.001) and to PD-MCI (p < 0.001). 
Additionally, the groups differed for the MOCA test performance (p < 0.001), with PD-MCI 
being worse than PD-N (p = 0.039) and PDD being worse than PD-N (p < 0.001) and PD-MCI 
(p < 0.001). 
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3.5.2 Test for visuo-spatial functions 
3.5.2.1 Benton Judgement of Line Orientation Test - JOLO 
The patient groups differed significantly in the JOLO test (p < 0.001) stemming from a 
significantly worse performance of the PDD compared to PD-N (p < 0.001). The PDD vs PD-MCI 
(p = 0.092) and PD-MCI vs PD-N (p = 0.052) comparison were not significant (Table 3-8). 
 
3.5.2.2 Figure copying 
In the pentagon copying test (overall: p < 0.001) the PDD scored significantly less compared 
to PD-N (p < 0.001) and PD-MCI (p < 0.001), but PD-N and PD-MCI did not show any difference 
(p = 1.0). The PDD also showed significantly lower abilities in the cube copying compared to 
PD-N (p < 0.001) and PD-MCI (p = 0.035), but the PD-MCI and PD-N did not differ significantly 
from each other (p = 0.0157) (Table 3-8). 
 
3.5.2.3 Navon 
Two PDD patients showed signs of simultanagnosia, but the patient groups did not differ 
significantly regarding their performance in the Navon test (p = 0.166). 
 
3.5.2.4 Clock drawing 
In the clock drawing tests (p < 0.001) the PDD group showed significantly lower abilities 
compared to PD-N (p < 0.001) and PD-MCI (p < 0.001), while there was no significant difference 
between PD-N and PD-MCI (p = 0.873) (Table 3-8). 
 
3.5.3 Tests for executive functions 
3.5.3.1 Stroop 
In the Stroop test, the patient groups differed significantly regarding the number of mistakes 
(p < 0.001) and the time difference (p = 0.016) but not regarding the amount of spontaneous 
corrections (p = 0.543) (Table 3-7). The PDD made significantly more mistakes than the PD-N 
(p < 0.001) and PD-MCI (p < 0.001) but the overall Stroop effect did not survive the Bonferroni 
corrected group comparison and using Bonferroni adjusted alpha (p < 0.017) (PD-MCI vs PD-
N: p = 0.055, PDD vs PD-N: p = 0.030, PDD vs PD-MCI: p = 1.0) (Table 3-8). 
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3.5.3.2 Wisconsin Card Sorting Test - WCST 
The three groups did not differ for the % of perseverative errors in the WCST (p = 0.147) but 
showed significant difference for both, the number of categories and number total errors 
(p < 0.001) (Table 3-7). While, the PD-MCI and PDD did not differ significantly regarding their 
performance in the number of completed categories (p = 0.669) and the total number of errors 
(p = 0.826), the PD-MCI and PDD completed significantly less categories compared to PD-N 
(PD-MCI vs PD-N: p = 0.002, PDD vs PD-N: p = 0.001). The PDD and PD-MCI also made 
significantly more errors in the WCST than PD-N (PD-MCI vs PD-N: p =0.003, PDD vs PD-N: 
p = 0.002) (Table 3-8). 
 
3.5.3.3 Verbal fluency 
The PD-N were significantly better in phonemic fluency when compared to PD-MCI (p = 0.017) 
and PDD (p < 0.001) but there was no difference for PD-MCI vs PDD (p = 0.101) (Table 3-8). 
PDD showed worse performance in the semantic fluency test compared to PD-N (p < 0.001) 
and PD-MCI (p < 0.001), while PD-N compared to PD-MCI did not show any significant 
difference (p = 0.414) (Table 3-8). 
 
3.5.3.4 SDMT 
The overall statistical comparison of the SDMT scores demonstrated significant difference 
between the study groups regarding the total number of answers (p < 0.001) and the number 
of correct answers (p < 0.001). While there was no difference between PDD and PD-MCI 
(p > 0.025), the PD-MCI showed significantly worse performance than the PD-N group 
(number of answers: p < 0.001, correct answers: p < 0.001) and PDD was also significantly 
worse than PD-N (number of answers: p < 0.001, correct answers: p < 0.001) (Table 3-8). 
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Table 3-7: The mean and standard deviation for all conducted neuropsychological tests and one-way ANOVA 
results 
 PD-N n=16 PD-MCI n=18 PDD n=18 One-way ANOVA 
 M ± sd M ± sd M ± sd F p 
ACE-R (100) a) 88.63 ± 3.56 77.28 ± 5.39 56.5 ± 17.59 F (2,49) = 37.57 0.000 
MMSE (30) a) 29.19 ± 0.83 28.17 ± 1.54 21.72 ± 4.62 F (2,49) = 33.88 0.000 
Phonemic fluency (7) a) 5.0 ± 1.1 3.56 ±1.29 2.5 ±1.82 F (2,49) = 12.64 0.000 
Semantic fluency (7) a) 5.44 ± 1.41 4.67 ± 1.37 2.17 ±1.66 F (2,49) = 22.93 0.000 
Pentagon copy (1) a) 0.94 ± 0.25 0.83 ± 0.38 0.11 ± 0.32 F (2,49) = 33.32 0.000 
Cube copy (2) a) 1.69 ± 0.60 1.17 ± 0.86 0.5 ± 0.79 F (2,49) = 10.41 0.000 
Clock Drawing (5) a) 4.56 ± 0.81 4.11 ± 1.02 1.83 ± 1.65 F (2,49) = 24.66 0.000 
 n=12 n=15 n=14   
MOCA (30) a) 25.25 ± 1.96 21.73 ± 2.76 14.14 ± 4,89 F (2,38) = 35.24 0.000 
 n=16 n=18 n=11   
JOLO (30) a) 24.19 ± 3.71 19.33 ± 6.04 14.46 ± 7.33 F (2,42) = 9.64 0.000 
 n=12 n=15 n=14   
Navon (2) a) 1.83 ± 0.39 1.93 ± 0.26 1.57 ± 0.76 F (2,38) = 1.89 0.166 
Stroop b) n=16 n=18 n=11   
Mistakes 0.38 ± 1.03 1.61 ± 3.05 24.55 ± 18.92 F (2,42) = 25.78 0.000 
Spontan. correction 3 ± 3.62 4.44 ± 3.91 3.91 ± 3.86 F (2,42) = 0.62 0.543 
Time diff. in s 59.19 ± 15.36 92.94 ± 43.51 101.46 ± 56.35 F (2,42) = 4.54 0.016 
WCST b) n=16 n=18 n=6   
Categories 4.38 ± 1.96 2.28 ± 1.27 1.33 ± 1.51 F (2,37) = 10.77 0.000 
Perseverative error % 20.86 ± 10.19 28.73 ± 10.75 29.43 ± 20.92 F (2,37) = 2.02 0.147 
Error 42.31 ± 21 89 64.39 ± 15.04 73.67 ± 11.45 F (2,37) = 9.65 0.000 
SDMT c) n=16 n=18 n=8   
Total 31.19 ± 10.34 16.89 ± 7.08 13 ± 6.72 F (2,39) = 17.32 0.000 
Correct 30.63 ± 10.53 15.11 ± 7.79 11.25 ± 6.52 F (2,39) = 18.54 0.000 
Remark: a) p < 0.05, b) p < 0.05/3 =0.017, c) p < 0.05/2 = 0.025. 
 
 
 
 
 
 
79 
 
Table 3-8: Bonferroni corrected (3 groups) multiple comparison results 
 PD-N vs PD-MCI 
p 
PD-N vs PDD 
p 
PD-MCI vs PDD 
p 
ACE-R a) 0.013 0.000 0.000 
MMSE a) 0.936 0.000 0.000 
Semantic fluency a) 0.414 0.000 0.000 
Phonemic fluency a) 0.017 0.000 0.101 
Pentagon copy a) 1.0 0.000 0.000 
Cube copy a) 0.157 0.000 0.035 
Clock Drawing   a) 0.873 0.000 0.000 
MOCA a) 0.039 0.000 0.000 
JOLO a) 0.052 0.000 0.092 
Navon a) 1.0 0.608 0.197 
Stroop b) 
Mistakes 1.0 0.000 0.000 
Spontaneous correction 0.823 1.000 1.00 
Time diff. in s 0.055 0.030 1.0 
WCST b) 
Categories 
 
0.002 
 
0.001 
 
0.669 
Perseverative error % 0.219 0.474 1.00 
Error 0.003 0.002 0.826 
SDMT c) 
Total 
 
0.000 
 
0.000 
 
0.853 
Correct 0.000 0.000 0.918 
Remark: a) p < 0.05, b) p < 0.05/3 =0.017, c) p < 0.05/2 = 0.025. 
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3.6 MR-DATA 
3.6.1 Group Independent Component Analysis of the rs-fMRI Data 
30 independent components (IC) were obtained using the group independent component 
analysis. After visual inspection and artifact rejection 16 ICs that best resembled the 
well-established RSNs in the literature were chosen for further analysis: somato-motor 
network (3 sub-components: SM1, L-SM2 and R-SM2), visual network (2 components: medial 
and lateral visual cortices), posterior- temporal network (PTN), salience network (SN), limbic 
network (LN), left and right fronto-parietal networks (L-FPN and R-FPN), dorsal attention 
network (DAN), parahippocampal network, thalamus, frontostriatal network (FSN), cerebellar 
network (CN) and the default mode network (DMN) (Figure 3-1). 
 
 
Figure 3 -1: Identified ICs as output of the Group Independent Component Analysis. Figure continues on next 
page. 
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Figure 3-1: Identified ICs as output of the Group Independent Component Analysis. The RSNs are displayed 
overlaid on the average MNI-152 T1 weighted brain extracted standard template (average anatomic image of 
152 person) and the respective MNI coordinates are shown under each picture. The color coding represents the 
relative contribution of each voxel to the specific independent component. The following RSNs are displayed: 
PTN: Posterior-temporal network, SN: Salience network, LN: limbic network, DMN: Default mode network, CN: 
Cerebellar network, FSN: Frontostriatal network, FPN: Frontoparietal network, med.Vis. and lat.Vis.: medial and 
lateral visual network, SM1 and SM2: Somato-motor networks, DAN: Dorsal attention network, parahippocampal 
network and thalamus. 
3.6.1.1 LOGISTIC REGRESSION ANALYSIS for NETWORK EXPRESSION 
The expression scores of the 16 RSNs in each subject were obtained by calculating the dot 
product of the subject’s and mean group spatial maps, and fed into the forward stepwise 
conditional binary logistic regression analysis in order to identify the combination of the RSNs 
that based on their expression level best discriminated PDD from other PD patients. For this 
purpose, the following pairs of groups were separately analyzed with binary logistic 
regression: PD-N vs PDD, PD-MCI vs PDD, PD-non-demented (PD-N+PD-MCI) vs PDD and PD-
N vs PD-MCI. 
In order to visualize the relative weights of the discriminative RSNs in each patient group, the 
means of the subjects back-reconstructed images are displayed in Figure 3-2, Figure 3-3 and 
Figure 3-4 for each component that significantly contributed to the logistic regression model. 
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PD-N vs PDD 
The logistic regression showed that the combination of the salience NW, the limbic NW, the 
frontostriatal NW and posterior DMN together in this order was successful in discriminating 
the PD-N from PDD (χ2 = 26.69, df=4, p < 0.001) with an overall accuracy of 85.3% (83.3-87.5%) 
with the final model (R2 = 0.726). The mean expression of these networks is displayed in Figure 
3-2. While, the expression scores of the limbic NW and frontostriatal NW were lower in PDD 
compared to PD-N, the expression scores of the DMN and salience NW were higher for the 
PDD group. The mean and range of the effect size (odds ratio) of the corresponding networks 
are: salience NW: 18.666 (1.436-242.564, p = 0.025), limbic NW: 0.007 (0.0-0.754, p = 0.038), 
frontostriatal NW: 0.004 (0.0-0.486, p = 0.025), posterior DMN: 5.737 (0.946-34.782, 
p = 0.057) (Figure 3-2). 
 
Figure 3-2: The group means of the salience NW, the limbic NW, the frontostriatal NW and the DMN in the PD-N 
and PDD are displayed on the MNI-152 T1 weighted standard template and the respective MNI coordinates are 
shown below each picture. The color coding represents % signal change. 
 
83 
 
PD-MCI vs PDD 
When comparing the PD-MCI and PDD, the logistic regression showed, that the limbic NW, 
the DMN and posterior temporal NW together where most successful in discriminating these 
groups (χ2 = 21.009, df=3, p < 0.001) with an overall correct prediction of 83.3% (83.3% and 
83.3%) for the final model (R2 = 0.589). The mean expression of these networks is displayed in 
Figure 3-3. Compared to PD-MCI, the PDD group expressed a stronger DMN but weaker limbic 
NW and posterior temporal NW connectivity. The effect size (odds ratio) of the corresponding 
networks are: DMN: 7.473 (1.371-40.721, p = 0.02), the limbic NW: 0.01 (0.0-0.269, p = 0.006) 
and the posterior temporal NW: 0.117 (0.01-1.133, p = 0.064) (Figure 3-3). 
 
Figure 3-3: The means of the DMN, the limbic NW and the posterior temporal NW in the PD-MCI and PDD groups 
are displayed superimposed on the MNI-152 T1 weighted template and the respective MNI coordinates are 
shown below each picture. The color coding represents % signal change. 
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PD-non-demented vs PDD 
When the PD-N and PD-MCI together were tested against the PDD, the logistic regression 
showed an overall correct prediction of 84.6% (77.8-88.2%) (R2= 0.593) in the final model that 
included the limbic NW, DMN, frontostriatal NW and salience NW (χ2 = 29.208, df=4, 
p < 0.001). The mean expression of these networks is displayed in Figure 3-4. The limbic and 
frontostriatal NW showed lower expression scores for the PDD, while the expression scores 
for the posterior DMN and salience NW were increased in PDD. The effect sizes (odds ratio) 
of the corresponding networks are: limbic NW: 0.024 (0.001-0.373, p = 0.008), frontostriatal 
NW: 0.028 (0.001-0.515, p = 0.016), DMN: 3.377 (0.933-12.219, p = 0.064), salience NW: 4.130 
(0.983-17.357, p = 0.053) (Figure 3-4). 
 
 
Figure 3-4: The group means of the limbic NW, DMN, frontostriatal NW and salience NW in the PD-non-demented 
(PD-nd.) and PDD groups are displayed superimposed on the MNI-152 T1 weighted standard template, and the 
respective MNI coordinates are shown below each picture. The color coding represents % signal change. 
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PD-N vs PD-MCI 
The logistic regression analysis did not reveal any significant difference in network expression 
levels between the PD-N and PD-MCI. However, the two important RSNs, DMN and SN, that 
showed significant effect in the regression model between the PDD and PD-non-demented 
groups actually showed a progressive increase in intrinsic functional connectivity from PD-N 
through PD-MCI and PDD, that is along the progression of the cognitive decline (Figure 3-5). 
 
 
Figure 3-5: The group means of the default mode network (DMN) and salience network (SN) in the three PD 
groups are displayed superimposed on the MNI-152 T1 weighted standard template. The color coding represents 
% signal change. 
 
3.6.1.2 VOXEL-BASED COMPARISON for FUNCTIONAL CONNECTIVITY 
While we used the logistic regression analysis on the expression scores of the networks for 
the evaluation of the discriminative power of the overall network pattern between the patient 
groups, in a second step we also applied voxel-based two sample t-test comparisons as 
implemented in the second-level analysis module of the SPM8 software in order to determine 
the specific regions of each network that show the strongest intrinsic connectivity difference 
between different patient groups. We tested the following contrasts: PD-N vs PDD, PD-MCI vs 
PDD, PD-non-demented vs PDD and PD-N vs PD-MCI. 
In order to run the comparisons within the specific spatial extent of each network, explicit 
mask of each network was created based on a one-sample t-test carried out on the 
reconstructed network maps of all subjects. Only voxels with a t value above 3 were included 
in the explicit mask. By this way, a common solution space was created for each network 
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before the group comparisons are carried out by two sample t-tests with family-wise error 
(FWE) correction. The clusters obtained with an uncorrected height-threshold of p < 0.001 
were compared between pairs of patient groups and clusters with cluster-level FWE-corrected 
p < 0.05 are reported. 
 
The PD-N vs PDD 
Complementary to the results of the binary logistic regression analysis, we found locally 
significant differences in the functional connectivity of the limbic NW and salience NW 
between PD-N and PDD. 
 
Limbic Network 
Compared to PD-N, PDD showed significantly reduced functional connectivity (p = 0.027) in a 
cluster of 206 voxels in the limbic NW with peak coordinates in the right thalamus (12 -14 4). 
The cluster also included the lentiform nucleus and putamen (Figure 3-6). 
 
Figure 3-6: Significant cluster of decreased functional connectivity in the right thalamus of the limbic NW in PDD 
compared to PD-N. 
 
Salience Network - SN 
Other than in the limbic NW, we found increased functional connectivity in two clusters of the 
salience NW in the PDD group compared to PD-N (Figure 3-7). One significant cluster 
(p = 0.046) composed of 147 voxels covers mainly extra nuclear space and cingulum in 
addition to a small portion of the caudate body. The other cluster with a FWE-corrected p 
value close to significance (p = 0.056) of 137 voxels was in the right insula (peak) and included 
also parts of the superior temporal gyrus. 
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Figure 3-7: Two significant clusters of increased functional connectivity in the right insula and extra- nuclear space 
within the salience NW of PDD compared to PD-N patients. 
 
 
PD-MCI vs PDD 
As in the binary logistic regression analysis, we found significant differences in the functional 
connectivity within the limbic network between PDD and PD-MCI using the voxel-wise 
comparison method. 
 
Limbic Network 
Compared to PD-MCI, PDD showed significantly reduced functional connectivity in two 
different clusters: one significant cluster (p = 0.004) of 312 voxels with its peak in the left 
hippocampus and another significant cluster (p = 0.014) of 233 voxels with its peak in the right 
hippocampus (Figure 3-8). In the same network, we also found the opposite contrast for PDD, 
namely increased functional connectivity in a significant cluster (p < 0.001) of 693 voxels 
mainly located on extra-nuclear space and white matter (corpus callosum). 
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Figure 3-8: Three significant cluster within the limbic NW when comparing PD-MCI and PDD. Significant 
decreased functional connectivity in the left and right hippocampus in the PDD and significantly increased 
functional connectivity mainly located on extra-nuclear space and white matter (corpus callosum). 
 
PD-non-demented vs PDD 
When the data of the PD-N and PD-MCI were brought together and tested against the PDD 
group, significant differences in functional connectivity were found in the limbic NW and the 
frontostriatal NW. 
 
Limbic NW 
As in the PD-N vs PDD and PD-MCI vs PDD comparison, we could identify three significant 
clusters in the limbic NW for PDD vs PD-non-demented (Figure 3-9). The PDD group showed 
significantly decreased functional connectivity in one cluster (282 voxels) in the left 
hippocampus (p = 0.008) and in another cluster (326 voxels) located on the right thalamus 
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(p = 0.004). The cluster with its peak in the right thalamus covers mostly the thalamus (the 
ventral lateral and the medial dorsal nuclei) and parts of the basal ganglia (lentiform nucleus, 
putamen, lateral globus pallidus). In the third cluster (850 voxels), the PDD group showed 
significantly increased functional connectivity (p < 0.001) compared to PD-non-demented, but 
an important part of this cluster resides in white matter and extra-nuclear space. 
 
 
Figure 3-9: Three significant clusters within the limbic NW in the comparison PDD vs PD-non-demented (PD-nd.). 
Significantly decreased functional connectivity is obtained in the left hippocampus and right thalamus in the PDD 
and significantly increased functional connectivity in a cluster that mainly resides in white matter and extra-
nuclear space. 
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Frontostriatal NW - FSN 
For the frontostriatal NW, we could find significantly decreased functional connectivity in a 
cluster of 641 voxels (p = 0.032) for the PDD when using a height-threshold of p < 0.005 but 
not with a height threshold of p < 0.001 as applied in all other comparisons (Figure 3-10). 
However, this result is still worth of reporting, because the same network did significantly 
contribute to the binary logistic regression model that discriminated the PDD form PD-non-
demented patients. The cluster covers mostly the left caudate head and body, parts of the 
putamen, the lentiform nucleus and to a lesser part the right caudate. 
 
Figure 3-10: Significant cluster at height-threshold p < 0.005 showing decreased functional connectivity in the 
caudate, putamen and lentiform nucleus within the frontostriatal NW in PDD when compared to PD-non-
demented (PD-nd.). 
 
PD-N vs PD-MCI 
No significant differences in functional connectivity were found between the PD-N and PD-
MCI groups. 
 
3.6.1.3 SUMMARY OF THE RS-FMRI DATA 
Both the logistic regression and voxel-based analyses delivered complementary results. Based 
on the resting state data we can summarize, that the PDD patients show significantly lower 
expression of the limbic network, posterior temporal network and frontostriatal network 
compared to non-demented PD patients, which are supported by decreased functional 
connectivity in the thalamus, hippocampus and the caudate/putamen in voxel-based 
comparisons. Opposite to that, the overall expression of the DMN and salience network are 
stronger in PDD patients, where the stronger expression of the salience network is supported 
by increased functional connectivity in the right insula in voxel-based comparison of PD-N vs 
PDD groups (Table 3-9). 
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Table 3-9: Summary for the binary logistic regression results of the expression scores and the voxel- based 
comparisons for functional connectivity of the rs-fMRI data 
Comparison RSNs 
Logistic regression – 
NW expression 
Voxel-based – 
Functional connectivity 
PD-N vs PDD Limbic NW ↓ R - Thalamus↓ 
 FSN ↓ - 
 DMN ↑ - 
 Salience NW ↑ Caudate ↑ & R - Insula ↑ 
PD-MCI vs PDD Limbic NW ↓ L- HC ↓, R - HC ↓, Caudate ↑ 
 PTN ↓ - 
 DMN ↑ - 
PD-nd. vs PDD Limbic NW ↓ L-HC↓, R-Thalamus↓, Caudate↑ 
 FSN ↓ Caudate, Putamen ↓ 
 DMN ↑ - 
 Salience NW ↑ - 
 
3.6.1.4 Correlations of the RSNs with Clinical and Neuropsychological Variables 
In order to associate the cognitive dysfunctions and motor symptoms of the PD patients with 
the functional connectivities, one-tailed non-parametric (Spearman’s) bivariate correlation 
analyses were carried out for the significant findings obtained with the expression of the RSNs 
and the clinical and neuropsychological data collected from the 52 PD patients. 
For Bonferroni correction, the clinical/neuropsychological variables were grouped into 
categories and based on the numbers of parameter in each category the alpha was adjusted: 
clinical data (p < 0.05/5= 0.01; UPDRS-total, UPDRS-III, UPDRS-cognitive score, Hoehn &Yahr, 
GDS), global neuropsychological tests (p < 0.05/7 = 0.0071; ACE-R, Semantic fluency, 
phonemic fluency, pentagon copying, cube copying, clock drawing, MOCA) and specific 
neuropsychological tests (p < 0.05/7 = 0.0071; Stroop-mistakes and Stroop-effect, SDMT-total 
and SDMT-correct, WCST-category and WCST-error, JOLO). 
The analyses showed that the expression of the limbic NW was negatively correlated with 
disease duration, the UPDRS - total and the UPDRS - cognitive score (p < 0.01), while the 
expression of the DMN was positively correlated with education and the Hoehn & Yahr score 
(p < 0.01). Beyond these, the expression of the FSN was positively correlated with better clock 
drawing performance (p < 0.0071), which is in line with stronger FSN expression and better 
performance in the clock drawing test in PD-N and PD compared to PDD. Finally, the salience 
network showed negative correlation with semantic fluency (p < 0.0071), which is reasonable 
as the PDD group showed bad performance in semantic fluency compared to PD-N and 
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PD-MCI and at the same time displayed stronger SN expression. The correlation analyses 
results for the RSNs are displayed in (Table 3-10). 
 
Table 3-10: Correlation of RSN expression and the clinical and neuropsychological parameters 
Expression scores of the RSNs 
Clinical / neuropsychological variables PTN DMN Limbic NW FSN SN 
Education a) Corr.Coef. 0.247 0.334 0.071 0.023 0.026 
p (1-tailed) 0.039 0.008 NS NS NS 
Disease Duration a) Corr.Coef. 0.037 0.145 -0.344 0.049 0.164 
p (1-tailed) NS NS 0.006 NS NS 
UPDRS – total b) Corr.Coef. -0.230 0.194 -0.328 -0.126 0.242 
p (1-tailed) NS NS 0.009 NS NS 
UPDRS - Cognitive b) Corr.Coef. -0.124 0.138 -0.386 -0.242 0.159 
p (1-tailed) NS NS 0.002 NS NS 
Hoehn & Yahr b) Corr.Coef. -0.187 0.344 -0.260 -0.036 0.296 
p (1-tailed) NS 0.006 NS NS NS 
Semantic Fluency c) Corr.Coef. 0.135 -0.314 0.244 0.119 -0.366 
p (1-tailed) NS NS NS NS 0.004 
Clock Drawing c) Corr.Coef. 0.036 -0.202 0.246 0.336 -0.316 
p (1-tailed) NS NS NS 0.007 NS 
Remarks: a) p < 0.05, b) p < 0.01, c) p < 0.0071. 
 
3.6.2 DTI-Results 
DTI data from all the PD patients were collected in order to gain information about the 
underlying structural white matter changes associated with cognitive decline in PD. 
We used a ROI-based approach for white-matter analysis using 20 white-matter-tracts from 
the Johns Hopkins University–ICBM atlas (JHU-ICBM-tracts-maxprob-thr0-1mm) (Figure 3-12) 
and compared the mean FA, MD, RD and AD values of the voxels within these ROIs among the 
three groups by one-way ANOVA. After correcting the ANOVA results for the multiple 
comparisons in 20 ROIs, post-hoc two-sample t-tests were carried out between the following 
pairs of groups: PD-N vs PDD, PD-MCI vs PDD and PD-N vs PD-MCI (see methods). 
For this purpose, the FA maps of all patients were first averaged and voxels of the obtained 
mean image with FA < 0.2 were excluded in order to exclude GM and CSF and obtain a 
study-specific white-matter mask corresponding to the investigated subjects (Figure 3-11). 
The JHU-ICBM atlas was multiplied with the study-specific white matter mask in order to 
obtain the study-specific ROIs (Figure 3-12, Table 3-11). In an automatized process using the 
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FSlstats command in FSL, each subject’s mean FA, MD, RD and AD values for each of the study-
specific ROIs have been calculated. 
 
Figure 3-11: Computation of the study-specific white matter mask. In the first row the FMRIB58 FA template is 
displayed. The second row shows the mean FA map of all subjects in our study and in the third row the 
thresholded (> 0.2) white-matter mask is displayed. 
 
Figure 3-12: Computation of the study-specific ROIs. The original ROIs of the JHU-ICBM tracts-maxprob-thr0-
1mm atlas are shown in the first and the study-specific ROIs obtained by voxel-wise multiplication of this atlas 
with the study-specific white matter mask (Fig. 3-11) in the second row. The study-specific ROIs in the second 
row consist of a sub-set of voxels of the same ROIs in the original atlas. 
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Table 3-11: ROI-size in total voxel number used in DTI ROI-based analyses 
 Study-specific ROI-size Original ROI-size 
ROI Left Right Left Right 
ATR 37105 33182 54291 49337 
CST 26706 28528 36577 37946 
Cingulum-Cingulate 17670 13672 26228 18969 
Cingulum-HC 6157 6881 9858 10118 
IFOF 25111 33720 41508 51961 
ILF 25900 25380 46905 42441 
SLF 51617 49266 103293 94044 
Uncinate 7103 5973 12074 10524 
SLF-temp 808 3562 1390 4635 
Forceps major 31617 - 49803 - 
Forceps Minor 28730 - 56701 - 
Remark: ROI-size displayed in number of voxels 
 
3.6.2.1 ANOVA analyses among the 3 patient groups 
For comparisons of the PD-N, PD-MCI and PDD groups one-way ANOVAs were first performed 
for FA values of each of the 20 ROIs with Bonferroni adjusted alpha (p < 0.0025). The results 
showed that anterior thalamic radiation (ATR) R, corticospinal tract (CST) L and R, cingulum 
cingulate gyrus L and R, inferior fronto-occipital fasciculus (IFOF) L and R, inferior longitudinal 
fasciculus (ILF) L and R, superior longitudinal fasciculus (SLF) L and R, superior longitudinal 
fasciculus – temporal region (SLF-temp.) L show significant differences among the 3 patient 
groups (Table 3-12).  
For those ROIs showing significant FA difference after Bonferroni correction, mean MD, RD 
and AD values were further tested with one-way ANOVAs among the groups with the same 
adjusted alpha (p < 0.0025). The results showed that the mean MD values differed significantly 
among the 3 groups in cingulum cingulate gyrus L and R, IFOF L, ILF L and R, SLF L and SLF 
temp. L (Table 3-13), while RD values significantly differed in cingulum cingulate gyrus L, IFOF 
L, ILF L and R, SLF L and SLF-temp. L (Table 3-14) and mean AD values significantly differed 
between the 3 groups in cingulum cingulate gyrus L, IFOF, ILF L and R and SLF L (Table 3-15). 
 
Overall, the FA values resulted in significant differences in 12 of the investigated 20 WM tracts 
(Figure 3-13). 
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Figure 3-13: ROIs with significant FA differences among the 3 patient groups displayed on FMRIB58 FA template. 
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Table 3-12: Mean FA values of the PD-N, PD-MCI and PDD patients and one-way ANOVA results for 20 ROIs 
 
PD-N n=16 PD-MCI n=18 PDD n=18 ANOVA 
ROIs M sd M sd M sd F (2,49) p 
ATR-L 0.390 0.027 0.379 0.031 0.355 0.033 6.001 NS 
ATR-R 0.397 0.023 0.390 0.022 0.367 0.027 7.558 0.001 
CST-L 0.468 0.016 0.468 0.023 0.444 0.022 8.360 0.001 
CST-R 0.468 0.015 0.462 0.024 0.439 0.022 9.082 0.000 
Cing. Cingulate. Gyr-L 0.390 0.018 0.384 0.020 0.361 0.024 9.220 0.000 
Cing. Cingulate. Gyr-R 0.367 0.018 0.364 0.021 0.342 0.025 7.088 0.002 
Cing.- HC.-L 0.305 0.017 0.299 0.014 0.288 0.018 4.622 NS 
Cing.- HC.-R 0.318 0.014 0.317 0.015 0.301 0.021 5.527 NS 
Forc.-Major 0.418 0.025 0.408 0.038 0.383 0.038 4.873 NS 
Forc.-Minor 0.423 0.027 0.412 0.033 0.385 0.040 5.744 NS 
IFOF-L 0.369 0.018 0.364 0.020 0.341 0.021 9.709 0.000 
IFOF-R 0.382 0.021 0.375 0.025 0.351 0.027 7.401 0.002 
ILF-L 0.355 0.014 0.344 0.024 0.326 0.021 8.843 0.001 
ILF-R 0.345 0.018 0.337 0.024 0.319 0.020 6.975 0.002 
SLF-L 0.360 0.017 0.352 0.024 0.330 0.022 9.569 0.000 
SLF-R 0.357 0.017 0.347 0.025 0.328 0.021 8.415 0.001 
Uncinate-Fasc.-L 0.357 0.024 0.352 0.016 0.339 0.026 2.997 NS 
Uncinate-Fasc.-R 0.347 0.035 0.346 0.028 0.340 0.030 0.276 NS 
SLF-temp-L 0.379 0.024 0.371 0.024 0.344 0.022 10.807 0.000 
SLF-temp-R 0.414 0.018 0.404 0.032 0.381 0.033 6.124 NS 
Remark: Bonferroni adjusted alpha = p < 0.0025. 
 
 
Table 3-13: Mean MD values of the PD-N, PD-MCI and PDD patients and one-way ANOVA results for 12 ROIs 
 PD-N n=16 PD-MCI n=18 PDD n=18 ANOVA 
ROIs 
 
M 
 
sd 
 
M 
 
sd 
 
M 
 
sd 
 
F 
(2,49) 
P 
 
ATR-R 98.156 E-5 12.48 E-5 102.54 E-5 11.77 E-5 112.35 E-5 12.407 E-5 6.108 NS 
CST-L 88.313 E-5 6.849 E-5 91.711 E-5 9.171 E-5 98.456 E-5 11.940 E-5 4.931 NS 
CST-R 87.450 E-5 7.076 E-5 91.122 E-5 8.413 E-5 97.944 E-5 11.320 E-5 5.778 NS 
Cing.gyr.-L 83.806 E-5 4.145 E-5 86.333 E-5 4.998 E-5 91.594 E-5 7.787 E-5 7.776 0.001 
Cing.gyr.-R 83.544 E-5 4.041 E-5 85.622 E-5 5.489 E-5 91.000 E-5 7.659 E-5 7.151 0.002 
IFOF-L 90.188 E-5 5.468 E-5 92.672 E-5 5.085 E-5 98.639 E-5 6.981 E-5 9.299 0.000 
IFOF-R 89.988 E-5 7.379 E-5 93.117 E-5 6.686 E-5 98.367 E-5 7.844 E-5 5.743 NS 
ILF-L 87.138 E-5 3.285 E-5 90.017 E-5 5.160 E-5 95.900 E-5 5.684 E-5 14.46 0.000 
ILF-R 85.475 E-5 4.157 E-5 89.156 E-5 5.596 E-5 94.861 E-5 6.538 E-5 12.35 0.000 
SLF-L 84.675 E-5 4.602 E-5 88.239 E-5 7.237 E-5 94.083 E-5 8.731 E-5 7.567 0.001 
SLF-R 85.263 E-5 5.289 E-5 87.889 E-5 7.218 E-5 93.617 E-5 8.141 E-5 6.338 NS 
SFL temp.-L 82.975 E-5 4.632 E-5 85.028 E-5 5.112 E-5 90.406 E-5 6.177 E-5 8.821 0.001 
Remark: Bonferroni adjusted alpha = p < 0.0025. 
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Table 3-14: Mean RD values of the PD-N, PD-MCI and PDD patients and one-way ANOVA results for 12 ROIs 
 PD-N n=16 PD-MCI n=18 PDD n=18 ANOVA 
ROIs M sd M sd M sd F (2,49) p 
ATR-R 78.882 E-5 12.53 E-5 83.128 E-5 12.28 E-5 93.256 E-5 12.765 E-5 6.002 NS 
CST-L 65.956 E-5 6.773 E-5 68.928 E-5 9.381 E-5 76.333 E-5 11.985 E-5 5.227 NS 
CST-R 65.294 E-5 6.882 E-5 68.772 E-5 8.810 E-5 76.1 E-5 11.232 E-5 6.153 NS 
Cing.Gyr-L 65.456 E-5 4.559 E-5 68.067 E-5 5.814 E-5 74.167 E-5 8.635 E-5 7.845 0.001 
Cing.Gyr-R 66.825 E-5 4.689 E-5 68.906 E-5 6.610 E-5 75.122 E-5 8.659 E-5 6.743 NS 
IFOF-L 72.45 E-5 5.927 E-5 75.0 E-5 5.778 E-5 81.417 E-5 7.162 E-5 9.193 0.000 
IFOF-R 71.775 E-5 7.949 E-5 74.867 E-5 7.597 E-5 80.778 E-5 8.431 E-5 5.619 NS 
ILF-L 70.669 E-5 4.051 E-5 74.022 E-5 6..292 E-5 80.261 E-5 6.525 E-5 12.145 0.000 
ILF-R 69.925 E-5 4.755 E-5 73.772 E-5 6.565 E-5 79.828 E-5 6.811 E-5 11.241 0.000 
SLF-L 68.9 E-5 5.243 E-5 72.533 E-5 8.177 E-5 79.128 E-5 9.409 E-5 7.409 0.002 
SLF-R 69.838 E-5 5.949 E-5 72.589 E-5 8.247 E-5 78.939 E-5 8.653 E-5 6.224 NS 
SFL temp.-L 65.775 E-5 5.571 E-5 68.089 E-5 6.429 E-5 74.617 E-5 7.184 E-5 8.721 0.001 
Remark: Bonferroni adjusted alpha = p < 0.0025. 
 
 
Table 3-15: Mean AD values of the PD-N, PD-MCI and PDD patients and one-way ANOVA results for 12 ROIs 
 PD-N n=16 PD-MCI n=18 PDD n=18 ANOVA 
ROIs M sd M sd M sd F (2,49) p 
ATR-R 136.706 E-5 12.61 E-5 141.378 E-5 10.997 E-5 150.539 E-5 12.018 E-5 6.051 NS 
CST-L 133.025 E-5 7.134 E-5 137.278 E-5 8.898 E-5 142.700 E-5 11.930 E-5 4.338 NS 
CST-R 131.763 E-5 7.647 E-5 135.822 E-5 7.710 E-5 141.633 E-5 11.574 E-5 4.949 NS 
Cing.Gyr-L 120.507 E-5 3.925 E-5 122.867 E-5 3.734 E-5 126.450 E-5 6.393 E-5 6.458 NS 
Cing.Gyr-R 116.981 E-5 3.357 E-5 119.056 E-5 3.628 E-5 122.756 E-5 6.016 E-5 7.141 0.002 
IFOF-L 125.663 E-5 4.755 E-5 128.017 E-5 3.999 E-5 133.083 E-5 6.840 E-5 8.635 0.001 
IFOF-R 126.413 E-5 6.560 E-5 129.617 E-5 5.088 E-5 133.544 E-5 6.850 E-5 5.655 NS 
ILF-L 120.075 E-5 2.436 E-5 122.006 E-5 3.745 E-5 127.178 E-5 4.615 E-5 16.586 0.000 
ILF-R 116.575 E-5 3.416 E-5 119.922 E-5 3.955 E-5 124.928 E-5 6.221 E-5 13.481 0.000 
SLF-L 116.225 E-5 3.651 E-5 119.650 E-5 5.586 E-5 123.994 E-5 7.540 E-5 7.463 0.001 
SLF-R 116.113 E-5 4.250 E-5 118.489 E-5 5.382 E-5 122.972 E-5 7.355 E-5 6.073 NS 
SFL Temp.-L 117.375 E-5 3.927 E-5 118.906 E-5 3.954 E-5 121.983 E-5 5.259 E-5 4.803 NS 
Remark: Bonferroni adjusted alpha = p < 0.0025. 
 
 
3.6.2.2 Post-hoc multiple comparisons of FA, MD, RD, and AD values between pairs of 
patient groups 
According to the 12 significant overall ANOVA results on FA values, the post-hoc two-sample 
t-tests between pairs of patient groups have been corrected with a Bonferroni adjusted alpha 
(p < 0.0042). The PDD patients showed significantly reduced mean FA values compared to the 
PD-N in all of the 12 ROIs, while only CST-L, IFOF-L and SLF-temp.-L displayed significant FA 
decrease in PDD compared with the PD-MCI group (Table 3-16). On the other hand, PD-MCI 
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group showed no significant difference in any of the investigated ROIs in comparison to the 
PD-N group. 
Significantly increased MD values were obtained in the cingulum cingulate gyrus L and R, IFOF-
L, ILF-L, SLF-L and SLF temp.-L of the PDD patients compared with the PD-N group. A similar 
pattern of increased RD was obtained in the PDD group with the exception of no significant 
difference in cingulum cingulate gyrus R compared with the PD-N group. Interestingly, the AD 
values also increased in PDD patients, but only in cingulum cingulate gyrus R, IFOF L, ILF L and 
R and SLF-L. On the other hand, none of the investigated WM structures showed a significant 
MD, RD and AD difference between the PDD and PD-MCI groups except for the increased MD 
and AD values in ILF-L. 
 
Table 3-16: Bonferroni corrected (group) multiple comparisons results for FA, RD, MD and AD 
 FA MD RD AD 
 
PD-N 
> PDD 
PD-MCI 
> PDD 
PD-N 
< PDD 
PD-MCI 
< PDD 
PD-N 
< PDD 
PD-MCI 
< PDD 
PD-N 
< PDD 
PD-MCI 
< PDD 
ROIs p p p p p p p p 
ATR-R 0.002 NS - - - - - - 
CST-L 0.003 0.003 - - - - - - 
CST-R 0.001 NS - - - - - - 
Cing. Gyr-L 0.001 NS 0.001 NS 0.001 NS - - 
Cing. Gyr-R 0.004 NS 0.002 NS - - 0.002 NS 
IFOF-L 0.000 0.004 0.000 NS 0.000 NS 0.001 NS 
IFOF-R 0.002 NS - - - -   
ILF-L 0.000 NS 0.000 .002 0.000 NS 0.000 0.000 
ILF-R 0.002 NS 0.000 NS 0.000 NS 0.000 NS 
SLF-L 0.000 NS 0.001 NS 0.001 NS 0.001 NS 
SLF-R 0.001 NS - - -  - - 
SFL Temp.-L 0.000 0.004 0.001 NS 0.001 NS - - 
Remark: Bonferroni adjusted alpha p < 0.00042. 
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3.6.2.3 Correlations of the White Matter Changes with Clinical and Neuropsychological 
Variables 
To associate the cognitive dysfunctions and motor symptoms of the PD patients with the 
structural changes, one-tailed non-parametric (Spearman’s) bivariate correlation analyses 
were carried out for the FA, MD, RD and AD values of the tracts that significantly differed 
among the patient groups in ANOVA tests and the clinical and neuropsychological data 
collected from all 52 PD patients. 
For Bonferroni correction, the parameters were grouped into categories and based on the 
numbers of parameter in the groups the alpha was adjusted: clinical data (p < 0.01), global 
neuropsychological tests (p < 0.0071) and specific neuropsychological tests (p < 0.0071). 
 
3.6.2.3.1 DTI - FA 
The neuropsychological test and clinical parameters displayed significant correlations with the 
DTI-derived FA values (Table 3-17). The increasing age lead to decreased FA in all ROIs 
(p < 0.05) except for SLF-L. The increases of disease duration and UPDRS – total and UPDRS – 
cognitive scores, that correspond to worse disease symptoms, similarly resulted in lower FA 
of the CST-R, the cingulum-L, the IFOF-L, the ILF-L, the SLF-L and R, and the SLF-temp.-L, while 
the increasing UPDRS- cognitive scores were further associated with decreased FA in the ATR-
R, right cingulum, right IFOF and right ILF (p < 0.01). The Hoehn & Yahr score representing the 
severity of the motor symptoms correlated negatively with the FA values of the ILF-L, SLF-L 
and SLF-temp.-L (p < 0.01), while the ACE-R as a measure for cognitive functions was positively 
correlated with the FA of CST-R, ILF-L and SLF-temp.-L (p < 0.0071). The pentagon copying 
performance was positively correlated with FA values of all ROIs, while phonemic fluency 
displayed positive correlation with ILF-L and SLF-L, and clock drawing performance was 
positively correlated with CST-R and SLF-temp.-L (p < 0.0071). The MOCA test as a global 
cognitive screening instrument showed a broad positive correlation with the FA of most ROIs 
(p < 0.0071) except for the ATR-R, Cingulum-L and SLF-L, while WCST-category was positively 
correlated with ATR-R, cingulum-L, IFOF-R, ILF-L and R, SLF-L and R and the SLF-temp.-L 
(p < 0.0071). 
Interestingly, the FA values of ILF-L, SLF-temp.-L showed mostly a non-specific pattern of 
correlation with all parameters except the clock drawing and phonemic fluency. 
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Table 3-17: Correlation of DTI-derived FA findings and the clinical and neuropsychological parameters 
Fractional Anisotropy - FA 
Clinical / neuropsychological 
variables ATR - R CST - L CST - R 
Cing. 
cingulate 
gyr.-L 
Cing. 
cingulate 
gyr.-R IFOF - L IFOF - R ILF - L ILF - R SLF - L SLF - R 
SLF-
temp.-L 
Age a) Corr.Coef. -0.414 -0.291 -0.383 -0.433 -0.423 -0.410 -0.465 -0.394 -0.430 -0.306 -0.410 -0.442 
p (1-tailed) 0.001 0.018 0.003 0.001 0.001 0.001 0.000 0.002 0.001 NS 0.001 0.001 
Disease Duration 
a) 
Corr.Coef. -0.142 -0.166 -0.233 -0.252 -0.181 -0.274 -0.177 -0.306 -0.218 -0.261 -0.272 -0.311 
p (1-tailed) NS NS 0.049 0.036 NS 0.025 NS 0.014 NS 0.031 0.025 0.012 
UPDRS - total b) Corr.Coef. -0.312 -0.317 -0.395 -0.368 -0.301 -0.367 -0.308 -0.438 -0.397 -0.373 -0.398 -0.443 
p (1-tailed) NS NS 0.002 0.004 NS 0.004 NS 0.001 0.002 0.003 0.002 0.001 
UPDRS – 
Cognitive b) 
Corr.Coef. -0.427 -0.300 -0.410 -0.476 -0.374 -0.458 -0.440 -0.407 -0.426 -0.360 -0.414 -0.499 
p (1-tailed) 0.001 NS 0.001 0.000 0.003 0.000 0.001 0.001 0.001 0.004 0.001 0.000 
Hoehn & Yahr b) Corr.Coef. -0.231 -0.221 -0.296 -0.281 -0.194 -0.285 -0.228 -0.330 -0.290 -0.284 -0.327 -0.381 
p (1-tailed) NS NS NS NS NS NS NS 0.008 NS NS 0.009 0.003 
ACE-R c) Corr.Coef. 0.267 0.245 0.342 0.313 0.220 0.310 0.245 0.342 0.305 0.322 0.327 0.379 
p (1-tailed) NS NS 0.006 NS NS NS NS 0.007 NS NS NS 0.003 
Phonemic 
Fluency c) 
Corr.Coef. 0.232 0.280 0.327 0.302 0.252 0.272 0.270 0.345 0.298 0.363 0.293 0.318 
p (1-tailed) NS NS NS NS NS NS NS 0.006 NS 0.004 NS NS 
Pentagon Copy c) Corr.Coef. 0.337 0.437 0.453 0.408 0.369 0.448 0.369 0.453 0.363 0.411 0.424 0.387 
p (1-tailed) 0.007 0.001 0.000 0.001 0.004 0.000 0.004 0.000 0.004 0.001 0.001 0.002 
Clock Drawing c) Corr.Coef. 0.209 0.303 0.352 0.263 0.126 0.290 0.248 0.311 0.294 0.266 0.304 0.383 
p (1-tailed) NS NS 0.005 NS NS NS NS NS NS NS NS 0.003 
MOCA c) Corr.Coef. 0.361 0.406 0.488 0.404 0.330 0.397 0.398 0.393 0.381 0.359 0.428 0.421 
p (1-tailed) NS 0.004 0.001 0.004 NS 0.005 0.005 0.006 0.007 NS 0.003 0.003 
WCST – 
Categories c) 
Corr.Coef. 0.395 0.330 0.366 0.423 0.318 0.361 0.430 0.457 0.443 0.424 0.400 0.486 
p (1-tailed) 0.006 NS NS 0.003 NS NS 0.003 0.002 0.002 0.003 0.005 0.001 
Remarks: a) p < 0.05, b) p < 0.01, c) p < 0.0071. L: left, R: right, ATR: anterior thalamic radiation, CST: cortico spinal tract, Cingulum cingulate gyrus, IFOF: inferior fronto 
occipital fasciculus, ILF: inferior longitudinal fasciculus, SLF: superior longitudinal fasciculus, SLF-temp.: superior longitudinal fasciculus temporal. 
 3.6.2.3.2 DTI - MD 
Generally, the DTI-derived MD values of the evaluated ROIs were positively correlated with 
the clinical and demographic parameters but negatively correlated with the NPT scores (Table 
3-18). 
All tracts that showed a significant MD difference among the groups in previous ANOVA tests, 
that are the Cingulum cingulate gyr.-L and R, IFOF-L, ILF-L and R, SLF-L and SLF temp.-L, 
significantly increased with increasing age and UPDRS scores. Disease duration was also 
positively correlated with MD values of the investigated ROIs except the IFOF-L and SLF temp.-
L, and Hoehn & Yahr score was positively correlated with the MD values of cingulum cingulate 
gyr.-L, ILF-L and R and SLF temp.-L. 
On the other hand, decreased ACE-R and MOCA scores representing worsening of the global 
cognitive performance of the subjects and decreasing Pentagon Copy test scores were 
correlated with increased MD values of all investigated tracts. Decrease of the WCST-
Categories score was associated in a similar non-specific manner with increased MD values in 
all of these tracts except cingulum cingulate gyr.-R. Beyond these global patterns, worse 
scores in phonemic fluency test were specifically associated with increased MD in Cingulum 
cingulate gyr.-L and ILF-L, while worsening semantic fluency performance was associated with 
increased MD in ILF-L and R and SLF temp.-L. Lower scores in clock drawing test were also 
correlated with increased MD in ILF-L and R and SLF temp.-L. Finally, increased number of 
errors in the WCST test were associated with increased MD values in ILF-R and SLF temp.-L. 
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Table 3-18: Correlation of DTI-derived MD findings and the clinical and neuropsychological parameters 
Mean Diffusivity (MD) 
Clinical / neuropsychological 
variables 
Cing. 
cingulate 
gyr.-L 
Cing. 
cingulate 
gyr.-R IFOF-L ILF-L ILF-R SLF-L 
SLF 
temp.-L 
Age a) Corr.Coef. 0.549 0.527 0.634 0.597 0.556 0.496 0.451 
p (1-tailed) 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Disease 
Duration a) 
Corr.Coef. 0.301 0.256 0.165 0.318 0.322 0.273 0.214 
p (1-tailed) 0.015 0.034 NS 0.011 0.010 0.025 NS 
UPDRS – total b) Corr.Coef. 0.445 0.384 0.408 0.548 0.572 0.441 0.517 
p (1-tailed) 0.000 0.002 0.001 0.000 0.000 0.001 0.000 
UPDRS - III b) Corr.Coef. 0.383 0.347 0.364 0.478 0.525 0.383 0.445 
p (1-tailed) 0.003 0.006 0.004 0.000 0.000 0.003 0.000 
UPDRS - 
Cognitive b) 
Corr.Coef. 0.435 0.414 0.506 0.558 0.517 0.380 0.474 
p (1-tailed) 0.001 0.001 0.000 0.000 0.000 0.003 0.000 
Hoehn & Yahr b) Corr.Coef. 0.341 0.307 0.318 0.449 0.450 0.318 0.382 
p (1-tailed) 0.007 NS NS 0.000 0.000 NS 0.003 
ACE-R c) Corr.Coef. -0.387 -0.336 -0.360 -0.483 -0.495 -0.353 -0.426 
p (1-tailed) 0.002 0.007 0.004 0.000 0.000 0.005 0.001 
Phonemic 
Fluency c) 
Corr.Coef. -0.337 -0.293 -0.233 -0.338 -0.331 -0.311 -0.328 
p (1-tailed) 0.007 NS NS 0.007 NS NS NS 
Semantic 
Fluency c) 
Corr.Coef. -0.296 -0.280 -0.309 -0.416 -0.445 -0.316 -0.373 
p (1-tailed) NS NS NS 0.001 0.000 NS 0.003 
Pentagon Copy 
c) 
Corr.Coef. -0.403 -0.416 -0.349 -0.547 -0.470 -0.412 -0.427 
p (1-tailed) 0.002 0.001 0.006 0.000 0.000 0.001 0.001 
Clock Drawing c) Corr.Coef. -0.227 -0.209 -0.270 -0.367 -0.382 -0.246 -0.342 
p (1-tailed) NS NS NS 0.004 0.003 NS 0.006 
MOCA c) Corr.Coef. -0.414 -0.384 -0.475 -0.509 -0.507 -0.427 -0.418 
p (1-tailed) 0.004 0.007 0.001 0.000 0.000 0.003 0.003 
WCST - 
Categories c) 
Corr.Coef. -0.408 -0.353 -0.498 -0.521 -0.584 -0.453 -0.495 
p (1-tailed) 0.005 NS 0.001 0.000 0.000 0.002 0.001 
WCST - Error c) Corr.Coef. 0.235 0.169 0.358 0.322 0.401 0.302 0.428 
p (1-tailed) NS NS NS NS 0.005 NS 0.003 
Remarks: a) p < 0.05, b) p < 0.01, c) p < 0.0071. 
 
3.6.2.3.3 DTI – RD 
The RD values of the investigated tracts display the same pattern of positive correlations with 
the demographic and clinical parameters and negative correlation with the NPTs similar to the 
correlation pattern of the MD values (Table 3-18, Table 3-19). The RD generally seems to be 
less specific, as the RD of almost all tracts show correlations with all parameters but phonemic 
fluency. 
While increasing age, UPDRS-total, UPDRS-III and UPDRS cognitive scores were associated 
with increase in RD of all investigated tracts, increasing ACE-R, pentagon copying, MOCA and 
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WCST- category scores were associated with decreased RD of all ROIs. The disease duration 
was positively correlated with the RD of all ROIs except the left IFOF and the Hoehn & Yahr 
score was positively correlated with the RD in all ROIs but not the left SLF. The semantic 
fluency was negatively correlated with the RD in the left and right ILF and the left temporal 
SLF, while the worse clock drawing performance and number of error in the WCST were 
correlated with higher RD values of the same ROIs, namely the right ILF and the left temporal 
SLF. 
 
Table 3-19: Correlation of DTI-derived RD findings and the clinical and neuropsychological parameters 
Radial Diffusivity (RD) 
Clinical / neuropsychological 
variables 
Cing. 
cingulate 
gyr.-L IFOF-L ILF-L ILF-R SLF-L 
SLF 
temp.-L 
Age a) Corr.Coef. 0.563 0.619 0.592 0.550 0.490 0.491 
p (1-tailed) 0.000 0.000 0.000 0.000 0.000 0.000 
Disease Duration a) Corr.Coef. 0.297 0.203 0.292 0.288 0.263 0.245 
p (1-tailed) 0.016 NS 0.018 0.019 0.030 0.040 
UPDRS - total b) Corr.Coef. 0.433 0.417 0.526 0.554 0.427 0.526 
p (1-tailed) 0.001 0.001 0.000 0.000 0.001 0.000 
UPDRS - III b) Corr.Coef. 0.370 0.361 0.465 0.499 0.367 0.444 
p (1-tailed) 0.003 0.004 0.000 0.000 0.004 0.000 
UPDRS - Cognitive 
b) 
Corr.Coef. 0.432 0.511 0.514 0.502 0.376 0.498 
p (1-tailed) 0.001 0.000 0.000 0.000 0.003 0.000 
Hoehn & Yahr b) Corr.Coef. 0.341 0.326 0.401 0.408 0.305 0.390 
p (1-tailed) 0.007 0.009 0.002 0.001 NS 0.002 
ACE-R c) Corr.Coef. -0.360 -0.360 -0.439 -0.466 -0.343 -0.428 
p (1-tailed) 0.004 0.004 0.001 0.000 0.006 0.001 
Phonemic Fluency 
c) 
Corr.Coef. -0.301 -0.238 -0.324 -0.328 -0.306 -0.335 
p (1-tailed) NS NS NS NS NS NS 
Semantic Fluency c) Corr.Coef. -0.292 -0.318 -0.380 -0.407 -0.325 -0.389 
p (1-tailed) NS NS 0.003 0.001 NS 0.002 
Pentagon Copy c) Corr.Coef. -0.385 -0.375 -0.498 -0.443 -0.386 -0.403 
p (1-tailed) 0.002 0.003 0.000 0.001 0.002 0.002 
Clock Drawing c) Corr.Coef. -0.239 -0.286 -0.326 -0.365 -0.259 -0.369 
p (1-tailed) NS NS NS 0.004 NS 0.004 
MOCA c) Corr.Coef. -0.409 -0.469 -0.483 -0.499 -0.419 -0.442 
p (1-tailed) 0.004 0.001 0.001 0.000 0.003 0.002 
WCST - Categories 
c) 
Corr.Coef. -0.404 -0.487 -0.550 -0.568 -0.440 -0.526 
p (1-tailed) 0.005 0.001 0.000 0.000 0.002 0.000 
WCST - Error c) Corr.Coef. .228 0.339 0.338 0.387 0.281 0.427 
p (1-tailed) NS NS NS 0.007 NS 0.003 
Remarks: a) p < 0.05, b) p < 0.01, c) p < 0.0071. 
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3.6.2.3.4 DTI - AD 
The correlation pattern for the AD with the other parameters was similar to the RD 
correlations (Table 3-20). Age, UPDRS-total, UPDRS-III, UPDRS-cognitive scores were positively 
and the ACE-R and pentagon copying were negatively correlated with the AD in all ROIs. 
Whereas the disease duration was positively correlated with the AD in all ROIs but not the 
IFOF-L, the Hoehn & Yahr scale was positively correlated with AD in all ROIs but the SLF-L. The 
phonemic and semantic fluency were both negatively correlated with the AD of left and right 
ILF. The clock drawing abilities were negatively correlated with the AD of left and right ILF and 
the left SLF, while the MOCA and WCST-categories were negatively correlated with the AD in 
all ROIs but the right cingulum cingulate gyrus. Finally, the WCST-error was positively 
correlated with the AD of the left IFOF and the right ILF. 
Table 3-20: Correlation of DTI-derived AD findings and the clinical and neuropsychological parameters 
Axial Diffusivity (AD) 
Clinical / neuropsychological variables 
Cing.cingulate 
gyr.-R IFOF-L ILF-L ILF-R SLF-L 
Age a) Corr.Coef. 0.423 0.644 0.535 0.491 0.489 
p (1-tailed) 0.001 0.000 0.000 0.000 0.000 
Disease Duration a) Corr.Coef. 0.271 0.135 0.298 0.346 0.231 
p (1-tailed) 0.026 NS 0.016 0.006 0.050 
UPDRS - total b) Corr.Coef. 0.370 0.401 0.507 0.605 0.451 
p (1-tailed) 0.003 0.002 0.000 0.000 0.000 
UPDRS - III b) Corr.Coef. 0.335 0.373 0.442 0.566 0.396 
p (1-tailed) 0.008 0.003 0.001 0.000 0.002 
UPDRS - Cognitive b) Corr.Coef. 0.382 0.472 0.570 0.494 0.358 
p (1-tailed) 0.003 0.000 0.000 0.000 0.005 
Hoehn &- Yahr b) Corr.Coef. 0.356 0.344 0.478 0.493 0.313 
p (1-tailed) 0.005 0.006 0.000 0.000 NS 
ACE-R c) Corr.Coef. -0.364 -0.355 -0.515 -0.566 -0.357 
p (1-tailed) 0.004 0.005 0.000 0.000 0.005 
Phonemic Fluency c) Corr.Coef. -0.295 -0.196 -0.339 -0.348 -0.281 
p (1-tailed) NS NS 0.007 0.006 NS 
Semantic Fluency c) Corr.Coef. -0.282 -0.320 -0.448 -0.514 -0.276 
p (1-tailed) NS NS 0.000 0.000 NS 
Pentagon Copy c) Corr.Coef. -0.474 -0.332 -0.598 -0.532 -0.402 
p (1-tailed) 0.000 0.008 0.000 0.000 0.002 
Clock Drawing c) Corr.Coef. -0.240 -0.232 -0.391 -0.416 -0.198 
p (1-tailed) NS NS 0.002 0.001 NS 
MOCA c) Corr.Coef. -0.349 -0.463 -0.520 -0.537 -0.428 
p (1-tailed) NS 0.001 0.000 0.000 0.003 
WCST - Categories c) Corr.Coef. -0.314 -0.508 -0.498 -0.596 -0.456 
p (1-tailed) NS 0.000 0.001 0.000 0.002 
WCST - Error c) Corr.Coef. 0.155 0.390 0.369 0.447 0.356 
p (1-tailed) NS 0.006 NS 0.002 NS 
Remarks: a) p < 0.05, b) p < 0.01, c) p < 0.0071. 
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3.6.3 ASL Results 
The ASL based cerebral blood flow (CBF) maps for all 52 subjects were calculated and 
registered to the 152-MNI standard space (Figure 3-14). As the ASL data were collected from 
a restricted field of view (FOV) during the scanning sessions and differed slightly regarding 
their position, due to anatomical differences of the patients, we chose a ROI-based approach 
for the calculation of differences in CBF. Seventy pre-defined ROIs were extracted from the 
lateralized Harvard Cortical Structural Atlas and the mean CBF from voxels within the ROIs 
were calculated and statistically compared between the patient groups (Table 3-21). 
 
 
Figure 3-14: Example of a PDD patients registered T2-weighted image to 152-MNI standard space in the first row 
and the co-registered CBF maps in the lower row. 
 
3.6.3.1 ANOVA analyses among the 3 patient groups 
For comparisons of the PD-N, PD-MCI and PDD groups one-way ANOVAs were performed for 
the 70 ROIs with Bonferroni adjusted alpha (p < 0.0007). While an overall progressive decrease 
of the CBF was observed from PD-N through PD-MCI to PDD groups, the differences among 
the 3 groups were significant only in 9 ROIs: the right inferior temporal gyrus posterior (Inf. 
Temp. G.-P), the right inferior temporal gyrus temporo-occipital region (Inf. Temp. gyr.–TO), 
right middle frontal gyrus (Mid. Front. gyr.), left middle temporal gyrus anterior portion (Mid. 
Temp. G.-A), left and right superior frontal gyrus (Sup. Front. gyr.), left superior temporal gyrus 
anterior portion (Sup. Temp. gyr.-A), right temporal fusiform cortex posterior portion (Temp. 
Fus. C.-P) and right temporal occipital fusiform cortex (Temp. Occ. Fus. C.) (Table 3-21). 
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Table 3-21: The mean CBF values of 70 lateralized ROIs in PD-N, PD-MCI and PDD patient groups and ANOVA 
results. 
  
Left Right One-Way NAOVA   
N M sd N M sd 
 
F p 
Inf. Temp. gyr. post. PD-N 15 43.91 25.45 16 49.80 17.46 L F (2,47) = 3,146 0.052 
PD-MCI 18 36.94 17.29 18 45.75 10.49 R F (2,48)=13,234 0.000 
PDD 17 28.20 6.61 17 29.36 6.55 
 
  
Inf. Temp. gyr. temp.-
occ. 
PD-N 15 36.13 26.18 16 46.25 20.85 L F (2,44) = 1,907 0.161 
PD-MCI 15 32.77 16.19 18 38.25 8.39 R F(2,48) =14,910 0.000  
PDD 17 24.30 6.13 17 21.97 5.52 
 
  
Middle Frontal gyr PD-N 14 54.36 24.91 16 50.98 22.62 L F (2,45) = 7,056 0.002  
PD-MCI 16 51.88 21.06 18 50.89 17.47 R F(2,49) =10,273 0.000  
PDD 18 32.02 8.64 18 28.70 7.71 
 
  
Middle Temp. gyr. ant. PD-N 12 53.45 27.10 16 49.43 25.37 L F (2,37)=11,768 0.000  
PD-MCI 11 60.08 14.43 18 47.74 18.59 R F (2,48) = 5,573 0.007  
PDD 17 30.50 6.74 17 30.36 6.54 
 
  
Superior Frontal gyr PD-N 16 61.10 17.28 16 57.98 20.86 L F (2,49)=16,815 0.000  
PD-MCI 18 57.83 13.50 18 57.85 16.22 R F (2,49) = 9,764 0.000  
PDD 18 37.83 5.50 18 38.27 4.79 
 
  
Superior Temp. gyr 
ant. 
PD-N 13 57.41 28.67 16 52.29 32.82 L F (2,37)=12,013 0.000 
PD-MCI 10 69.03 14.41 18 49.78 26.92 R F (2,48) = 1,889 0.162 
PDD 17 35.48 5.03 17 36.95 5.37 
 
  
Temporal Fusiform 
Cortex post 
PD-N 16 44.57 26.48 16 52.31 16.16 L F (2,48) = 1,733 0.188 
PD-MCI 18 36.81 17.24 18 51.00 10.41 R F (2,48) = 9,417 0.000 
PDD 17 32.95 4.76 17 37.07 4.96 
 
  
Temporal Occipital 
Fusiform 
PD-N 16 39.65 26.10 16 50.78 19.22 L F (2,48) = 1,002 0.375 
PD-MCI 18 35.04 21.64 18 48.07 13.69 R F (2,48) = 9,664 0.000 
PDD 17 29.99 4.03 17 31.63 4.03 
 
  
Remark: Bonferroni adjusted alpha p < 0.0007. 
 
3.6.3.2 Post-hoc multiple comparisons of BF values between pairs of patient groups 
The post-hoc two-sample t-tests for these 9 ROIs (Figure 3-15) between pairs of patient 
groups, each of which are initially Bonferroni corrected for 3 between-group comparisons, 
have been further corrected with the Bonferroni adjusted alpha (p < 0.0055) against the 9 
repeated comparisons (Table 3-22). The CBF significantly decreased in all of the 9 ROIs in the 
PDD group compared to PD-MCI and PD-N, but the significance level did not survive for the 
left superior temporal gyrus between PDD and PD-N after Bonferroni correction (p = 0.007). 
The PD-N and PD-MCI groups did not show any significant CBF difference in the investigated 
ROIs. 
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Figure 3-15: ROIs for which significant decreased CBF in PDD patients were found. The ROIs are displayed on the 
152-MNI standard template. 
 
Table 3-22: Bonferroni corrected post-hoc multiple comparison results for CBF ROI analysis 
          PD-N > PDD PD-MCI > PDD 
 Left Right Left Right 
ROIs p p p p 
Inf. Tmp. gyr. - post. - 0.000 - 0.001 
Inf. Tmp. gyr. - TO. - 0.000 - 0.002 
Mid. Frt. gyr. - 0.001 - 0.001 
Mid. Tmp. gyr. - ant. 0.003 - 0.000 - 
Sup. Frt. gyr. 0.000 0.001 0.000 0.001 
Sup. Temp. gyr. NS - 0.000 - 
Tmp. Fus. C. - post. - 0.001 - 0.002 
Tmp. Occ. Fus - 0.001 - 0.003 
Remark: Bonferroni adjusted alpha for 9 ROIs (p<0.0055). 
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3.6.3.3 Correlations of the CBF values with Clinical and Neuropsychological Variables 
In order to further investigate the dependency of the clinical and neuropsychological status of 
the PD patients on cerebral blood flow changes in various parts of the brain, one-tailed non-
parametric (Spearman’s) bivariate correlation analyses were carried out for the significant 
findings obtained in ASL analyses and the clinical and neuropsychological data collected from 
the 52 PD patients. 
For Bonferroni correction, the parameters were grouped in categories and based on the 
numbers of parameter in the groups the alpha was adjusted: clinical data (p < 0.01), global 
neuropsychological tests (p < 0.0071) and specific neuropsychological tests (p < 0.0071). 
 
The correlation analysis of the CBF in the investigated ROIs of the ASL analyses and the clinical 
and neuropsychological variables delivered a rich set of multiple correlations (Table 3-23). The 
CBF in all investigated ROIs were positively correlated with disease duration and negatively 
correlated with clock drawing. The SDMT and cube copying showed positive correlations only 
with the temporo-occipital region of the right inferior temporal gyrus. The semantic fluency 
and pentagon copying were similarly correlated with the CBF of all ROIs except with the 
anterior part of the superior temporal gyrus. The phonemic fluency positively correlated with 
the posterior and temporo-occipital regions of the right inferior temporal gyrus. The UPDRS – 
total, UPDRS - cognitive score, Hoehn & Yahr scale, and ACE-R showed similar negative 
correlations with the CBF values of most of the ROIs, while the UPDRS-III was negatively 
correlated only with the left superior frontal gyrus and the temporo-occipital region of the 
right inferior temporal gyrus. 
The MOCA showed positive correlations with the CBF of the left superior frontal gyrus, the 
right middle frontal gyrus and posterior and the temporo-occipital parts of the right inferior 
temporal gyrus. The number of the mistakes during the Stroop test was negatively correlated 
with the CBF of the right inferior temporal gyrus and the right temporal fusiform cortex. 
Finally, the number of the categories of the WCST was positively and the number of WCST 
errors was negatively correlated with the CBF of the left superior frontal gyrus, right middle 
frontal gyrus, the posterior and temporo-occipital parts of the right inferior temporal gyrus, 
the posterior part of the temporal fusiform cortex and the right temporal occipital fusiform 
cortex. 
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Table 3-23: Correlation of ASL findings and the clinical and neuropsychological parameters 
Arterial Spin Labeling - ROIs 
Clinical / 
neuropsychological 
variables 
MTG-
ant.-L 
STG-
ant.-L SFG-L 
ITG-
post.-R 
ITG-TO-
R MFG-R SFG-R 
TFC-
post.-R 
TOFC.-
R 
Disease 
Duration a) 
Corr.Coef. -0.466 -0.373 -0.324 -0.304 -0.450 -0.321 -0.234 -0.284 -0.308 
p (1-tailed) 0.001 0.009 0.009 0.015 0.000 0.010 0.047 0.022 0.014 
UPDRS – 
Total b) 
Corr.Coef. -0.375 -0.302 -0.410 -0.392 -0.425 -0.334 -0.330 -0.325 -0.220 
p (1-tailed) 0.009 NS 0.001 0.002 0.001 0.008 0.009 0.010 NS 
UPDRS – 
III b) 
Corr.Coef. -0.279 -0.237 -0.362 -0.312 -0.367 -0.282 -0.302 -0.260 -0.215 
p (1-tailed) NS NS 0.004 NS 0.004 NS NS NS NS 
UPDRS – 
Cognitive 
b) 
Corr.Coef. -0.495 -0.351 -0.408 -0.472 -0.507 -0.380 -0.258 -0.439 -0.414 
p (1-tailed) 
0.001 NS 0.001 0.000 0.000 0.003 NS 0.001 0.001 
Hoehn & 
Yahr b) 
Corr.Coef. -0.373 -0.388 -0.475 -0.344 -0.373 -0.418 -0.411 -0.326 -0.269 
p (1-tailed) 0.009 0.007 0.000 0.007 0.003 0.001 0.001 0.010 NS 
ACE-R c) Corr.Coef. 0.445 0.299 0.484 0.502 0.598 0.425 0.319 0.445 0.437 
p (1-tailed) 0.002 NS 0.000 0.000 0.000 0.001 NS 0.001 0.001 
Phonemic 
Fluency c) 
Corr.Coef. 0.314 0.298 0.331 0.371 0.406 0.273 0.261 0.326 0.305 
p (1-tailed) NS NS NS 0.004 0.002 NS NS NS NS 
Semantic 
Fluency c) 
Corr.Coef. 0.499 0.324 0.469 0.434 0.502 0.416 0.411 0.421 0.398 
p (1-tailed) 0.001 NS 0.000 0.001 0.000 0.001 0.001 0.001 0.002 
Pentagon 
Copy c) 
Corr.Coef. 0.462 0.366 0.477 0.444 0.540 0.514 0.479 0.383 0.377 
p (1-tailed) 0.001 NS 0.000 0.001 0.000 0.000 0.000 0.003 0.003 
Cube 
Copy c) 
Corr.Coef. 0.254 0.128 0.221 0.316 0.421 0.250 0.156 0.282 0.310 
p (1-tailed) NS NS NS NS 0.001 NS NS NS NS 
Clock 
Drawing c) 
Corr.Coef. 0.440 0.294 0.424 0.452 0.548 0.451 0.344 0.401 0.459 
p (1-tailed) 0.002 NS 0.001 0.000 0.000 0.000 0.006 0.002 0.000 
MOCA c) Corr.Coef. 0.301 0.118 0.391 0.393 0.532 0.409 0.228 0.349 0.370 
p (1-tailed) NS NS 0.006 0.006 0.000 0.004 NS NS NS 
Stroop - 
Mistakes c) 
Corr.Coef. -0.244 -0.261 -0.357 -0.447 -0.296 -0.220 -0.284 -0.425 -0.237 
p (1-tailed) NS NS NS 0.001 NS NS NS 0.002 NS 
SDTM - 
Total c) 
Corr.Coef. 0.056 0.034 0.343 0.330 0.424 0.302 0.234 0.272 0.271 
p (1-tailed) NS NS NS NS 0.003 NS NS NS NS 
SDTM - 
Correct c) 
Corr.Coef. 0.084 0.033 0.337 0.340 0.400 0.292 0.227 0.283 0.276 
p (1-tailed) NS NS NS NS 0.005 NS NS NS NS 
WCST - 
Categorie
s c) 
Corr.Coef. 0.242 0.343 0.452 0.455 0.456 0.389 0.384 0.481 0.427 
p (1-tailed) 
NS NS 0.002 0.002 0.002 0.007 0.007 0.001 0.003 
WCST - 
Error c) 
Corr.Coef. -0.205 -0.285 -0.357 -0.507 -0.430 -0.414 -0.343 -0.492 -0.350 
p (1-tailed) NS NS NS 0.000 0.003 0.004 NS 0.001 NS 
Remarks: a) p < 0.05, b) p < 0.01, c) p < 0.0071. R: right, L: left, MTG-ant.: medial temporal gyrus, STG-ant.: 
superior temporal gyrus anterior, SFG: superior frontal gyrus, ITG-post.: inferior temporal gyrus posterior, ITG-
TO: inferior temporal gyrus temporooccipital, MFG: middle frontal gyrus, TFC-post.: temporal fusiform cortex 
posterior, TOFC: temporal occipital fusiform cortex. 
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3.6.4 MR Spectroscopic Imaging (MRSI) 
In order to investigate the metabolical changes related to cognitive decline in PD, we 
measured the resonances of NAA+NAAG, creatine (Cr), choline (Cho), glutamine/glutamate 
complex (Glx) and myo-Inosytol (mI) from two separate FOVs (Figure 3-16) obtained in two 
separate proton MR spectroscopic imaging (1H-MRSI) scans on two FOVs and evaluated the 
metabolite ratios with respect to creatin: NAA+NAAG/Cr, Cho/Cr, Glx/Cr, and mI/Cr. Because 
of the high temporal requirements of the MRSI measurements, whole brain coverage is not 
feasible, hence the two FOVs have been placed in such a way that mainly areas possibly related 
with cognitive dysfunctions in PDD were covered. 
 
Figure 3-16: Example of the two FOV positions displayed on an original PDD patient’s brain 
 
The MRSI data of all patients were obtained but due to a failure in the data set of two PD-N 
patients, the analyzed data set was composed of 50 patients. 
Using the LCModel and the recently developed software by Cengiz and Öztürk-Isık (2016a and 
b), the metabolite concentrations were estimated and evaluated using the ROI-based 
approach. In total, 54 ROIs were extracted from the Harvard-Oxford Cortical Structural Atlas, 
the MNI Structural Atlas and the Harvard-Oxford Subcortical Structural Atlas. 
Because of the relatively higher variability of the MRSI variables among the investigated 
population, we limit the between-group comparisons for MRSI data to focus on the 
differences between the PDD patients and the rest of the PD-non-demented group (PD-N and 
PD-MCI together). 
 
3.6.4.1 Independent samples T-test 
The mean metabolite ratios of voxels within the ROIs were compared for PDD vs PD-non-
demented by using t-tests. The adjustment of alpha for multiple comparisons (p < 0.05/54 = 
0.00093) was very conservative for MRSI results, thus no significant differences survived the 
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comparisons. Therefore, we report the results for uncorrected data with p < 0.05, which, 
however, will only be discussed in terms of their conjunction with significant results in other 
MRI modalities. 
 
The PDD group showed significantly reduced NAA+NAAG/Cr ratios in the posterior portion of 
the left middle temporal gyrus (L-mid. temp. gyr.-P), the left and right precuneus (L and R-
precuneus), the right angular gyrus (R-angular gyr.), the right central opercular cortex (R-
central opercular C.), the right superior frontal gyrus (R-sup. front. gyr.) and caudate nucleus 
compared to the non-demented PD group (p < 0.05) (Table 3-24). 
The PDD patients further displayed significantly increased Cho/Cr in the temporo-occipital 
portion of both the right inferior temporal gyrus (R-inf. temp. gyr.-TO.) and the right middle 
temporal gyrus (R-mid. temp. gyr.-TO.) compared to PD-non-demented (p < 0.05) (Table 3-25). 
Beyond that, the PDD group displayed significantly higher Glx/Cr in the left and right superior 
frontal gyrus (L- and R-sup. front. gyr.), the temporo-occipital region of the right middle 
temporal gyrus (R-mid. temp. gyr.-TO.) and the juxtapositional lobule cortex when compared 
to PD-non-demented (p < 0.05) (Table 3-26). 
Finally, the PDD group displayed significantly increased mI/Cr ratios in the left superior frontal 
gyrus (L-sup. front. gyr.) compared to PD-non-demented (p < 0.05) (Table 3-27). 
 
Table 3-24: NAA+NAAG/Cr comparison between PDD and PD-non-demented 
NAA+NAAG/Cr     Independent t-test 
ROI Group n M sd t p 
L-mid. temp. gyr.-P PD-nd. 27 4.33 2.16 2.057 0.046  
PDD 18 3.21 1.48   
L-precuneus PD-nd. 32 1.49 0.08 2.458 0.021  
PDD 18 1.41 0.12   
R-precuneus PD-nd. 32 1.62 0.39 2.112 0.041 
 PDD 18 1.46 0.13   
R-angular g. PD-nd. 32 1.97 0.89 2.058 0.046  
PDD 18 1.62 0.32   
R-central opercular C. PD-nd. 32 1.64 1.04 2.178 0.035  
PDD 17 1.19 0.41   
R-sup. front. gyr. PD-nd. 31 1.80 0.86 2.125 0.040  
PDD 17 1.45 0.24   
Caudate PD-nd. 32 1.29 0.17 2.811 0.009  
PDD 18 1.11 0.22   
Remarks: p < 0.05 
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Table 3-25: Cho/Cr comparison between PDD and PD-non-demented 
Cho/Cr     Independent t - test 
ROI Group N M sd t p 
R-inf. temp.gyr.-TO. PD-nd. 31 0.27 0.05 -3.362 0.002  
PDD 18 0.33 0.06 
  
R-mid. temp. gyr.-TO. PD-nd. 32 0.28 0.06 -3.209 0.003  
PDD 18 0.34 0.06 
  
Remarks: p < 0.05 
 
 
Table 3-26: Glx/Cr comparison between PDD and PD-non-demented 
Glx/Cr 
    
Independent t - test 
ROI Group N M sd t p 
L-sup. front. gyr. PD-nd. 31 2.60 1.11 -2.139 0.044  
PDD 17 3.70 1.96 
  
R-sup. front. gyr. PD-nd. 31 2.27 0.92 -3.631 0.002 
 PDD 16 4.19 2.00   
R-angular gyr. PD-nd. 30 3.63 2.22 -2.106 0.041  
PDD 18 5.12 2.60 
  
R-mid. temp. gyr.-TO. PD-nd. 30 2.77 1.56 -2.403 0.025  
PDD 17 4.42 2.57 
  
Juxtapositional Lobule C. PD-nd. 31 1.87 0.84 -2.173 0.043  
PDD 17 3.00 2.04 
  
Remarks: p < 0.05. 
 
 
Table 3-27: mI/Cr comparison between PDD and PD-non-demented 
mI/Cr 
    
Independent t - test 
ROI Group N M sd t p 
L-sup. front. gyr. PD-nd. 31 1.32 0.23 -2.094 0.042  
PDD 17 1.50 0.39 
  
Remarks: p < 0.05. 
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3.6.5 Discriminant analyses for the combination of significant multimodal MRI findings for 
the diagnosis of PDD 
In a final step, we tried to create a multimodal model based on the variables of various 
neuroimaging methods that when tested in a single modality resulted in significant differences 
between the patient groups. This is carried out by testing the performance of a discriminant 
function by stepwise entering the variables from rs-fMRI, DTI and ASL modalities for the 
correct classification of the PDD cases with leave-one-out cross-validation technique. For this 
purpose, we entered in three main steps the expression scores of the RSNs that best 
discriminated the three groups from each other, mean values of the FA, MD, RD and AD values 
in the DTI ROIs and mean CBF values obtained from the ROIs of the ASL measurements that 
resulted in significant group differences in variance analyses among the three groups in a 
stepwise discriminant analysis and evaluated the performance of the resulting discriminant 
functions in discriminating the PDD patients from PD-N or PD-MCI groups. The results of the 
discriminant analyses are shown in Table 3-28 and Table 3-29. 
 
Table 3-28: Discriminant analyses using the RSNs 
PDD vs PD-N (RSN) PDD vs PD-MCI (RSN) 
Limbic NW 
 
FSN 
 
SN 
 PD-N PDD  
DMN 
 
Limbic NW 
 PD-MCI PDD 
PD-N 11 5 PD-MCI 13 5 
PDD 3 15 PDD 4 14 
% 
 
68.8 31.3 % 
 
72.2 27.8 
16.7 83.3 22.2 77.8 
 
 
Table 3-29: Discriminant analyses using the combined RSNs and DTI-derived FA, MD, RD and AD values 
PDD vs PD-N (RSN + DTI) PDD vs PD-MCI (RSN + DTI) 
FA-SLF temp.-L 
MD-Cingulum 
cingulat gyr.-L 
AD-ILF-L 
FSN 
SN 
 PD-N PDD  
 
 
AD ILF-L 
 
Limbic NW 
 PD-MCI PDD 
PD-N 15 1 PD-MCI 15 3 
PDD 0 18 PDD 3 15 
 
% 
 
93.8 6.3  
% 
83.3 16.7 
0.0 100.0 16.7 83.3 
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The rs-fMRI variables resulted in a cross-validated accuracy of 76.5% with 83.3% sensitivity 
and 68.8% specificity for the discrimination of the PDD patients from the PD-N patients, while 
the cross-validated classification accuracy for the PDD vs PD-MCI discrimination was 75.0% 
with 77.8% sensitivity and 72.2% specificity. With the inclusion of the DTI variables in the 
discriminant model, the performance for the PDD vs PD-N discrimination increased to 97.1% 
overall accuracy with 100.0% sensitivity and 93.8% specificity, while for the PDD vs PD-MCI 
classification the performance increased to 83.3% overall accuracy with 83.3% sensitivity and 
specificity. Further inclusion of the ASL variables into the stepwise discriminant analysis did 
not further increase, but even slightly decrease the accuracy for the PDD vs PD-N classification 
to 88.2% with 100.0% sensitivity but 75.0% specificity. A similar effect was also observed with 
the inclusion of the ASL values for the discrimination of PDD cases from PD-MCI cases, yielding 
80.0% overall accuracy with 100.0% sensitivity but only 61.1% specificity. In short, the 
discriminant analyses performed best when rs-fMRI and DTI parameters were used in a 
multimodal manner for the discrimination of PDD group from both PD-N and PD-MCI groups. 
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4 DISCUSSION 
Cognitive decline is common in Parkinson’s disease, that is primarily considered as a 
movement disorder, and the presence of mild cognitive impairment in PD may represent a 
prodromal state for the specific type of dementia observed in PD patients. Still, it is not well 
understood, whether PD-MCI and PDD display different severity stages of the disease 
progression or whether they may indeed represent different pathological patterns. Therefore, 
it is important to identify the clinical and neuropathological characteristics of different stages 
of cognitive decline in PD and to identify the predictors for the development of PDD. Although 
clinical diagnostic criteria for cognitive decline have been developed in recent years (Litvan et 
al., 2012; Emre et al., 2007), the diagnosis of PD-MCI and PDD is still only based on the 
judgment of a clinician and arbitrarily set cut-off values of neuropsychological test scores. So 
far, there are no reliable biomarkers available that directly represent the underlying 
pathophysiological processes in PD-MCI and PDD or that can be used for the identification of 
PD patients with high dementia risk. 
Being able to follow the neuropathological changes along the progression of cognitive deficits 
with methods that have anatomical localization capability and sensitivity to pathological 
changes in the brain tissue will help to define a discriminative biomarker for cognitive decline 
in PD, and help to identify PD patients with increased risk of developing dementia. 
In this study, we investigated the progressive neuropathological changes occurring at different 
stages of cognitive decline in Parkinson’s disease using multimodal MRI techniques, with the 
aim to derive a discriminative biomarker for dementia in PD. 
Therefore, we analyzed the combined clinical, neuropsychological and multimodal MRI data 
from 52 age-matched PD-N, PD-MCI and PDD patients. 
 
4.1 Demographic and Clinical Observations 
The PDD showed significantly longer disease duration and severe motor deficits than PD-N 
and PD-MCI as indicated by their scores for the UPDRS and Hoehn & Yahr scale. Disease 
duration and symmetry of motor symptoms have already been reported to be risk factors for 
PDD (Emre et al., 2007). As PD-N and PD-MCI did not differ significantly from each other in any 
of the demographic or clinical parameters, our findings for the non-demented patients and 
PDD exactly support the described findings in the literature. The cognitive score obtained from 
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the UPDRS revealed to be quite accurate, as the PDD group scored significantly worse than 
the PD-N and PD-MCI, while the PD-N and PD-MCI did not differ significantly from each other. 
As high age is known to be one major risk factor for PDD (Hanagasi et al., 2017), we matched 
the mean age of the groups and thereby tried to investigate the cognitive decline in PD 
independent form age but related to the neuropathological changes. Still, the PD-N showed 
significantly higher education level than PDD, which is also in line with findings about lower 
education being a risk factor for the development of cognitive decline. 
 
4.2 Differences in Neuropsychological Test Performance 
The Addenbrooke's Cognitive Examination Revised proofed to be a handy global test for quick 
administration and examination of most of the cognitive domains. Still, during examination it 
became clear, that the ACE-R was more sensitive for higher educated patients than patients 
with lower education. However, supported by other test performances, the chosen cut-off of 
≤ 83 for PD-MCI diagnosis seems to be appropriate. 
The ACE-R and MOCA test results differed significantly between the PD-N, PD-MCI and PDD 
groups, while the MMSE scores did not differ between the PD-N and the PD-MCI groups. 
None of the groups showed significant difference regarding the Navon, number of 
spontaneous corrections in the Stroop and the % of perseverative errors in the Wisconsin Card 
Sorting Test. 
PD-MCI and PDD did neither differ regarding their performance in the JOLO, the phonemic 
fluency test, the Stroop effect, the WCST nor the SDMT. In contrast, significantly worse 
performance in the semantic fluency, pentagon copying, cube copying and clock drawing as 
well as the number of mistakes in the Stroop test seems to be specific for PDD, as we did 
observe significant differences between PDD vs PD-MCI groups and between PDD vs PD-N 
groups, but not in PD-N vs PD-MCI comparison. 
 
The findings may proof that the cognitive decline in PD starts with executive dysfunction (Emre 
et al, 2007) and that the additional dysfunction of more temporally located abilities (semantic 
fluency), visuo-spatial and visuo-construction abilities as well as planning skills may be an 
indicator or risk factor for dementia in PDD (Williams-Gray et al., 2007 and 2009). 
Although, the PDD and PD-MCI did not differ significantly for the JOLO test, the amount of 
PDD patients not being able to complete the JOLO test might be an indicator for an even more 
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affected visuospatial function in PDD. Most of the PDD patients, who could not complete the 
JOLO test, understood the task, but, due to unsuccessful performance in the training part, 
their tests could not be scored. 
 
In summary, the clinical and neuropsychological observations confirmed the correct 
assignment of the PD patients to the related study groups, namely the PD-N, PD-MCI and PDD, 
which was necessary for the reliable analysis of the related MRI data. 
 
4.3 Dementia related resting-state fMRI differences in PD 
After the resting-state networks (RSN) in the rs-fMRI data were obtained using the GIFT 
toolbox based on the independent component analysis (ICA), we used two different methods 
for the analysis of the RSN differences among the patient groups, namely the binary logistic 
regression based on the expression level of each RSN in each single subject and voxel-based 
comparison of the RSNs between pairs of patient groups. 
The expression score of each RSN in each subject is a scalar value that represents the level of 
the similarity of the subject’s RSN topography with that of the aggregate RSN representing the 
whole group of patients. As a result, these scalar expression scores create a comprehensive 
but significantly reduced set of variables that represent efficiently the whole spectrum of 
large-scale neural networks existing in the resting-state data. The mathematical constraint of 
the spatial ICA algorithm for the estimation of the RSNs to be spatially maximally independent 
from each other, allows for optimal application of multivariate regression analyses on these 
expression scores, as already applied for various brain disorders in previous studies (Gruner 
et al., 2014). Therefore, the discriminative power of the RSN expression scores among the 
patient groups was tested by means of binary logistic regression analyses. 
Based on the logistic regression analyses we identified the combination of the RSNs that best 
discriminated PDD from the non-demented PD patients. Those networks discriminating PDD 
from PD-N or PDD from the combined group of PD-N and PD-MCI (PD-non-demented) were 
the limbic network, frontostriatal network (FSN), default mode network (DMN) and salience 
network (SN) with lower expression of the first two networks and stronger expression of the 
latter two networks in PDD. Furthermore, the lower expression of the posterior-temporal 
network (PTN) in combination with the lower expression of the limbic network and higher 
expression of the DMN was successful in discriminating PDD from PD-MCI. 
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While the decreasing expression of the PTN representing generally the ventral visual stream, 
the limbic network and the frontostriatal network in PDD are more or less in accordance with 
the general pattern of the cognitive impairments in visuo-spatial, memory and executive 
domains, the increased intrinsic connectivities of both DMN and SN builds a contra-intuitive 
pattern, because in many disorders the DMN hypo-connectivity is the main correlate of the 
cognitive decline as it is a characteristic feature in Alzheimer pathology (Seeley et al., 2009. 
Additionally, DMN hypo-connectivity was also previously reported in several studies on 
cognitively unimpaired PD patients vs healthy controls (Tessitore et al., 2012; Amboni et al., 
2015, Goettlich et al., 2013). 
On the other hand, several studies (Eimeren et al., 2009; Ibarretxe-Bilbao et al., 2011) 
pronounced the reduced level of deactivation of the posterior DMN nodes in PD patients 
during an executive task independent from the age of the patients, while Baggio and 
colleagues (2015) reported even increased connectivity between the DMN and occipito-
parietal regions that were associated with visuospatial dysfunction in PD-MCI. As the 
progressive increase of the DMN connectivity in our results is observed in PD patients with 
increasing cognitive symptoms, it is possible that, when compared to age-matched healthy 
controls, our data would also yield an overall reduced DMN connectivity in-line with the 
results of first group of studies. On the other hand, as the identified DMN in our study displays 
a more posteriorly weighted spatial pattern, with almost no fronto-medial involvement, our 
finding of a progressively increasing DMN connectivity from PD-N to PDD groups is generally 
in accordance with the reports on the posterior DMN reactivity in the task-based fMRI studies 
by Eimeren et al (2009) and Baggio et al. (2015). 
One might speculate that the anti-dementia drugs (acetylcholinesterase inhibitors) and anti-
psychotics (quetiapine, lithium, clozapine) used only in the PDD group might have an effect on 
the higher DMN expression, but although the expression of the DMN was statistically 
significant in the PDD group, the PD-MCI group also exhibited a stronger DMN compared to 
the PD-N suggesting that the DMN hyperactivity stems not from this type of drug treatment. 
Finally, there are studies suggesting a modulatory effect of L-Dopa, in terms of restoring the 
reduced DMN deactivation during task based fMRI (Deleveau et al., 2010,). As, however, 
similar number of patients in our 3 patient groups received L-Dopa treatment, the progressive 
increase of the DMN connectivity along the PD-N to PDD axis cannot be explained by the effect 
of L-Dopa administration. 
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In summary, the DMN related findings in PD and PDD dementia in recent literature are 
controversial but mostly related to reduced deactivation pattern in task-fMRI studies, where 
our finding of the increased posterior DMN connectivity in PDD in resting-state shows that 
such dysfunctional property of the DMN can also be obtained in resting-state recordings 
without the need of applying a complex cognitive task. 
Similar to the DMN pattern we also observed a progressive increase of the SN connectivity 
from PD-N through PD-MCI to PDD, while the difference reached significance only between 
the PDD vs PD-N or PD-non-demented patients. This pattern of the increasing DMN and SN 
connectivities with increasing cognitive decline is in contrast to the decreased DMN vs 
increased SN connectivity pattern in Alzheimer’s dementia (AD) and increased DMN vs 
decreased SN connectivity pattern in behavioral variant of the fronto-temporal dementia 
(bvFTD) (Zhou et al., 2010). According to the model proposed by Bressler and Menon (2010), 
under physiological conditions SN acts as a dynamic switch that in the presence of salient 
events gets activated and suppresses the DMN and mobilizes the cognitive resources in favor 
of the central-executive network, while in the absence of salient events the decreased 
activation of SN results in increased DMN activity. This model explains the anticorrelated 
activation of SN vs DMN, which seems to be disrupted in PDD. 
Christopher et al (2013 and 2014) by using PET found combined striatal dopamine denervation 
and D2 receptor loss in the bilateral insula to be related with cognitive decline in PD-MCI that 
seems especially associated with the executive dysfunction. This reduction of the inhibitory 
input to insula might lead to aberrant connectivity within the SN, which than cannot efficiently 
modulate the DMN and executive networks. In fact, alpha-synuclein deposition in the insula 
in the later stage of the disease (stage 5 of 6) has been described by Braak et al. (2003), and 
the deposition might be responsible for various alterations regarding neural activity, synaptic 
function and receptor modulation leading to altered within-network connectivities 
(Christopher et al., 2013 and 2014). 
Studies on the functional connectivity of the insula in healthy subjects (Cauda et al., 2011) 
suggest the involvement of the insula in two major networks. The connections of the anterior 
insula with the middle temporal, inferior temporal and anterior cingulate cortex, 
corresponding by large to the SN, associates the insula with the limbic network, while the 
posterior insula connects by large with the middle posterior cingulate cortex, the premotor, 
sensorimotor and supplementary motor areas related with sensorimotor integration. The 
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reduced functional connectivity in parts of the limbic network in the PDD group in our data 
might therefore be an indirect result of abnormal insula functional connectivity pattern. 
While the two important modulatory RSNs, DMN and SN, increase their intrinsic connectivity 
with increasing cognitive decline, other RSNs related with executive, memory and visuo-
spatial functions, namely FSN, limbic network and PTN showed significant reductions of their 
intrinsic connectivity, which will be discussed in detail below in connection with correlated 
findings in other MRI modalities. 
The findings of the functional connectivity analysis using whole-brain voxel-based 
comparisons by large supported the findings from the logistic regression analysis (Table 3-9), 
but could further shed light on the spatial details of the dysfunctions in the RSNs. We found 
decreased functional connectivity in the thalamus as part of the limbic network and increased 
functional connectivity in the right insula of the salience network in PDD compared to PD-N. 
When PD-MCI and PDD were compared, decreased functional connectivity was found in PDD 
in the left and right hippocampi as part of the limbic network. Furthermore, the PDD group 
showed decreased functional connectivity in the left hippocampus and right thalamus within 
the limbic network when compared to PD-non-demented group in addition to decreased 
functional connectivity of the caudate and putamen in the frontostriatal network. Our findings 
about the decreased functional connectivity in limbic network are in accordance with previous 
reports on atrophies in various limbic structures in PDD (Goldman, 2012). Additionally, 
decrease of the functional connectivity in the FSN of PDD patients, specifically in the caudate, 
has been previously reported by Seibert and colleagues using a seed-based approach in native-
space analyses of rs-fMRI data (Seibert et al., 2012), which is also in-line with our FSN findings. 
 
In short, in terms of large-scale functional network characteristics the FSN, limbic NW and PTN 
related with executive functions, memory and visuo-spatial functions show significant 
decreases in intrinsic connectivities specifically in PDD patients, while the two modulatory 
neuro-cognitive networks, DMN and SN, show a progressive increase in network connectivity. 
These findings, in general, point to that in fMRI signals the degeneration in neuro-cognitive 
networks directly related with the functional loss in PDD are manifested in relatively late 
stages of the process, while the dysfunctional signals in the neuro-modulatory networks 
appear in earlier stages of the cognitive decline. In the present study, the increases in DMN 
and SN connectivities that reached significance in the PDD group were still observable in 
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PD-MCI group, although at a non-significant level. This might depend on the fact that around 
50% of the PD-MCI cases that will convert to PDD in long term (Hanagasi et al., 2017; Pigott et 
al., 2015) show this pattern, while the non-converters dilute the finding to a non-significant 
level. On the other hand, when tested on a larger group of PD-MCI cases with sub-grouping 
according to longitudinal evaluation of conversion to PDD, the DMN and SN features might be 
predictive markers for dementia development. 
 
4.4 Dementia related structural changes in PD revealed by DTI data 
Additional to the functional data, we collected DTI data to gain information about structural 
changes related to cognitive decline in PD. A ROI-based approach was used in order to 
investigate white matter changes for the study groups. We evaluated the fractional anisotropy 
(FA) values among the groups and identified 12 regions of interest (ROIs) with significantly 
differing FA values, stemming from decreased FA values in PDD patients compared to PD-N in 
the right anterior thalamic radiation (ATR-R), left and right cortico spinal tract (CST-L and R), 
the left and right cingulum cingulate gyrus (Cing. Cingulate gyr-L and R), left and right inferior 
fronto-occipital fasciculus (IFOF-L and R), the inferior fronto longitudinal fasciculus (ILF-L and 
R), the left and right superior longitudinal fasciculus (SLF-L and R) and the left temporal 
superior longitudinal fasciculus (SFL Temp.-L) as well as decreased FA values of the PDD group 
in the CST-L, IFOF-L and SFL Temp.-L compared to PD-MCI, while PD-MCI did not show any 
significant FA difference compared with PD-N. 
We further investigated the corresponding mean diffusivity (MD), radial diffusivity (RD) and 
axial diffusivity (AD) values in the same RIOs and found in general increased MD, RD and AD 
values in PDD. While increased MD and RD values support the white matter degeneration in 
ROIs with low FA, the increase of AD seems to be inconsistent with decreased FA values. 
However, it has been reported before, that simultaneous increase of AD in parallel with 
stronger increase in RD is consistent with decreased FA values in degenerating WM fibers 
(Mascalchi et al., 2015). 
Notably, although the ROI based approach had the trade-off of rather large-sized ROIs, which 
were limited in localization sensitivity within the tracts, the obtained measurements were 
strong enough to reveal significant differences in DTI measurements among the patient 
groups which points to a global white matter disruption in PDD compared to the non-
demented patients. 
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Our findings further suggest a mainly bilateral pattern of white matter changes in various 
white matter tracts in the PDD patients compared to PD-N but a left lateralization pattern 
when compared to PD-MCI. Hence, the degeneration in the left CST, left IFOF and the left 
temporal SLF as indicated by reduced FA values may be crucial for the discrimination between 
MCI and dementia in PD, and as the MD and AD of the left ILF were further significantly 
increased in PDD compared to PD-MCI, we will discuss these tracts in more detail in the 
following. 
The SLF consists of three sub-parts (I, II, III), with the SLF II representing its main component. 
While the dorsally located SLF I is mostly known to be involved in the regulation of motor 
aspects and the initiation of motor activity by connecting the supplementary and premotor 
areas with the superior parietal and medial parietal cortex (Schmahmann et al., 2008), the SLF 
II is located more lateral and links the caudal inferior parietal cortex and parietooccipital areas 
with the dorsolateral prefrontal cortex. Based on the anatomical connection of the SLF II it is 
suggested that it contributes largely to the dorsal visual stream (Ffytche et al., 2010) and 
thereby is important for visual awareness and spatial attention (Schmahmann et al., 2008). 
Finally, the ventrally in the operculum located SLF III is thought to play a major role in the 
transfer of somatosensory information between the operculum, the premotor areas and 
parietal lobe (supramarginal gyrus) and therefore is thought to be important for articulatory 
and phonemic language aspects (Schmahmann et al., 2008). 
The IFOF on the other hand is especially known for its involvement in the ventral visual stream 
by linking the occipital lobe with parts of the parietal lobe, temporal lobe and the frontal lobe. 
The IFOF therefore is important for the integration of peripheral vision and the processing of 
visual spatial information (Ffytche et al., 2010; Migliaccio et al., 2012). The ILF is like the IFOF 
considered to be part of the ventral visual stream as it connects the occipital and temporal 
cortices and is thought to be involved in the symptoms of visual agnosia after damage of this 
tract (Migliaccio et al., 2012). 
 
To summarize, the SLF, ILF and IFOF contribute in large parts to both the ventral and dorsal 
visual streams and therefore play a major role for the visuo-spatial and visuo-perceptive 
function. The structural changes in these tracts correlated with the pentagon copying and 
clock drawing performance among the whole study-group but also with test scores for the 
executive functions. This finding may be especially important in terms of the proposed 
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concept of stronger exhibited visuo-spatial dysfunction as a risk factor and marker for PDD 
(Williams-Gray et al., 2007 and 2009). 
The corticospinal tract on the other hand plays a major role in the control of movement, as it 
contains descending fibers, mainly originating from the motor cortex including the premotor 
area, supplementary motor area towards the cingulum, brainstem and spinal cord. As the CST 
also connects parts of the prefrontal, parietal and ventral temporal cortex, including the 
parahippocampal gyrus and entorhinal cortex the CST is thought to be further involved in 
somatic sensation, attention and motivation (Schmahmann et al., 2008). As such, these WM 
changes are related with increasing motor symptoms in PDD. 
The anterior thalamic radiation on the other hand is a portion of the anterior limb of the 
internal capsule (ALIC) and relates the prefrontal cortex and the thalamus (Mamah et al., 
2010). The changes in this tract might be associated with the functional connectivity decrease 
observed in the FSN. 
Our findings are in line with widespread cerebral white matter deterioration in PDD patients 
previously shown by Hattori et al. (2012) and Kamagata (2013). Neural degeneration and 
white matter lesions together with Lewy body deposition may characterize the white matter 
changes, which in turn lead to the motor and cognitive symptoms in PD and are displayed in 
the significant decrease of FA and increase of MA, RD and AD values in the PDD compared to 
the PD-N and PD-MCI patients. Agosta and co-workers (2013) showed that the dysfunction of 
global cognitive abilities correlates with the degree of structural changes in the white matter 
and that the involvement of structural changes exceeding the nigrostriatal system correlates 
with increasing clinical stage. 
 
4.5 Dementia related perfusion changes in PD revealed by ASL data 
The ASL method was used to track changes in cerebral blood flow related with cognitive 
decline in PD. Various lateralized ROIs were used to compare the CBF among the patient 
groups, and the PDD groups showed significant hypoperfusion in regions including the 
posterior part of the right inferior temporal gyrus, the right temporo-occipital part of the 
inferior temporal gyrus, the right middle frontal gyrus, the anterior portion of the left middle 
temporal gyrus, bilateral superior frontal gyrus, left superior temporal gyrus and the posterior 
portion of the right temporal fusiform cortex together with the right temporal occipital 
124 
 
fusiform cortex compared to PD-N and PD-MCI, while there were no significant differences in 
CBF between PD-N and PD-MCI. 
The identified extensive cortical hypo-perfusion in PDD patients support the recent literature 
findings of decreased CBF in PDD and PD compared to healthy controls (Kamagata et al., 2011, 
Lin et al., 2016). However, as we found the CBF decrease specifically in the PDD compared to 
PD-N and PD-MCI groups, this may point to a PDD specific decrease of CBF. 
On the other hand, Lin and colleagues (2016) demonstrated an inverse effect of dopaminergic 
therapy on cortical perfusion in PD patients, showing a higher perfusion decrease under L-
Dopa therapy, though the modulation effect becomes less in PDD patients as the perfusion 
was significantly decreased during both on and off L-Dopa states in their study. On the 
contrary, Le Heron et al. (2014) reported comparable pattern of hypoperfusion for PDD and 
AD patients, pointing to shared mechanisms of neurodegeneration leading to dementia. In 
our study, where similar number of patients in each of the PD-N, PD-MCI and PDD groups 
receive L-Dopa treatment, the hypoperfusion in PDD patients has to depend on biological 
changes rather than the L-Dopa treatment. 
The performed correlation analyses for the investigation of the dependency of the clinical and 
neuropsychological status of the PD patients on cerebral blood flow changes revealed a rather 
broad pattern of CBF correlations of the significant ROIs and the demographical, clinical and 
NPT scores, indicating a non-specific global decrease of CBF in PDD. 
 
4.6 Dementia related metabolite changes in PD revealed by MRSI data 
MRSI data were evaluated for PDD vs PD patients, in order to compare differences in 
prominent metabolite ratios within various ROIs. The investigated ROIs were chosen according 
to the rs-fMRI, DTI and ALS findings and the FOV size of the MRSI measurements. While many 
studies investigated a limited amount of voxel, our FOV size allowed the investigation of a 
larger area at the same time. 
We did not obtain significant differences for the corrected statistics between the two groups, 
thus the uncorrected statistical results for the NAA+NAAG/Cr, Glx/Cr, Cho/Cr and mI/Cr ratios 
will only be discussed in the framework of their conjunction with results in other modalities. 
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4.7 Integrative Evaluation of the Multimodal Neuroimaging Findings 
The findings from the different MRI modalities complement each other in in the following 
ways. 
Divisions of the higher expressed DMN in PDD patients overlapped with white matter tracts 
in which structural changes were found for the PDD group. The increased connectivity within 
the DMN network is focused to the posterior part of the network with a rather missing 
connectivity to the medial prefrontal region, which is in-line with the decreased fractional 
anisotropy of the left and right cingulum in PDD patients, that connects the anterior and 
posterior parts of the DMN (Greicius et al., 2009). Additionally, MRSI data showed reduced 
NAA+NAAG/Cr in the left and right precuneus of PDD patients indicating a loss of neuronal 
integrity within that region (Figure 4-1). While the increased DMN in PDD patients may 
represent a compensatory mechanism for neuronal loss, it might also be related to the altered 
insula activation pattern we observed in PDD patients in the salience network, which has 
regulatory influence on the DMN activity under normal physiological conditions. 
The increased functional connectivity of the insula within the salience network of the PDD 
patients compared to PD-N patients seems to depend mainly on the reduced inhibitory input 
to the insula due to combined striatal dopamine denervation and D2 receptor loss as shown 
in a previous study on PD-MCI (Christopher et al., 2013). Additionally, Braak et al. (2003) 
described alpha-synuclein deposition in the insula in the later stage of the disease, which 
might also count for alteration of the network connectivity (Christopher et al., 2014). On the 
other hand, the aberrant connectivity within the SN of the PDD patients is accompanied by 
WM degeneration in the left and right inferior fronto-occipital fasciculus (IFOF) and partly 
inferior longitudinal fasciculus (ILF), which might play a role in the connections of the insular 
region with the temporo-occipital regions (Figure 4-1). 
The reduced NAA+NAAG/Cr in the right central operculum of PDD patients might complement 
these findings on the MRSI basis, as the opercular cortex borders and slightly overlaps with 
the insular cortex and partly connects with the ILF, although the operculum is mainly related 
with the SLF-III. The SLF-III on the other hand is considered to play a crucial role not only in 
articulatory but also in phonemic language aspects which was also displayed by correlation of 
the FA values of the SLF with phonemic fluency. The expression of the salience network as 
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well as the MD, RD and AD values of the bilateral ILF were negatively correlated with semantic 
fluency performance (Figure 4-1). 
 
Figure 4-1: Complementary multimodal MRI findings for the default mode network (DMN) and the salience 
network (SN). DMN: The stronger expressed DMN in PDD is green, the right and left cingulum with decreased FA 
in PDD are in red and the precuneus with reduced NAA+NAAG/Cr in PDD is in blue. The additive overlap is 
indicated in yellow and turquoise. 1.SN: The stronger expressed SN is red, the IFOF with decreased FA is green 
and the ILF is violet. IFOF and SN overlaps are yellow. 2.SN: The SN is red, the SLF is green and the central 
opercular cortex blue. Overlaps are pink and yellow. 
 
The lower expression of the limbic network together with the reduced functional connectivity 
of the right thalamus derived from the functional data in PDD patients compared to PD-N, 
might be partly complemented with the structural changes of the right anterior thalamic 
radiation obtained with DTI measurements in the PDD group (Figure 4-2). The right anterior 
thalamic radiation spatially also overlaps with clusters of the lower expressed frontostriatal 
network, in which we obtained reduced functional connectivity mainly in parts of the caudate 
and putamen in PDD patients compared to non-demented PD patients, and these findings 
might be supported by the metabolic changes displayed by the reduced NAA+NAAG/Cr in the 
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caudate of PDD patients revealed by MRSI data. Furthermore, the hypo-perfusion and 
metabolic changes in the middle and superior frontal gyrus revealed by ASL measurements 
also correspond to structures of the FSN, which may lead to an overall lower expression of the 
FSN in PDD (Figure 4-3). 
 
Figure 4-2: Complementary multimodal MRI findings for the limbic network (Lim.NW). 
The decreased limbic network in PDD is in red and the right anterior thalamic radiation with decreased FA is in 
blue. The overlap is in pink. 
 
 
Figure 4-3: Complementary multimodal MRI findings for the frontostriatal network (FSN). 
1.FSN: The decreased FSN in PDD is in green and the right left and right superior frontal gyri in blue and the right 
middle frontal gyrus in red displaying hypoperfusion in PDD. The overlap is dark green. 2.FSN: The decreased FSN 
in PDD is in blue, the right anterior thalamic radiation with decreased FA is in red and the caudate with decreased 
NAA+NAAG/Cr is green. The overlap is in pink, turquoise and yellow. 
 
The posterior- temporal network (PTN), that was previously also introduced as ventral stream 
network in other literature (Veer et al., 2010), highly corresponds to the ventral visual stream 
and the reduced expression of this network in PDD patients therefore might correspond to 
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the structural changes of the ILF, SLF and SLF-temp in the PDD groups, as these tracts are 
known to be parts of the ventral stream. The changes within the PTN are also represented by 
decreased perfusion in the parts of the left superior and middle temporal gyri and the changes 
of NAA+NAAG/Cr, Cho/Cr and Glx/Cr within this region in PDD patients. While the expression 
level of the PTN simultaneously decreased with the years of education, the FA, MD, RD and 
AD values of the ILF, SLF and SLF-temp showed various correlations with the pentagon and 
cube copying test and the clock drawing performance over the whole group, which could 
represent the biological counterpart of disturbed visuo-spatial dysfunction in PDD together 
with the hypoperfusion in the occipital region in PDD (Figure 4-4). 
 
Figure 4-4: Complementary multimodal MRI findings for the posterior-temporal network (PTN). 1.PTN: The 
decreased PTN in PDD is in red and the right left and right ILF with decreased FA in PDD are green. The overlap 
is yellow. 2.PTN: The decreased PTN in PDD is in green and the right left and right SLF with decreased FA in PDD 
are yellow and the left SLF-temporal is orange but only very few voxels can be seen. 3.PTN:  The PTN is red, the 
left anterior middle temporal gyrus is blue, the left posterior middle temporal gyrus is yellow and the left anterior 
superior temporal gyrus is green. The right temporo-occipital middle temporal gyrus is also green. Overlaps are 
yellow. 
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Finally, the severity of motor-dysfunction may be related to the degenerations in the SLF and 
CST of PDD patients and the metabolic changes in the supplementary motor cortex, as the 
mean FA of the SLF and CST were correlated with the UPDRS and Hoehn & Yahr scores 
(Figure 4-5).  
 
Figure 4-5: Complementary multimodal MRI findings for the corticospinal tract (CST), superior longitudinal 
fasciculus (SLF) and the supplementary motor area. The CST is blue and the SLF is green both showing decreased 
FA in PDD and the supplementary motor area with increased Glx/Cr in PDD is orange. 
 
4.8 Discriminant analyses on multimodal MRI data 
The above presented framework of multimodal MRI findings may provide insights about the 
evolution of neuropathological changes in PD that lead to cognitive decline and dementia. On 
the other hand, our results also provide a pragmatic approach for the classification of PD cases 
in demented and non-demented subgroups by means of a logistic regression model created 
on the basis of multiple RSNs obtained from fMRI data. In a last step, we will discuss the 
possibility to enhance the sensitivity and specificity of such regression model in discriminating 
the demented patients by adding significant variables of other MRI modalities into the model. 
As the MRSI differences among the patient groups did not survive the statistical correction 
procedures, variables obtained with the rs-fMRI, DTI and ASL neuroimaging methods were fed 
stepwise into a discriminant analysis in order to build a multimodal regression model for the 
correct identification of PDD patients. For this purpose, we limited the variables to those that 
when tested in a single modality resulted in significant differences between the patient 
groups. 
Indeed, the addition of the DTI variables into the model with leave-one-out cross-validation 
resulted in significant increases for both sensitivity and specificity, which reached 100% and 
93.8% for the discrimination of PDD from PD-N and to 83.3% and 83.3% for the discrimination 
of the PDD from PD-MCI cases, respectively. 
130 
 
The variables displayed by the model for PDD vs PD-N patient discrimination were the FA 
values of the SLF temp.-L, MD values of cing.-cingulate gyr.-L, AD values of ILF-L and the 
intrinsic connectivities of frontostriatal and salience networks, while the AD value of the ILF-L 
and the intrinsic connectivity of the limbic network efficiently discriminated PDD and PD-MCI 
cases.  
Both results are very strong in terms of classification power, and if validated with data of larger 
patient groups, can reliably be used as biomarkers for PDD. The further addition of ASL data 
did not further increase but rather decreased the sensitivity and specificity of the model, 
hence the two easier applicable modalities of rs-fMRI and DTI are sufficient for a classifier 
design for determination of dementia in PD. 
 
4.9 Limitations for this study 
In future work, it would be of big advantage being able to refine the normalization process of 
the data in a way that the subject’s brains would be registered to an age matched and/or 
disease-related standard template or even to work directly in the subject space, instead of 
registering the patient’s brains to a standard template obtained from the average of 152 
healthy subjects of different ages. Although the usage of the MNI-152 template is the common 
way in reference literature, we believe the usage of a specific template and atlas-tools would 
improve the data analyses and this, in addition to the need of a gray matter mask, might also 
be the reason why some of the identified clusters around the ventricle obtained with rs-fMRI 
data analysis in this study partly resided in white-matter. 
But indeed, there is fMRI literature directly addressing the investigation of WM activity, and 
as the BOLD signal depends on the blood in the tissue, it isn’t too surprising also detecting 
activity in the WM, but less strong than in the gray matter (Gawryluk 2014). 
As we collected the data from a patient group, we cannot fully exclude the impact of any 
medication treatment on the functional MRI data and neuropsychological assessment, but it 
would be ethically unacceptable to pause the patients drug intake and cause a worsening of 
the patient’s symptoms. On the other hand, we would also risk motion artifacts due to severe 
motor-symptoms during the MRI scans when the Parkinson-related drugs would be stopped 
for that period, hence all recordings were performed during on-stage of the patients. But, as 
the type of Parkinson-related medication was balanced within the three patient groups and 
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we did not compare our data to a healthy control group, we believe that our results are not 
biased by the medication of the patients. 
5 CONCLUSION 
To conclude, in this study we were able to provide novel information about the mechanisms 
underlying the pathogenesis and progression of the cognitive decline from PD-N to PDD using 
multimodal MRI techniques. 
By this, we first obtained the RSNs that yield discriminative power among the three patient 
groups, which were the DMN, SN, FSN, PTN and the limbic network. Contra intuitively, the 
expression of the DMN and SN, which are functionally related in a way that the SN regulates 
the activation and deactivation of the DMN and the CEN in the presence/absence of salient 
stimuli, were simultaneously increased in the PDD group, pointing to an altered switching 
mechanism in PDD patients that is different from altered activation pattern that have been 
described for AD and bvFTD cases. Although the DMN and SN increase became statistically 
significant only in the PDD group, the intrinsic functional connectivity of the DMN and SN 
increased from PD-N trough PD-MCI to PDD. As not all PD-MCI patient will evolve into PDD, 
the non-converters might have diluted this effect and it would be interesting to follow the 
long-term progression of those patients within the PD-MCI group with and without increased 
DMN and SN functional connectivity in terms of prognostic features of alterations of these 
networks. 
The FSN, PTN and limbic network on the other hand showed decreased intrinsic functional 
connectivity in the PDD group and relate to the executive, visuo-spatial and memory 
dysfunction in PDD patients. 
We were further able to show complementary DTI derived differences in various white matter 
tracts that not only indicate global neurodegenerative processes in PDD but were also linked 
the structural changes of specific tracts with the RSN alterations observed in PDD. 
Additionally, the ASL and MRSI techniques provided sensitive information about various 
pattern of hypoperfusion and altered metabolite ratios in the PDD group that were supportive 
for the RSN and white matter findings. 
Furthermore, the biological results obtained with the different MRI techniques significantly 
correlated with motor-symptom severity and the cognitive decline among the groups. As for 
example the FSN was related with clock drawing performance, the SN with semantic fluency 
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and the limbic network showed several correlations with the UPDRS-cognitive score, 
UPDRS-total score and disease duration, it seems that semantic fluency and clock drawing 
performance are indeed valuable tests for fast clinical evaluation of the cognitive state of the 
PD patients and poor performance in these tests point to dementia risk. 
 
In a second step, we were able to create a multimodal neuroimaging-based biomarker for the 
discrimination of PDD cases from PD-N and PD-MCI based on the significant parameters of the 
rs-fMRI analysis together with the significant changes within DTI derived parameters, and 
obtained a discrimination model with 100.0% sensitivity for the discrimination of PDD from 
PD-N and 83.3% sensitivity between PDD and PD-MCI cases. The obtained discriminative 
function of the combined modalities was even more successful than the logistic regression 
model using the expression of the RSNs alone. 
 
As the rs-fMRI and DTI data can be easily recorded during the MRI and yielded reliable 
discriminative power in this study, the application of these measurements in clinical diagnosis 
and follow-up of the PD patients cognitive status would provide the clinicians an eminent tool 
for the reliable diagnosis and the generation of appropriate treatment strategies for the 
individual patient. The establishment of a reference value of RSN expression for PD-MCI and 
PDD would allow the fast diagnosis of newly diseased patients by comparing the individual 
scores with the reference value and the early intervention for an optimal treatment would be 
of great interest for the slowing of the patient’s symptoms. 
On the other hand, our results exposed neuro-pathological changes in the brains of PD 
patients at different stages of cognitive decline that can predict PDD and represent important 
inside in the PDD specific disease pattern in contrast to other forms of dementia. This 
identified regions could represent promising targets for innovative therapies that yet have to 
be developed. 
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